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Summary 
The aims of this study were to develop novel in vitro models of Human Papillomavirus (HPV) -
associated vulval and vaginal neoplasia and to use them to investigate the mechanism(s) of 
action of the nucleoside analogue, Cidofovir (CDV), for which a mechanism is unknown. Single 
cell clones were successfully isolated from heterogeneous vulval and vaginal parental 
populations. The clonal cell lines were characterised morphologically and in terms of cell 
proliferation; a range of growth rate and morphological variants were identified. Clonal lines 
were also characterised with respect to HPV integration state using Amplification of 
Papillomavirus Oncogene Transcripts (APOT) and Detection of Integrated Papillomavirus 
Sequences (DIPS). Cell lines were identified that represented naturally occurring episomal and 
integrated HPV infections. HPV gene expression analysis was also performed using quantitative 
real-time reverse transcription PCR (qRT-PCR) which displayed different expression profiles for 
each line. Patterns of HPV gene expression appeared to correlate with gene disruptions 
associated with integration. Characterised clonal lines were used to investigate the effects of 
CDV on cell viability, morphology and HPV gene expression. CDV (10 µM) reduced cell viability 
in all HPV-positive clonal lines and HPV negative HEK cells; viable cell counts showed that a 
more considerable response was detected in vulval lines compared to vaginal lines and that 
response in HEK lines was similar to vulval lines. Cell enlargement was observed in response to 
treatment in the clonal lines but not the HEK line. CDV treatment did not cause significant 
reduction in expression of HPV E6 or E7. mRNA sequencing confirmed HPV integration and 
gene expression profiles. Differentially Expressed Gene (DEG) analysis identified a large 
percentage of the top 20 most significant Gene Ontology (GO) categories to be involved in 
nucleotide synthesis and RNA polymerase activity. Gene Ontology Over Representation 
Analysis (GO-ORA) showed that 4 GO categories relating to cellular senescence were found in 
over 300 GO categories comprising the top 500 most significant gene transcripts. 
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1 Introduction 
1.1 Human papillomavirus (HPV) and HPV associated cancer 
Papillomaviruses (PVs) belong to the Papillomaviridae family and are small (52-55nm 
diameter) viruses that consist of a double stranded, circular, DNA genome of approximately 
8kb. PVs are non-enveloped. They have an icosahedral capsid consisting of 72 capsomeres. The 
capsomeres include L1 and L2 proteins; L1 is the major protein forming ~80% of the capsid and 
functions to mediate viral infectivity (Joyce et al., 1999). PVs are a diverse group of viruses that 
infect a broad range of hosts including humans, other mammalian species, and birds. Over the 
past few decades, PVs have been linked to chronic infection of stratified squamous epithelia of 
the skin and mucosa, causing benign, pre-malignant, and malignant lesions (Munoz et al., 
2006, Howley and Lowy, 2007). Each PV genus is classified according to the host species it 
infects and the resulting manifestation of disease. Nucleotide sequencing has provided a 
means of phylogenetically assessing PVs by comparing the nucleotide sequence of the L1 open 
reading frame (ORF), which is highly conserved in all PVs. Within a genus, DNA comprising the 
L1 ORF shares at least 60% homology with all members within the same genus. PV genera are 
divided by species, representing 60-70% L1 sequence identity to other PV of the same species; 
viral type (71-89% L1 identity); viral subtype (90-98% L1 identity) and variant (over 98% L1 
identity). Phylogenetic classification presents 12 genera of PVs, 5 of which are human 
associated (human papillomaviruses (HPV)) and the remaining are entirely animal associated 
(de Villiers et al., 2004). The 5 genera of HPVs are represented by the letters of the Greek 
alphabet: α, β, γ, μ, and ν. 
1.1.1 Structure and taxonomy  
HPVs belonging to the α genus infect both cutaneous and mucosal epithelia, causing a variety 
of benign lesions such as cutaneous or mucosal warts, as well as pre-malignant lesions, and 
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cancer. HPV types belonging to the α genus, such as HPV2 and 57, infect cutaneous epithelia 
and cause common cutaneous warts. Mucosal α-HPV types, such as HPV 6, 11, 16 and 18, are 
the most clinically relevant infections and are associated with genital warts, respiratory 
papillomas, and anogenital pre-malignant lesions and cancers. HPVs of the β genus are 
implicated in infections specific to individuals with epidermodysplastic verruciformis and 
immunodeficiency diseases, and are commensals of the hair and skin in healthy individuals 
(Knipe and Howley, 2007). HPVs of γ, μ and ν genus, such as HPV1 and HPV 4, are associated 
with cutaneous warts.  
1.1.2 Epidemiology  
Epidemiology refers to the factors contributing to the cause, frequency, and distribution of 
disease in the human population. According to the Centers for Disease Control in the United 
States of America (CDC), HPV is the most common sexually transmitted infection (Centers for 
Disease Control, 2013) and by age 50, at least 80% of women will have acquired, and most 
likely subsequently cleared, a genital HPV infection.  
 Mucosal HPV types associated with cancer are categorised as high risk (HR); the most 
significant HR HPV types are 16, 18, 45 and 31. Low risk (LR) mucosal HPVs represent types 
that are not associated with cancer, such as types 6 and 11. In the human population, 
persistent infection with HR HPV infection is clinically significant because it contributes to the 
global cancer burden. Infection with HR HPV types 16 and 18 is the underlying cause of 
approximately 70% of cervical cancers (Muñoz et al., 2004, World Health Organisation (WHO), 
2013). In an updated European meta-analysis of HPV type distribution in cervical intraepithelial 
neoplasia (CIN), HPV 16 and/or 18 was found in 52%, 61% and 76% of cytologically detected 
high-grade squamous intraepithelial lesions, histologically confirmed cervical intraepithelial 
neoplasia grade 2/3, and invasive cervical carcinoma, respectively (De Vuyst et al., 2009). 
World-wide studies over the last decade have also demonstrated the association between 
 3 
 
persistent infection with HR HPVs and other genital cancers, for example, HR HPV DNA has 
been detected in cancers of the cervix, vulva and vagina in women, and in men HPV has been 
shown to cause cancers of the penis and oropharynx (Stanley, 2007, Giuliano et al., 2008), 
illustrated in Table 1.1. In both sexes HPV has been shown to infect the anal canal, perianal, 
and oropharyngeal regions, and over the past decade the increased incidence of certain head 
and neck cancers has been attributed to increased prevalence of HPV in the oral cavity (Marur 
and Forastiere, 2008). LR HPV types of the α genera, such as HPV 6 and 11, predominantly 
cause genital warts in both sexes and although they are not usually linked to cancer, they are 
associated with considerable psychosocial distress (Ireland et al., 2005) and contribute to the 
clinical burden of HPV related disease. Genital warts affect around 1% of the sexually active 
population (Brentjens et al., 2002). 
1.1.2.1 Risk factors 
Both sexes are able to carry, transmit, and become infected by HPV via sexual contact 
therefore the risk of infection is related to the sexual behaviour of an individual. Early age at 
start of sexual activity, sexual relations with a high risk individual, and a high number of sexual 
partners, contribute to the increasing likelihood of HPV infection and transmission (Pecorinio, 
2008). Infection with HPV usually occurs within the first several years of sexual initiation. The 
age of highest sexual activity in the female population ranges from 18 to 25 years (late teens 
and young women). During this time the incidence of HPV infection without clinical concern 
(defined as HPV positive but without clinical symptoms) is highest. In a study involving meta-
analysis of cervical HPV prevalence in 5 continents, the age distribution of cervical HPV 
infection showed a bimodal curve (Bruni et al., 2010); a first peak in prevalence at younger 
ages (late teens / early twenties) was common to all populations. A second smaller peak at 
approximately 40 years of age was also identified in some populations. This is thought to be 
related to circumstances such as divorce or menopause. Aside from the relationship between   
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Site 
 
Attributable 
to HPV (%) 
Developed countries Developing countries 
Total 
cancers 
Attrib. to 
HPV 
% all 
cancer 
Total 
cancers 
Attrib. to 
HPV 
% all 
cancer 
Cervix 
Penis 
Vulva,vagina 
Anus 
Mouth 
Oropharynx* 
All sites  
100 
40 
40 
90 
3 
12 
83, 400 
5, 200 
18, 300 
14, 500 
91, 200 
24, 400 
5, 016, 000 
83, 400 
2, 100 
7, 300 
13, 100 
2, 700 
2, 900 
111, 500 
1.7 
0.0 
0.1 
0.3 
0.1 
0.1 
2.2 
409, 400 
21, 100 
21, 700 
15, 900 
183, 100 
27, 700 
5, 827, 500 
409, 400 
8, 400 
8, 700 
14, 300 
5, 500 
3, 300 
449, 600 
7 
0.1 
0.1 
0.2 
0.1 
0.1 
7.7 
 
1.1 Cancers attributable to HPV infection  
The table shows the estimated cancer burden attributable to HPV infection (data relates to the 
year 2002). Certain anogenital and oropharyngeal cancers are thought to have increased in 
incidence since 2002 due to the increased prevalence of HR HPV in the population (especially 
oropharyngeal cancers). Adapted from (Stanley, 2007).  
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age and sexual behaviour, age is also a contributing risk factor because age is related to 
cellular changes in the transformation zone which increase the risk of infection (Burd, 2003). 
The transformation zone of the cervix is a region where one type of epithelia replaces another 
(metaplasia) and is the site from which most cervical cancers originate (Jordan and Singer, 
1976). 
The prevalence of neoplastic lesions differs in different regions of the genital tract. The 
incidence of cervical intraepithelial neoplasia (CIN) is much higher than incidence of vulval or 
vaginal intraepithelial neoplasia (VIN and VaIN). This may be because HPV does not infect all 
regions of the female genital tract at the same frequency. 
1.1.2.2 Persistent infection with HR HPV 
In most cases HR HPV cause transient infections which clear spontaneously (Evander et al., 
1995). In a relatively small percentage of individuals with HR HPV infection (~10%), transient 
infection is not cleared and HPV chronically persists (Holowaty et al., 1999, Ostor, 1993). 
Persistent infection with HR HPV can cause development of histological changes within 
infected epithelia; this is usually attributable to the 4 most significant HR HPV types, 16, 18, 45, 
and 31, and highly associated with the risk of developing neoplasia and progression to cancer 
(Howley and Lowy, 2007). HPV 16 is currently the most prevalent type and is frequently 
associated with anogenital neoplasias and cancers. During persistent infection, the immune 
status of the host, co-infection with other sexually transmitted microorganisms, long term use 
of oral contraceptives, diet, and tobacco use are also thought to facilitate neoplastic 
progression to cancer (Castellsague, 2008).  
1.1.2.3 The disease burden associated with HPV infection  
Chronic infection with HR HPV is considered necessary for the progression of neoplastic lesions 
to invasive cancer, with HPV persistence contributing as a major risk factor for cellular 
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transformation (Schlecht et al., 2001, zur Hausen, 2002, Paavonen, 2007, Ho et al., 1995, 
Ferenczy and Franco, 2002). HPV 16 is the most prevalent type detected in cervical cancer and 
along with types 18, 33, and 45, has been classified by the International Agency for Research 
on Cancer (IARC) Monographs as a human carcinogen (International Agency for Research on 
Cancer (IARC), 2013). Almost 100% of cervical carcinomas contain HR HPV DNA, between 70-
90% in high grade cervical intraepithelial neoplasias (CIN II & III) and 20-50% in low grade CIN 
(I). HPVs are also associated with malignancies in other mucosal and skin cancers, and with 
regard to other anogenital cancers, HR HPV types 16 and 18 account for 70-85% anal cancers, 
~40% vulval/vaginal/penile cancers, as well as ~40% head and neck cancers (Paavonen, 2007, 
De Vuyst et al., 2009).  
1.1.2.4 Vaccination: prevention of HPV infection 
Vaccination strategies aim to prevent precancerous and cancerous lesions by targeting the 
aetiological agent of disease (HPV). Vaccination works by effectively preventing initial infection 
with HPV in previously unexposed women; it is not effective in women with existing HPV 
infections (Monsonego et al., 2010).  
The immunisation program introduced into the UK in 2008 initially used the bivalent vaccine, 
Cervarix™, containing Virus Like Particles (VLPs) composed of L1 proteins of HR HPV 16 and 18 
(GlaxoSmithKline, 2013). More recently, the UK has switched to Gardisil®, a quadrivalent 
vaccine, containing VLPs against HPV 16, 18, 6 and 11 (Merck Sharp & Dohme, 2013). Both 
vaccines protect against HR HPV 16 and 18, which are associated with cancer. Gardisil® also 
protects against LR HPV types 6 and 11, which cause genital warts. 
1.1.3 HPV lifecycle (productive infection) 
The classic HPV life cycle is commonly described as productive infection, which entails entry of 
the virus into the squamous epithelial cells and thereafter the production of new virus 
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particles (Stanley et al., 2007, Doorbar, 2005), as illustrated in Figure 1.1. Productive infection 
by HPV may manifest as cutaneous warts from which shedding of infectious viral particles 
occurs. The HPV life cycle is dependent on the differentiation pattern of the keratinocytes 
within the stratified layer of squamous epithelia (Kajitani et al., 2012). To establish productive 
infection HPV requires access to cells comprising the basal cell layer. HPV infects basal cells 
when they are exposed through micro-abrasions formed during sexual contact.  
1.1.3.1 Attachment and entry 
Once HPV has been exposed to basal cells, L1 proteins bind to heparin sulphate proteoglycans 
on the epithelial basement membrane causing conformational changes that expose L2. L2 is 
cleaved and the entire L1 protein becomes exposed to cell surface receptors on keratinocytes 
that migrate across the basement membrane through the wound healing process (Schiller et 
al., 2010, Kines et al., 2009). After attaching to keratinocytes, HPV virions enter the cell via 
endocytosis and become localised within an endosome where HPV uncoats. An L2 dependent 
mechanism permits escape from the endosome and L2 bound HPV DNA moves through the 
cytoplasma and enters the nucleus of the cell and co-circularize to form an episome. The L2-
DNA complex associates with sub-nuclear domains within the nucleus, and transcription is 
initiated (Schiller et al., 2010). 
Viral genomes establish as episomes within the nucleus, and episome replication is 
synchronised with the host cell replication machinery. As HPV infected basal cells divide, viral 
genomes are partitioned into daughter cells and detach and move through layers of stratified 
epithelia toward the surface where mature virions are shed. Once cells have become infected, 
tightly controlled sequences of molecular events are initiated which involve expression of viral 
genes in co-ordination with epithelial cell differentiation using the host cell replication 
machinery (Figure 1.1) (Doorbar, 2005, Stanley et al., 2007). 
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Figure 1.1. HPV genes expressed at different stages of epithelial differentiation.  
Early (E) genes permit viral replication and DNA synthesis, after which late (L) genes express 
structural proteins for viral assembly and encapsidation before release from the epithelial 
surface. Adapted from (Stanley et al., 2007). 
  
 9 
 
Viral genomes establish as episomes within the nucleus, and episome replication is 
synchronised with the host cell replication machinery. As HPV infected basal cells divide, viral 
genomes are partitioned into daughter cells and detach and move through layers of stratified 
epithelia toward the surface where mature virions are shed. Once cells have become infected, 
tightly controlled sequences of molecular events are initiated which involve expression of viral 
genes in co-ordination with epithelial cell differentiation using the host cell replication 
machinery (Figure 1.1) (Doorbar, 2005, Stanley et al., 2007).  
1.1.3.2 Molecular aspects of HPV 16 productive lifecycle 
The double stranded DNA genome of HR HPV16 consists of 7904bp. Only 1 strand of double 
stranded DNA functions as the coding strand for transcription. The genome of HPV16 is divided 
in to early (E) genes (6-7-1-2-4-5) and late (L) genes (1 and 2), as shown in Figure 1.2. Several of 
the HPV open reading frames (ORF) overlap and protein production is influenced by alternative 
splicing of mRNAs to allow differential expression of HPV proteins at different times in the HPV 
lifecycle.  
There are at least two promoters within the HPV16 genome; a promoter is a sequence of DNA 
where transcription is initiated. In HPV16, the p97 promoter region is located upstream of the 
E6 ORF and regulates expression of E genes (Smotkin and Wettstein, 1986) while the P670 
promoter lies within the E7 ORF and is responsible for expression of L genes (Zheng and Baker, 
2006).  
1.1.3.2.1 Intitiation of viral DNA replication 
The LCR is a non-coding sequence of DNA (~1kb) in the HPV genome which is important for 
viral DNA replication because it contains the origin of replication. It also contains binding sites 
for numerous viral and cellular transcription factors which function to either activate or 
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repress the early p97 promoter, which initiates transcription of early (E) genes (Doorbar, 2006, 
Kammer et al., 2000).  
1.1.3.2.2 E1 & 2: viral replication and expression of E genes 
E1 and E2 genes encode proteins that associate with and bind to DNA at the origin of viral 
replication (within the LCR) resulting in recruitment of polymerases and other proteins to 
initiate viral replication. The E2 protein induces E1 to migrate to the viral origin of replication 
(Longworth and Laimins, 2004), permitting helicase to allow separation of viral DNA strands so 
replication can proceed. E2 protein has affinity for promoters located throughout the HPV 
genome and regulates viral transcription through activation/repression of the early promoter 
p97 (Hines et al., 1998). Regulation of transcription through E2 occurs in a concentration 
dependent manner, whereby in low E2 concentrations transcription is initiated through 
stimulation of HPV promoters and in high concentrations transcription is repressed (Steger and 
Corbach, 1997). Transcription of HPV oncogenes, E6 and E7, are also regulated by E2. E2 also 
directs the anchorage of viral episomes to mitotic chromosomes to ensure the correct 
separation of viral genomes into the resulting daughter cells (Hamid et al., 2009).  
1.1.3.2.3 E4 & E5 
The functions of E4 and E5 are incompletely understood. However it is thought that E4 is 
involved in the HPV DNA amplification (Nakahara et al., 2005). Efficient viral release from 
cornified epithelia at the epithelial surface may be facilitated by E4, since E4 has been found to 
affect the membranes of cornified squamous epithelia which is related to virus release/viral 
shedding (Doorbar, 2006). E5 is thought to participate in helping HPV evade host immune 
responses, by down-regulating communication signals between cells which affect major 
histocompatability complex class I (MHCI) and growth factor receptors (Ashrafi et al., 2002). It 
is also thought that E5 enhances the transforming properties of HPV, together with E6 and E7, 
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Figure 1.2. Episomal HPV 16 genome.  
Schematic representation of circular (episomal) HPV 16 genome showing early (E) and late (L) 
genes and the lower control region (LCR); corresponding linearised representation of HPV 16 
genome also illustrated.  
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by interacting with epidermal growth factors and cell cycling pathways (Venuti et al. 2011).  
1.1.3.2.4  E6 & 7: disruption to the cell cycle and cell transformation 
High risk E6 and E7 are the most studied HPV genes and are termed oncogenes due to their 
association with cellular transformation and cancer. E7 protein maintains cell cycle activity in 
differentiating cells by interfering with the activity of retinoblastoma (pRB) tumour suppressor 
protein, and other members of the pocket proteins, e.g. p21 (Munger et al., 2001, Funk et al., 
1997). Under normal conditions, pRB forms a complex with transcription factor E2F which 
regulates the cell cycle by repressing the transcription of genes that allow cell proliferation. 
However, when E7 is present it binds to pRB causing displacement of E2F which allows 
expression of genes that promote DNA replication; this leads to constant expression of cell 
cycle genes and continual cell proliferation.  
E6 has been shown to inhibit the action of p53. In normal cells the activity of p53 is low and 
this is due to mdm2 mediated p53 ubiquitination which flags p53 for proteosomal degradation. 
During severe DNA damage, mdm2 is inhibited causing levels of p53 to increase to a threshold 
level which is sufficient to arrest the cell cycle and activate cell death (apoptosis) (Kubbutat et 
al., 1997). When E6 protein is present it associates with cellular E6 associated protein to form 
the complex E6-AP which has a high affinity for p53 and causes p53 ubiquitination and 
degradation; E6-AP induced p53 degradation therefore allows continuous cell proliferation and 
evasion of apoptosis (Scheffner et al., 1990, Scheffner et al., 1993, Scheffner, 1998). 
Additionally, E6 permits DNA damage to go unnoticed and allows mutations to accumulate and 
transfer to subsequent generations of daughter cells, which facilitates cell transformation. 
Disruption to p53 also causes c-myc and sp1 transcription factors to induce transcription of 
human telomerase reverse transcriptase (hTERT), an enzyme that maintains telomere length 
(Gewin and Galloway, 2001, Oh et al., 2001). Telomeres are located at the ends of each 
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chromosome and shorten with cell proliferation due to the end replication problem. 
Telomeres function to protect the DNA comprising the chromosome, and stop chromosome 
ends being recognised as DNA breaks. Erosion of telomeres beyond a critical level leads to 
cellular senescence. E6 related activation of hTERT therefore prevents telomeres from eroding 
and enables the cell to continually replicate, which contributes to cellular transformation 
(Veldman et al., 2001).  
In summary, E6 and E7 related deregulation of normal cell cycle and loss of DNA repair 
mechanisms leads to genomic instability and accumulation of further mutations, which can 
then lead to cell transformation and carcinogenesis. 
1.1.3.2.5 L1 & L2: capsid proteins, virus assembly, and release 
Expression of L1 and L2 occurs after HPV genome amplification and facilitates the packaging 
and assembly of infectious virions in the upper epithelial layers (to avoid host immune 
surveillance) (Schwartz, 2000). L1 and L2 are capsid proteins and combine in the cytoplasm to 
form capsomeres; cytoplasmic L1 assembles into capsomeres and migrates to the nucleus 
once L2 has associated with the nucleus (Florin et al., 2002). The E2 protein is also thought to 
aid in the formation of the capsid by inducing expression of the late genes (Mole et al., 2009). 
L2 enhances infectivity of HPV and the efficient packaging of the HPV virions. Together, L1, L2, 
E2 and E4 are necessary for the assembly of infective virions during the final stage of HPV 
lifecycle, and also aid in virus release (shedding) when cells reach the surface of differentiated 
epithelia (Nakahara et al., 2005, Wang et al., 2004) 
1.1.4 Pathogenesis  
Pathogenesis refers to the chain of events that occur during development and manifestation of 
disease. 
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1.1.4.1 Non-productive infection  
Most individuals that become infected with HR HPV will clear the virus within a matter of 
months, however there are a small percentage of individuals that do not clear infection 
(Evander et al., 1995, Ostor, 1993). Persistent infection may be followed by loss of regulation 
of viral gene expression, such that it is no longer synchronised with epithelial cell 
differentiation and L1 and L2 proteins are no longer produced; this is referred to as non-
productive infection. In non-productive infection, the E6 and E7 oncogenes are still expressed, 
and interact with tumour suppressor pathways which control the cell cycle. Several factors 
may underlie loss of control of viral gene expression including viral integration, methylation 
and mutation of the LCR. The clinical implications of this include the development of neoplasia 
with the potential to progress to invasive cancer. 
1.1.4.2 Pathology  
Cancers develop through a succession of neoplastic stages that are graded according to the 
degree of dysplasia and to the proportion of the cross section of biopsied stratified epithelia 
that contains dysplastic cells (Figure 1.3). The histological classification of biopsies can be 
through 2 tier Bethesda classification i.e. grouped into low grade or high grade squamous 
intraepithelial lesions (LSIL and HSIL, respectively), or using the 3 tier system of cervical 
intraepithelial neoplasia, i.e. grade 1, 2 and 3 (CIN1, CIN2 and CIN3, respectively).  
1.1.5 HPV Integration  
As previously described, the productive HPV lifecycle and gene expression is synchronised with 
epithelial differentiation. During productive infection HPV exists as an episome inside the cell 
nucleus. During non-productive infection, viral gene expression becomes deregulated which 
allows E6 and E7 proteins to disrupt the cell cycle through the processes previously described; 
this can lead to genomic instability and neoplastic progression (Doorbar, 2006). Integration of   
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Figure 1.3. Schematic representation of histological classification of HPV infected cells 
When basal cells of stratified epithelia are exposed to HPV a series of changes can occur which 
are classified depending on the degree of dysplasia and proportion of the epithelium affected. 
CIN 1, 2 and 3 refers to increasing grades of abnormal cells (neoplasia); 1 and 2 are referred to 
as low grade (low grade squamous intraepithelial lesions = LSIL), and 3 as high grade (high 
grade squamous intraepithelial lesions = HSIL). Grade 3 can progress to cancer, where cells 
invade through the epithelial basement membrane. Adapted from (Wheeler, 2007). 
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HPV in to the host genome often underlies deregulation of viral gene expression and increases 
the risk of progression to cancer; integrated HPV has been detected in ~80% of cervical cancers 
(Luft et al., 2001, Walboomers et al., 1999, Klaes et al., 1999, Ziegert et al., 2003). Reports are 
inconsistent when trying to associate the grade of neoplasia (and cancer) with integration 
status. It is currently unclear whether integration of HPV is a late or early event. Studies have 
found purely integrated HPV in CIN 2 and 3 (Peitsaro et al., 2002, Kulmala et al., 2006) and 
vulval intraepithelial neoplasia (VIN) 2 and 3 (Hillemanns and Wang, 2006) and suggested that 
integration is a late event. Other studies (Huang et al., 2008) have suggested that integration 
of HPV is an early event. 
1.1.5.1 Molecular events that contribute to HPV integration 
The mechanism of HPV integration is still not fully described. When episomal HPV integrates it 
causes disruption to the HPV genome itself but also causes disruption to the host genome. It is 
generally accepted that HPV integration occurs through a succession of events. First DNA 
damage occurs to the host and viral DNA, followed by DNA repair mechanisms that insert the 
HPV DNA in to the genome. Selection of a cell containing integrated HPV forms an 
immortalised cell that multiplies clonally and progresses to invasive cancer; all of which will be 
explained in subsequent sections.  
1.1.5.1.1 Chromosomal fragile sites 
Fragile sites (FS) are regions of genomic instability that are visible as gaps and breaks on 
metaphase chromosomes due to partial inhibition of DNA synthesis. FS have been identified in 
many oncogenes, and therefore a link has been recognised between FS and cancer (Gecz et al., 
1997, Chan et al., 1994, Hansen et al., 1997). 
There are several mechanisms by which FS may induce carcinogenesis. The first describes how 
FS could directly or indirectly inactivate a gene leading to altered transcripts. The second 
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describes how FS might allow chromosomal breakage in response to DNA damaging agents 
(Sutherland et al., 1998). In the context of HPV and carcinogenesis, the latter would probably 
be most relevant. The reason why DNA at FS is more prone to breakage is still unclear. Over 
the past few decades studies have shown that HPV integration commonly occurs within 
regions of FS (Wentzensen et al., 2004).  
1.1.5.1.2 DNA damage and repair 
DNA damage occurs within the cell as a result of exposure to various endogenous and 
exogenous chemicals, UV, and ionising radiation. During the cell cycle, check points detect 
DNA damage and create a delay in response before the cell divides. Integration of HPV may be 
facilitated by non-homologous end joining. Non-homologous end joining occurs is an error 
prone DNA repair pathway that predominates when repair by homologous recombination is 
not possible. A few complementary bases are used to direct repair of the break and this 
sometimes results in small insertions of deletions at the site of repair (Shrivastav et al., 2008).  
In regard to HPV integration, and consistent with non-homologous end joining as a mechanism 
of DNA repair, overlapping sequences of homology have been detected between HPV and 
human sequence as well as small sequence insertions that are not homologous with human or 
HPV sequence, at the site of integration (Ziegert et al., 2003, Durst et al., 1987). 
1.1.5.2 Linking HPV integration with cancer 
During cancer formation, lesions usually consist of populations of several sorts of cells 
(heterogeneous) which are involved in a battle of competitive growth advantage. In HPV 
infected cells, HPV integration is considered a selective advantage to a cell, driving 
carcinogenesis.  
1.1.5.2.1 Actively transcribed HPV integrated loci 
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Transcription of HPV integration loci has been described as a late event in the progression of 
cancer, although the literature is contradictory as previously described. Integrated transcripts 
are reportedly most frequent in cervical cancer, with low levels in cervical intraepithelial 
neoplasia (Klaes et al., 1999, Vinokurova et al., 2008). Similarly, in some reports episomal 
transcripts are frequently detected in early-late grade cervical intraepithelial neoplasia (CIN I-
III), but in cancers episomal transcripts are considerably reduced (Klaes et al., 1999). This is 
significant because it might suggest that transcription of HPV integration loci confers a 
selective advantage to the cell which supports neoplastic progression to cancer.  
1.1.5.2.2 Expression of HPV oncogenes, E6 and E7 
Many studies have shown that when HPV integration occurs, parts of the HPV genome are lost, 
which results in disruption to E1, E2, E4 and E5 ORFs, however E6 and E7 ORF are retained 
(Matsukura et al., 1986, Pater et al., 1986). Expression of oncogenes E6 and E7 are detected at 
higher levels in HPV integrated cells, and through the molecular interactions previously 
described, increased production of E6 and E7 is vital for ongoing cell proliferation and 
subsequent transformation (Romanczuk and Howley, 1992). E1 and E2 ORFs can reduce E6 
and E7 over-expression and therefore repress cell immortalisation, however due to the 
disruption of E1 or E2 ORFs upon integration, this cannot occur. This might provide a selective 
growth advantage to the cell. However, integration into the host DNA alone is not sufficient to 
drive transformation, as transcription of integrated HPV will be inhibited in cells possessing a 
mixed population of integrated and episomal HPV (Pett et al., 2006); thus loss of episomal E2 is 
thought to play a key role. 
1.1.5.2.3 Oncogenic genes of the host genome 
Integration within a gene or near a gene that has oncogenic properties might disrupt the 
function of the gene or protein and confer a selective growth advantage to the cell. It is also 
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possible that deletions near integration sites may cause disruption to human genes and 
consequently effect the expression of these genes (Thorland et al., 2003). More importantly, 
integration might occur within a gene but this might not have detrimental structural or 
functional effects (Dall et al., 2008, Ferber et al., 2003a, Ferber et al., 2003b).  
 
1.2 Vulval Intraepithelial Neoplasia (VIN) 
VIN is a premalignant condition and a precursor of vulval cancer. It can be caused by infection 
with HR HPV, which is referred to as ‘usual VIN’. VIN can also be associated with a skin 
condition called lichen sclerosus, which is referred to as ‘differentiated VIN’. Usual VIN 
accounts for approximately 80% of VIN cases, and differentiated VIN accounts for a smaller 
percentage (~20%) (van de Nieuwenhof et al., 2011). Differentiated VIN is more common in 
older women and results in differentiated keratinised squamous cell carcinoma, whereas usual 
VIN tends to progress to non-keratinising squamous cell carcinoma and occurs in younger 
women. Regression of ‘usual VIN’ to normal epithelia is common (van de Nieuwenhof et al., 
2008). The two pathways associated with usual and differentiated VIN are illustrated in Figure 
1.4. The rest of this chapter will describe usual VIN (HPV related), which will be referred to as 
VIN.  
In 1912 Bowen first described neoplastic squamous epithelial lesions and the disease was 
subsequently termed ‘Bowen’s disease (Kaufman, 1995). However, more recent classification 
of intraepithelial neoplasia by International Society for the Study of Vulvovaginal Disease 
(ISSVD) has resulted in the preferential use of VIN as terminology for this disease. 
HPV DNA was first detected in vulval lesions in 1982 and has been detected in 86.7 % of VIN 
cases worldwide (de Sanjose et al., 2013). Early studies showed that HPV 16 DNA was found to  
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Figure 1.4. Two pathways to vulval intraepithelial neoplasia (VIN) and progression to 
squamous cell carcinoma  
Adapted from (van de Nieuwenhof et al., 2008). 
 
 
  
 21 
 
be actively transcribed in multifocal and multicentric VIN lesions, suggesting a role of HPV in 
pathogenesis of VIN (van Beurden et al., 1995).  
1.2.1 Epidemiology of VIN and cancer 
In a recent report, HPV DNA was detected in 86.7% (587) of VIN cases and 28.6% (1709) 
invasive vulval cancers (de Sanjose et al., 2013). In invasive cancers, HPV 16 was found to be 
the most common type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%) (de Sanjose et 
al., 2013). In a meta-analysis by De Vuyst and colleagues, HPV infection was investigated in VIN 
1 and 2/3 (De Vuyst et al., 2009). In VIN 1, HPV 16 DNA was detected in 9.8%, and low risk HPV 
6 and 11 DNA was detected in 22.4% and 9%. In VIN 2/3, HPV16 (71.9%), 33 (8%) and 18 (5%) 
were the most frequent HPV types detected (De Vuyst et al., 2009). HPV 16 was also found to 
be the most prevalent type in a a separate meta-analysis of type distribution study of vulval 
and vaginal cancers (Smith et al., 2009).  
Usual VIN is most common in young women between the ages of 20 and 30. Since usual VIN is 
highly associated with HPV infection, the increasing prevalence of HPV and HPV related genital 
infection is thought to contribute to the increasing incidence of VIN worldwide (incidence of 
5/100, 000 women per year)(Joura, 2002). Even though the incidence of VIN is increasing, the 
relationship between incidence of VIN and vulval carcinoma is not directly proportional. 
Various factors are thought to contribute to this, for example, improved rates of diagnosis and 
treatment, and the high frequency of spontaneous disease regression. The increase in HPV 
associated VIN without similar increase in invasive vulvar carcinoma may be explained through 
the application of diagnostic vulval biopsy, and thus earlier diagnosis and treatment. 
Treatment is then likely to prevent progression of neoplastic disease to cancer (van de 
Nieuwenhof et al., 2008) (Kautman 1995).  
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1.2.2 Risk factors 
The risk factors of VIN are similar to those for HPV infection and include; age, tobacco use, 
history of genital warts, immunosuppression, and a high number of sexual partners (van de 
Nieuwenhof et al., 2008). In relation to age as a risk factor, HPV is the aetiological agent of 
disease, and is more prevalent in younger populations that are at the height of sexual activity.  
1.2.3 Histology and characterisation of VIN 
The system provided by the International Society for the Study of Vulvovaginal Diseases 
(ISSVD) is the preferred grading system for determining VIN severity, since it is capable of 
distinguishing between the type of VIN (usual or differentiated), which is not considered when 
using Bethesda classification. Prior to update by ISSVD, the grading system measured an 
approximate percentage of dysplastic cells within a cross section of differentiated epithelia 
from a punch biopsy of suspicious vulval tissue; this is consistent with the grading of CIN 
(Figure 1.3). Revised terminology in 2006 no longer characterises VIN I due to its poor 
reproducibility, although this is not universally accepted (McCluggage, 2009).  
Usual VIN lesions are easy to recognise microscopically. They demonstrate ‘wind-blown’ 
epidermis and disorganised keratinocytes with an array of nuclear abnormalities. There are 2 
types of usual VIN lesions which demonstrate thickened epidermis and hyperkeratosis, these 
are ‘warty’ (textured surface) and ‘basaloid’ (flattened surface), and both lesions can occur in 
the same region (van de Nieuwenhof et al., 2008). 
1.2.4 Clinical manifestations and symptoms 
Usual VIN primarily affects the labia majora, labia minora and posterior fourchette although it 
occasionally occurs at the mons pubis, perineal and perianal regions. Dysplastic regions appear 
raised or asymmetrical and can be discoloured (white/reddened) or pigmented (Figure 1.5). 
Between 25-66% are multicentric (lesions are present at more than one genital region) which   
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Figure 1.5. VIN 3 lesion 
The VIN 3 lesion extensively affects the labia, which is characteristically raised and discoloured. 
Taken from (Tristram and Fiander, 2005).  
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signifies the importance of cervical screening as a precaution when VIN is diagnosed (van 
Beurden et al., 1998). Additionally, more than one VIN lesion can occur in the same region 
(multifocal). Eighty one percent of VIN 3 cases were multifocal (van Beurden et al., 1995). 
The majority of patients experience pruritus, and other symptoms include pain, ulceration and 
dysurea. Significant sexual and psychological stress is associated with disease (Shylasree et al., 
2008). A substantial portion of sufferers do not have symptoms and discover vulval 
abnormalities during self-examination or examination related to cervical screening (van de 
Nieuwenhof et al., 2008). 
1.2.5 Treatment options, patient management and disease prevention 
Usually VIN is treated with surgery, although other treatments have been assessed with 
varying degrees of success (van de Nieuwenhof et al., 2008). The clinical objectives of 
treatment aim to prevent progression to invasive carcinoma, relieve symptoms, eradicate HPV 
infection, and sustain remission whilst preserving healthy normal tissue and maintaining 
genital function (van de Nieuwenhof et al., 2008). Treatment strategies that target VIN lesions 
without affecting healthy tissue are desirable, particularly through topical treatments, which 
would cause less distress to patients, can be applied easily, and reduce hospital visits.  
1.2.5.1 Surgery 
Surgery involves excision of VIN using a cold knife, diathermy or laser ablation. There are 
advantages and disadvantages for all surgical techniques and surgical success varies according 
to recurrence rates demonstrated post-surgery (Bruchim et al., 2007). The preferred route of 
surgery involves multiple local excisions over an extended time period rather than extensive 
surgery because this better preserves the remaining vulval tissue and is less significantly 
associated with physical, psychological and sexual trauma (Campion and Singer, 1987). 
Extensive, repeat surgery as a result of recurrence has the potential for genital mutilation and 
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associated morbidity. There is therefore a desire for alternative treatment options (Campion 
and Singer, 1987).  
1.2.5.2 Photodynamic therapy 
Photodynamic therapy causes cell death through the formation of highly reactive oxygen 
species; a topical photosensitizer and light of an appropriate wavelength are combined to 
destroy tissue (van de Nieuwenhof et al., 2008). 
1.2.5.3 Imiquimod 
Imiquimod (Aldara®) is an imidazoquinoline amine which acts as an immune response 
modifier. It also inhibits viral replication, thereby focusing on the cause of usual VIN (HPV) 
without having an effect on healthy vulval tissue (van de Nieuwenhof et al., 2008). Small-scale 
studies using topical applications of imiquimod have shown encouraging results (van Seters et 
al., 2008) and it is currently registered to treat genital warts 
1.2.5.4 Cidofovir 
Cidofovir is an acyclic nucleoside phosphonate and has antiviral properties against a range of 
DNA viruses. It has been clinically investigated for topical treatment of VIN (Tristram and 
Fiander, 2005), and showed promising results (described in more detail in the following 
section). The use of CDV as a topical treatment for VIN would be desirable because it would be 
less distressing for patients than surgery, and could be applied by the patient and therefore 
reduce hospital visits.  
 
1.3 Development of acyclic nucleoside phosphonates (ANPs)  
Collaboration between De Clercq and colleagues in 1976 resulted in the exploration of new 
acyclic nucleoside analogues (ANA) for use as antivirals. The first ANA, called DHPA [9-(2,3-
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dihydroxypropyl)adenine], was shown to act as an adenosine analogue and demonstrated 
inhibition of viral RNA maturation. Early ANAs were then supplanted by Acyclic Nucleoside 
Phosphonates (ANP) which have a phosphonate group chemically attached to the alkyl side 
chain of purine or pyrimidine molecules (Ballatore et al., 2001). ANPs display broad-spectrum 
antiviral activity against a range of DNA and RNA viruses as well as displaying anti-neoplastic 
activity (De Clercq, 2011). ANPs include (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine 
(HPMPA). Discovered in 1986 HPMPA was a prodrug i.e. it required metabolic activation, and 
displayed a wide spectrum of activity against DNA viruses. However HPMPA was not 
developed further, but a year later the antiviral properties of (S)-9-(3-hydroxy-2-
phosphonylmethoxypropyl) cytosine (HPMPC), also referred to as Cidofovir (CDV), were 
described (De Clercq, 2011). Similar to HPMPA, CDV is a prodrug and demonstrated antiviral 
activity against a wide range of DNA viruses (De Clercq, 2011). CDV is currently approved for 
CMV infection, but is also potentially an effective treatment option for benign and 
premalignant vulvar and extra-genital HPV lesions, including VIN (Snoeck et al., 2001, Tristram 
and Fiander, 2005). Currently, CDV is clinically approved and marketed under the branding 
Vistide®.  
1.3.1 Antiviral action of cidofovir 
The mechanism of action of CDV in CMV infections is well characterised (Xiong et al., 1997). 
CDV is a water-soluble polar molecule and is taken into cells passively by endocytosis (Van 
Pachterbeke et al., 2009). Once inside the cell, CDV undergoes two phosphorylations to yield 
the active metabolite, Cidofovir diphosphate (CDVpp), through the process illustrated in Figure 
1.6  (Cihlar and Chen, 1996). The first phosphorylation is catalysed by GMP kinase/AMP kinase 
to produce CDVp and the second by nucleoside diphosphate kinase (NDP) to produce CDVpp. 
The resulting CDVpp is referred to as the active triphosphate form, and termed ‘triphosphate’ 
since 1 phosphate comprises the phosphonate bridge prior to the first and second 
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phosphorylation events, so that 3 phosphate molecules in total are present in the active form 
of the molecule. CDVpp is structurally similar to naturally occurring nucleotides and hence acts 
as a competitive inhibitor and an alternative substrate for CMV DNA polymerase, as shown in 
Figure 1.7  (Xiong et al., 1997). CDVpp is then incorporated into a growing strand of DNA 
complimentary to dGMP; the incorporation of a second CDVpp molecule (i.e. incorporation in 
tandem) is required to inhibit DNA elongation (Xiong et al., 1997). This is related to the 
availability of the 3’ OH which aids in addition of adjacent nucleotides to the growing 
nucleotide sequence. Since classical acyclic nucleoside analogues do not exhibit the hydroxyl 
group, only one insertion into the extending nucleotide chain is required which results in 
complete termination of nucleotide elongation. CDV also produce a longer lasting viral 
response than their classical acyclic nucleoside counterparts because CDV phosphorylated 
metabolites provide a long intracellular half-life.  
1.3.2 Current clinical applications 
CDV has demonstrated activity against a broad range of DNA viruses, particularly amongst 
herpes viruses (herpes simplex virus (HSV) 1 and 2, varicella zoster virus (VZV), 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human herpesviruses 6-8) as well as 
other viruses such as pox viruses, adenovirus and HPV. It is the only licensed antiviral 
stockpiled for the therapy and short term prophylaxis of small pox (variola) and small pox 
vaccination (vaccinia) complications (De Clercq and Holy, 2005). CDV is currently licensed for 
the treatment of CMV related retinitis in AIDS patients, demonstrating antiviral activity by 
inhibiting CMV DNA synthesis within infected cells via the mechanism previously described. 
Over the past decade CDV has demonstrated significant selectivity for adenovirus infected and 
high risk (HR) HPV immortalised cell lines in vitro (Andrei et al., 1998) and shown promising 
results in a number of clinical trials involving topical and intralesion treatment of patients with 
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Figure 1.6. Illustration of phosphorylation events required to produce active cidofovir (CDV) 
Active CDV acts to competitively incorporate itself ‘in tandem’ into the growing nucleotide 
sequence which reduces the rate of viral DNA synthesis. Adapted from (De Clercq and Holy, 
2005) 
 
     
     
      
Figure 1.7. Structures of cidofovir and deoxycytidine 
(A) Structure of Cidofovir: presence of phosphonate bridge (circled red) and available 
3’hydroxyl group (circled blue) required for binding of adjacent nucleotide for nucleotide 
sequence extension during DNA synthesis. (B) Structure of deoxycytidine: normal substrate of 
DNA synthesis (cidofovir represents its analogue). 
A B 
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productive and non-productive HPV infection (Van Pachterbeke et al., 2009, Calista, 2009, 
Koonsaeng et al., 2001, Snoeck et al., 2000, Stragier et al., 2002). 
1.3.2.1 Molecular effects in HPV infected cells 
In vitro studies using CDV have demonstrated positive effects on HPV infected cells suggesting 
a potential therapeutic value and providing some molecular rationale. However, the 
mechanism of action of CDV in HPV infected cells remains elusive and is thought to differ to 
that described for CMV infection since HPV does not encode its own viral DNA polymerase. In 
one study, the molecular effects of CDV were examined at concentrations ranging from 0.5 to 
200 µg/ml (1.6 - 635 µM) over 7-8 days in several HPV positive tumour cell lines including 
CaSki, Siha and Hela (Andrei et al., 2000). Higher concentrations of CDV (> 15 µg/ml) were 
observed to result in induction of apoptosis, which was assessed by DNA fragmentation, 
caspase activation, Annexin V staining and increased levels of p53 protein.    
A study by a different group (Johnson and Gangemi, 1999) treated keratinocytes transformed 
with HPV16 E6 and E7 and untransformed controls with CDV at doses ranging from 0.1 – 2 µM 
for 14 days (with treatment 3 times per week). Under these conditions, inhibition of cell 
proliferation was noted in both transformed and untransformed cells. HPV transformed cells 
appeared to be more vulnerable to this effect, with a 95% reduction in cell counts in the 
transformed cells relative to untransformed in the 2 µM sample. The authors did not observe 
DNA fragmentation but used fluorescent cell sorting to show that cells accumulated in S phase. 
They hence interpreted CDVs action as cytostatic rather than cytotoxic. These results are 
consistent with the time and concentration dependence described in Andrei et al. (2000). The 
authors suggested that the selectivity of CDV for HPV transformed cells was due to altered 
metabolism of CDV due to modulation of cellular kinases in HPV transformed cells. This was 
confirmed by assessment of CDV anabolism using radio-labelled CDV and liquid scintillation 
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counting of HPLC fractionated cell extracts, which showed higher levels of CDVpp in HPV 
positive cells.  
Another in vitro study using cervical carcinoma and head/neck squamous cell carcinoma cell 
lines, suggested that 10 µg/ml CDV over 3-6 days could induce accumulation of p53 and pRB 
specifically through reducing the expression of E6 and E7 at the transcriptional level, although 
this effect was modest (50% reduction in E6/E7 transcripts at 3 days post treatment) and was 
based on experiments performed using semi-quantitative RT-PCR (Abdulkarim et al., 2002). 
The authors demonstrated nuclear accumulation of p53 after CDV treatment and suggested 
that reduced E6/E7 expression revived tumour suppressor pathways that regulate the cell 
cycle resulting in G2/M blockage and accumulation of HPV positive cells in S phase. There was 
no increase in apoptotic cell death and the absence of apoptosis in response to 10 µg/ml CDV 
was confirmed by TUNEL assay. In the same study, decreased expression of cyclin A 
corresponded with accumulation of cells in S-phase of the cell cycle demonstrating inhibition 
of cell proliferation. This study also suggested that combining radiation and CDV might have 
therapeutic value; irradiation may cause up-regulation of E6 and E7 expression, however in 
conjunction with CDV, radiation did not cause up-regulation of E6 and E7 expression. 
Abdulkarim and colleagues also suggested that there was a synergistic effect between CDV and 
ionising radiation and that this effect was greater in HPV positive cells. However this was based 
on a comparison of HPV positive tumour cell lines with HPV negative tumour cell lines, not on 
comparison of HPV positive tumour cell lines with non-malignant cells. 
In summary, several studies have shown that CDV results in inhibition of cell proliferation, and 
some studies report selectivity for HPV transformed cells. These results might be explained by 
a model in which, in HPV infected cells expressing E6 and E7, CDV interferes with E6/E7 at the 
transcriptional level causing down regulation of oncogenes which results in revival of protein 
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suppressor pathways (up-regulation of p53 and p21). This could encourage negative control of 
cell cycle progression and also induce apoptosis in HPV infected cells.  
More recently, CDV has demonstrated anti-metastatic action in an in vitro assay by reducing 
transcription of E6 and E7 (Amine et al., 2009). E6 and E7 positive lung carcinoma cells 
demonstrated upregulation of CXCR4 gene expression (which is implicated in the signalling 
mechanism for metastasis), which was reversed by E6/E7 knockout. CDV also demonstrated 
inhibition of Rho/ROCK signalling pathways which also contribute to tumour cell invasiveness.  
1.3.2.2 CDV toxicology 
Genotoxicity studies showed that CDV was not mutagenic in the Ames test. However, it 
showed a dose dependent clastogenic effect (i.e. results in chromosomal breaks) in human 
peripheral lymphocytes and it was clastogenic at high toxic/lethal doses in the in vivo mouse 
micronucleus assay. The product characteristics for CDV summarised by the European 
Medicines Agency states that CDV is clastogenic in vitro at 100 μg/ml (European Medicines 
Agency, 2011). 
1.3.2.3 Clinical potential of cidofovir treatment  
Several studies have demonstrated the potential use of CDV as an alternative treatment 
therapy for HPV/cancer related diseases in vivo as well as in vitro. Studies on consenting 
patients have been carried out to gain a better understanding of the effects of CDV treatment 
on lesions in vivo. A study using 1% CDV in Beeler base and 2.5 mg/mL CDV injection 
successfully treated 3 out of 4 patients presenting with diverse anatomical HPV-associated 
benign lesions that had relapsed following previous alternative treatments (Stragier et al., 
2002). 
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High risk HPV related cervical intraepithelial neoplasia (CIN) contributes significantly to 
morbidity in women, particularly as a result of cancer progression. Alternative therapies to 
surgery are attractive, since many young women with CIN want to preserve their anatomy. The 
use of topical CDV was investigated in a preliminary study including 15 CIN III patients (Snoeck 
et al., 2000). Once percent CDV gel was applied to the cervix, 3 times every other day for 1 
month after which the cervix was surgically removed and histology examined and HPV-PCR 
carried out. Complete or partial response occurred in 13/15 patients. There were no toxic 
effects and normal/uninfected epithelia remained unaffected. Similarly, topical treatment of 
CIN II and III patients with 2% CDV was carried out in a phase II, double-blind, prospective, 
placebo controlled trial (Van Pachterbeke et al., 2009). Fifty three women were randomised to 
receive topical CDV (2% gel) or placebo. Colposcopic analysis of cervical appearance after CDV 
treatment showed ulceration to infected lesions (consistent with apoptosis) but preservation 
of surrounding normal epithelia. Complete clearance of the CIN lesion was observed in 60.8% 
of the treatment arm and in 20% of patients receiving placebo. 
Positive responses to CDV have also been reported in small studies involving patients with 
usual and differentiated vulval intraepithelial neoplasia (VIN) (Calista, 2009, Koonsaeng et al., 
2001). The most significant recent study of VIN by Tristram & Fiander (Tristram and Fiander, 
2005) assessed the application of CDV (1% gel) in 12 women presenting with biopsy proven 
VIN III lesions. After written informed consent, a punch biopsy was taken for histology 
examination and HPV-PCR was performed prior to the start of treatment. Lesions were self-
treated on alternate days for 16 weeks with vulvoscopy at 4 week intervals to assess 
symptoms. At 16 weeks a clinical response, based on recorded symptoms, clinical and 
photographic evidence and HPV status/histology (via punch biopsy), was obtained. Ten of 
twelve women completed follow up; 4 demonstrated viral clearance/normal histology 
(complete regression) and 4 women partially responded (their lesions were reduced by at least 
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50%). During treatment, symptoms such as pain and ulceration were occasionally recorded 
and the study also demonstrated that infected hair follicles do not improve after topical 
treatment (Tristram and Fiander, 2005). This study demonstrated the prospective use of CDV 
for VIN therapy and justifies further investigation. The study also showed that in clinical 
practice the effects of CDV appear specific to the VIN lesion and did not cause ulceration of the 
surrounding normal tissue. Images from this pilot study are shown in Figure 1.8 (kindly 
provided by Dr Tristram). 
1.4 RT3VIN 
In areas affected by VIN, preservation of healthy tissue would be an advantage. Current 
treatment strategies such as excision surgery are invasive and sometimes mutilating. In spite 
of obvious advantages such as ease of use through self-administration and fewer hospital 
visits, there is no licensed topical treatment option for VIN (Shylasree et al., 2008). RT3VIN is a 
multi-centre randomized phase II clinical trial of topical Imiquimod and CDV in women with 
usual and differentiated high grade VIN (International Standard Randomised Controlled Trial 
Number (ISRCTN) Register, 2013). Patients were recruited to the trial from October 2009 to 
January 2013.  
Women were eligible if: they were older than 16 years of age at trial commencement; they 
agreed to using efficient contraception for the duration of the trial; they had a VIN 3 biopsy 
taken no longer than 3 months previous to entering the trial, which was ≥ 20 mm in diameter. 
Patients with perianal disease could be included but the disease must not have extended into 
the anal canal. Finally, patients had to give a three way written informed consent (for 
screening, trial and cross-over). 
Exclusion criteria of the trial included: Patients with current invasive vulval or anogenital 
carcinoma; Pregnancy, breastfeeding or patients trying to conceive; Patients who were  
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Figure 1.8. Treatment of VIN with CDV 
(A) VIN lesion before treatment, (B) VIN lesion during treatment (ulceration visible), and (C) 
post treatment (lesion cleared). Images kindly provided by Dr Tristram (School of Medicine, 
Cardiff University). 
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unresponsive to previous treatment with CDV or Imiquimod; Patients with impaired renal 
function; Patients who were unable to comply with protocol treatment; Patients who were 
undergoing treatment or had treatment in the previous 4 weeks. A total of 180 patients were 
recruited and randomized on a 1:1 basis to either CDV or Imiquimod using a Fleming single- 
stage design. Topical treatments (CDV or Imiquimod) were applied 3 times a week for up to 24 
weeks. A thin layer of CDV gel or Imiquimod cream was spread over the VIN lesion at night and 
the area was washed using aqueous cream and water the following day. Patients were advised 
to avoid contact with the treated area until the area was washed the next day. 
For the duration of the trial, regular clinical assessments were used to monitor responses. In 
addition, Response Evaluation Criteria in Solid Tumours (RECIST) assessments were made. 
These are a standardised set of published criteria to help assess when patients respond, 
stabilize, or progress during treatments (Eisenhauer et al., 2009). After 30 weeks a biopsy was 
taken from each patient to examine the histology of the lesion (even if the lesion was cleared) 
and to determine HPV status of the tissue. 
At the end of the trial, patients were assigned to one of four categories determined by their 
response to the treatment. The categories were: 
1. Complete Response (CR) – all treated lesions disappeared within the 24 weeks 
2.  Partial Response (PR) – at least a 30% decrease was seen in the pathological severity 
of the lesion 
3.  Progressive Disease (PD) – at least a 20% increase in the pathological severity of the 
lesion was seen 
4.  Stable Disease (SD) – No positive or negative change was seen in the disease state 
At the time of submission of this thesis the clinical results of the RT3VIN clinical trial were 
under analysis.  
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1.5 Experimental models of HPV associated neoplasia  
A variety of experimental models exist which facilitate development of new treatments and 
diagnostic tools, contributing to the understanding of health and disease in humans. For 
ethical reasons, potential drug therapies cannot be administered to humans without prior 
investigation using other biological model systems. After successful validation in this way, drug 
therapies can be incorporated in to a clinical trial setting. This section will summarise the 
experimental models which are currently applied in a laboratory setting, their advantages and 
disadvantages, and their link with investigation of vulval neoplastic disease.  
1.5.1 Murine models 
Laboratory mice have been used in preclinical drug tests for many years. These commonly 
consist of mouse xenografts (i.e. human tissue is introduced in to the body of an 
immunocompromised mouse for experimentation) or genetically engineered mice (i.e. genetic 
mutations associated with particular human malignancies are introduced in to the mouse for 
experimentation). Research using mice has led to advances in treating a number of human 
diseases. Mice share 99% homology with the human genome with obvious similar biological 
functions, and with the animal’s small size it provides the potential for high through-put 
studies, which makes murine models particularly appealing. Murine models have been used to 
investigate treatment strategies in a range of diseases such as cancers (Kogan, 2007, 
Meuwissen and Berns, 2005, Valkenburg and Williams, 2011), as well as inflammatory 
disorders, bacterial and viral diseases, and dysfunctions of the central nervous system, etc.  
Particularly in terms of investigating drug therapies for acute promyelocytic leukaemia (APL), 
work using mice resulted in successful treatments for a disease that was previously 
untreatable (Kogan, 2007). 
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Although murine models are used frequently in research, their relevance is still debated. 
Various studies have shown that particular drugs have worked well in murine models but have 
been unsuccessful when translated to human clinical trials (Pound et al., 2004, Hackam and 
Redelmeier, 2006, van der Worp et al., 2010, Rice, 2012). To address this uncertainty, in 2010 
the European Commission proposed investigation in to the usefulness of using mice as 
preclinical models. It was briefly concluded that murine models do not aim to fully model 
disease or disease mechanisms but rather set out to obtain specific functional information; 
murine models have previously proven effective in some cases; genetically modified mice need 
to be validated, reproducible, robust and cost-effective to be considered optimal by the 
pharmaceutical industry.   
Some studies on CDV have been conducted using mouse models (Andrei et al., 1998) using 
xenografts of cervical cancer cells (Siha) into athymic mice. Intertumoural injections of CDV 
resulted in reduced growth of tumours but topical and systemic application of CDV was 
ineffective.  
1.5.2  Cell culture models 
Cell culture refers to the removal of cells from an animal or plant and their subsequent growth 
in a favourable artificial environment, usually through aseptic methods within a laboratory 
setting.  Primary cells refer to the outgrowth of migrating cells from a piece of tissue or from 
homogenised tissue preparation (Freshney, 2005b). Primary culture refers to initial growth of 
cells after isolation from animal tissue, and after this cultures are referred to as cell lines.  
Normal cell lines (i.e. those that do not have neoplastic/oncogenic potential) replicate a 
limited number of times before becoming senescent. Other cell lines with oncogenic potential, 
as a result of spontaneous, chemical, or viral induction, or from being derived from a cancer, 
can replicate continuously; these cell lines are referred to as immortalised. The method of 
culturing cell lines is a selective process; continual replication allows cells in a culture with a 
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growth advantage to predominate, which eventually results in a cell culture containing cells 
with a high degree of homology. Clonal cell lines can be derived from cell lines by selecting 
single cells and culturing them individually so that they establish as a clonal population of cells 
(Freshney, 2005b).  
Cell culture can be used for studying cellular and molecular biology, providing insight in to the 
normal physiology and biochemistry of cells. It is also useful for assessing the cellular effects of 
drugs and other toxic compounds, as well as investigations in to diseases and disorders, 
particularly cancer. Use of cell culture for recombinant DNA technology and genetic 
manipulations are also important in the field of biotechnology.  
The major advantage of using cell culture for any application is the consistency and 
reproducibility of results that can be obtained from a population of clonal cells, particularly in 
terms of assessing response to drug treatment where a population of identical cells are 
desirable. Immortalised cells derived from tumours or transformed intentionally, grow very 
efficiently in culture and have been successfully used to investigate the biology of certain 
cancers, as well as therapeutics (Weinberg, 2013). Primary cell cultures are a good in vitro 
representation of disease because they are closely related to the tissue from which they are 
derived and give a better reflection of disease seen clinically (Burdall et al., 2003). The major 
disadvantage of primary cells is that they can be fastidious, slow growing, and may not be a 
renewable resource. 
1.5.3 HPV related VIN and VaIN cell culture models  
There are few studies in the literature describing the isolation or use of cell culture models of 
vulval or vaginal neoplastic disease, and both studies to be described were published over a 
decade ago.  The study by Hietanen et al. (Hietanen et al., 1992) describes the explantation of 
a VaIN cell line (UT-DEC-1) from HPV33 positive VaIN I tissue and a cell line (UT-DEC-2) from 
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HPV16 positive VaIN II tissue, showing that cells from early neoplastic tissue were capable of 
continual culture for 40 and 25 passages respectively; this study produced a cell culture model 
which could be used to investigate early stages of squamous cell carcinogenesis in vitro. The 
study by Schneider-maunoury et al. (Schneider-Maunoury et al., 1987) involved the use of a 
cell line (SK-v) established from a vulval biopsy infected with HPV16, specifically found to be 
integrated within the E2 and L2 ORFs. A combination of investigative models contributed to 
this study; the use of a murine model confirmed that tumours with histological features of 
vulval carcinoma in situ were induced when SK-v cells were injected in to a mouse.  Thereafter 
the SK-v cell culture model itself was used to investigate the biology of HPV integration. 
However none of the lines mentioned in these two papers appear to have lead to the insights, 
or a vast array of publications, produced by the W12 cervical line (Stanley et al., 1989).The 
majority of other studies tend to use HR HPV immortalised cell lines derived from tumours 
such as SiHa, CaSki, and HeLa to investigate HPV related anogenital disease (Johnson and 
Gangemi, 1999, Andrei et al., 1998, Andrei et al., 2000, Amine et al., 2009, De Schutter et al., 
2013, Johnson and Gangemi, 2003). The derivation and characteristics of these lines are 
described briefly, as follows:  
CaSki: HPV 16 positive (c. 600 copies at multiple sites), derived in 1977 from a small bowel 
metastases of a cervical tumour in 40 yr old Caucasian female (American Type Culture 
Collection (ATCC), 2012b).  SiHa: HPV 16 positive (single copy), derived in 1970 from a primary 
cervical tumour in a 55 yr old Asian female. Modal chromosome number = 71 (American Type 
Culture Collection (ATCC), 2012d). HeLa: HPV 18 positive, derived in 1953 from a primary 
adenocarcinoma in a 31 year old Black female. Modal chromosome number = 82 ((American 
Type Culture Collection (ATCC), 2012c). C33A: HPV negative, derived in 1964 from a primary 
cervical tumour in a 66 yr old Caucasian female (american Type Culture Collection (ATCC), 
2012a). 
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Immortalised cell lines are easily obtainable, since they are distributed widely in the 
scientific/medical research community, and their non-fastidious growth in culture makes them 
a desirable option for cell culture.  However, in terms of assessing neoplastic disease in vitro, 
there is considerable difference between neoplastic cells and tumour cells and therefore 
experimental outcomes have limited relevance to pre-cancerous disease presenting in 
patients.    
 
1.6 Transcriptome sequencing  
mRNA sequencing was performed as part of the current study. A brief introduction to the 
subject is given below. 
The transcriptome of a cell is the collection of RNA molecules that are present in a cell at a 
given time. It is a dynamic entity and is significant because it consists of the transcripts that 
generate cellular proteins, which determines the biochemical functions of the cell. The field of 
transcriptome investigation is referred to as transcriptomics.  
1.6.1 RNA sequencing of the transcriptome (RNA-seq) 
Over the past decade, microarrays have been the primary tool to investigate the 
transcriptome. More recently the use of next-generation sequencing technology has emerged 
as a potentially superior technology for obtaining quantitative expression profiles, and is 
commonly referred to as RNA-Seq. RNA-Seq is an effective method of generating precise 
measurements of transcript levels and does not limit the detection of transcripts to only those 
present on a pre-defined chip, hence both known and unknown transcripts can be 
investigated.  RNA-Seq also enables quantification of very large dynamic expression levels, 
with absolute values rather than relative values (Wang et al., 2009). 
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1.6.1.1 AB SOLID RNA-seq 
To date RNA-seq has been performed in various eukaryotic and prokaryotic organisms using 
different RNA-Seq platforms, such as Illumina IG (Nagalakshmi et al., 2008) Roche 454 Life 
Science (Emrich et al., 2007) and AB SOLiD (Cloonan et al., 2008). The RNA-Seq platform 
selected is dependent on the overall objective because each platform has slight variations in 
error rate, although all methods effectively generate transcriptome data. AB SOLiD and 
Illumina provide the lowest sequencing error rate and also offer a greater sequencing depth, 
which allows lowly expressed transcripts to be detected more easily (Metzker, 2010). 
1.6.1.2 Genome wide assessment of gene expression in CDV treated HPV positive cells  
There are limited studies in the literature that have investigated the transcriptomes of HPV 
infected cells that have undergone treatment with CDV. One other study has previously 
examined the transcriptional response to CDV using genome wide technology. This was a study 
by De Schutter and colleagues which examined SiHa (HPV16+), HeLa (HPV18+) and HaCaT (HPV 
negative) immortalized cell lines and primary human keratinocytes at 24, 48 and 72 hours post 
treatment with 50 μg/mL (159 μM) CDV using whole genome gene expression microarrays; 
validation of array data was performed using RT-qPCR (De Schutter et al., 2013). In SiHa cells, 
20 genes showed similar changes in expression in both the 48 and 72 hour samples. Expression 
was also examined in HeLa, HaCaT and normal keratinocytes at 72 hours. Only 2 genes (AOX1 
and CLIC3) were differentially expressed in all 4 cell lines. Gene ontology analysis of 
differentially expressed genes showed ‘immune response’ and ‘inflammatory response’ to be 
the only functional groupings which were significantly up-regulated in all four cell lines. 
Further functional analysis showed that HPV positive cells showed differential regulation of 
genes linked to ‘cell death of tumour cells’ following CDV treatment.  
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1.7 Chapter introductions 
There is a distinct lack of literature surrounding the effects of CDV using a relevant in vitro 
model of VIN. The overall aim of the study was to isolate, characterise and make use of a series 
of novel VIN/VaIN short term cultures to assess response to CDV treatment.   
In this project, interrelated studies were devised and presented as individual chapters. Aspects 
of each chapter are relevant to other chapters, and the results of earlier studies influenced the 
design of later studies.   
1.7.1 Chapter 3: Phenotypic characterisation of short term VIN and VaIN cell 
cultures 
The initial aim of this investigation was to derive a series of clonal cell lines from naturally 
occurring HPV16 infected heterogenous cell lines of vulval and vaginal origin. These clonal lines 
formed the basis of the entire project. The major steps involved single cell cloning and 
maintaining clonal cell lines in short-term culture. At each passage during this time, a selection 
of clonal lines were characterised in terms of cell morphology and growth rate, essentially to 
confirm the stability of the lines.  This body of work also incorporated historical data for the 
parental heterogeneous lines for growth rate comparison.  
1.7.2 Chapter 4: Preliminary cell culture and optimisation studies  
Preliminary studies are presented secondly because they formed a platform for the standard 
and consistency of cell culture work carried out throughout the rest of the project. However 
this work was actually performed before characterisation data was obtained, which is 
presented in the chapter before (3) and after (5). Preliminary studies were performed using a 
select few clonal cell lines that were the first to establish in culture (i.e. post isolation from 
parental lines).  It was important to carry out preliminary investigations before progressing to 
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fully characterising each cell line so that key parameters of cell culture could be established to 
ensure stability and usability of the cells.   
1.7.3 Chapter 5: Molecular characterisation 
This chapter linked with chapter 3, whereby clonal cell lines in short-term culture were 
characterised further at a molecular level. Techniques which had previously been optimised, 
such as Amplification of Papillomavirus Oncogene Transcripts (APOT) and Detection of 
Integrated Papillomavirus Sequences (DIPS), were used to determine the status of HPV 
infection within the different clonal cell lines to investigate whether HPV had integrated in to 
the host genome (or remained separate in the form of an episome). Relative expression of HPV 
genes was also investigated through qRT-PCR to obtain expression profiles for each clonal cell 
line and assess stability over time.   
1.7.4 Chapter 6: Optimisation of CDV dosing protocol 
There are limited and inconsistent studies in the literature describing in vitro CDV dosing 
protocols in HPV related disease; inconsistency lies at the level of the type of cell culture 
model, drug concentration and exposure, as well as the dosing protocol time-frame. This 
section of work describes the design of a dosing protocol which was performed on the novel, 
fully characterised clonal cell lines, for validation and optimisation purposes. The aim was to 
produce a final CDV dosing regime that would be used to assess response to CDV treatment in 
the following chapter (7).  
1.7.5 Chapter 7: Response to CDV in clonal cell lines 
The final CDV dosing protocol, established through the work carried out in chapter 6, was used 
on a select group of clonal cell lines and a HPV negative control cell line to investigate 
response(s) to CDV. The aim here was to identify the molecular mechanism(s) of action of CDV 
in an in vitro cell culture system which closely reflects high grade vulval and vaginal disease 
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seen clinically. Response(s) to CDV were focussed on assessing changes in cell morphology and 
gene expression profiles. The literature suggests (in a variety of HPV infected cell models, and 
dosing strategies) that CDV affects expression of E6 and E7 and may induce apoptosis. It has 
also been suggested that HPV infected cells are more sensitive to CDV compared to cells which 
do not contain HPV; these hypotheses were explored in this section of work.   
1.7.6 Chapter 8: Whole transcriptome sequencing 
Extra funding was provided to perform RNA sequencing of CDV treated and untreated clonal 
cell lines. This is the first documented description of RNA-seq on HPV16 infected vulval or 
vaginal keratinocytes. This body of work allowed the entire transcriptome to be explored, 
which avoided limiting the focus to particular gene transcripts of certain molecular pathways, 
for example, apoptosis pathways, which were stated in the current literature. Instead RNA-
sequencing provided more insight in to the action of the drug by encompassing the differences 
in all gene transcripts between treated and untreated clonal cell lines (differential gene 
expression).  Whole transcriptome sequencing also provided a means of validating the HPV 
integration and gene expression data generated in chapter 5. 
1.7.7 Central aims 
The overall aims of the project are as follows: 
1. Revive cryopreserved parental cell lines. 
2. Derive vulval and vaginal clonal cell lines from parental lines (produce a novel cell 
culture system). 
3. Maintain clonal cell lines in short-term culture (for at least 5 passages). 
4. Characterise clonal cell lines, 
i. in terms of morphology and rate of proliferation 
ii. at a molecular level (HPV integration and gene expression). 
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5. Design, validate and optimise a CDV dosing protocol using novel cell culture system.  
6. Investigate the molecular mechanism(s) of action of CDV.  
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2 Methods and Materials 
2.1 Cell lines 
A variety of cell lines were cultured during this PhD: vulval keratinocytes (PC08), vaginal 
keratinocytes (PC09), PC08 and PC09 derived clonal cell lines, 3T3 mouse fibroblasts, human 
epidermal keratinocytes (HEKn), and CaSki. Details of these cell lines will be described in this 
section. 
2.1.1 Heterogeneous keratinocyte cell lines: PC08 and PC09  
A pilot study was carried out by Dr Ned Powell and Professor Alison Fiander (HPV Research 
Group, Cardiff University) to investigate the feasibility of deriving and culturing primary cell 
lines from biopsies taken from a 46 year old female with grade III vulval intraepithelial 
neoplasia (VIN) and a 31 year old female with grade III vaginal intraepithelial neoplasia (VaIN). 
Ethical approval was obtained from South East Wales Research Ethics Committee (REC 
Reference number 08/WSE02/32), and risk reviewed by the Joint Trust/University Peer/Risk 
Review Committee with approval by Cardiff and Vale NHS Trust Research and Development 
Office. Primary cell cultures of VIN and VaIN were established via explant procedure, producing 
2 heterogeneous keratinocyte cell lines named PC08 and PC09, respectively. PC08 and PC09 
primary cells were cultured for 19 and 21 passages (p) respectively, and as a result of their long 
term replication in culture they are referred to as cell lines throughout this thesis. PC08 and 
PC09 were found to be infected with HPV16 via PCR immunoassay HPV typing, and southern 
blot revealed entirely integrated HPV at p19 for PC08, and mixed integrated concatenated HPV 
and episomal HPV at p21 for PC09.  
The pilot study confirmed the feasibility of primary culture of VIN and VaIN, and provided 2 
continuously replicating cell lines (PC08 and PC09) which formed the initial foundation for the 
research carried out as part of this investigation.  
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2.1.2 Clonal cell lines derived from PC08 and PC09 
Clonal keratinocyte cell lines were isolated from heterogeneous PC08 and PC09 cell lines. 
Clonal cell lines derived from PC08 were named M, P, and Y, and clonal cell lines derived from 
PC09 were named A-L. These clonal cell lines were fully characterised and also used as vulval 
and vaginal in vitro experimental systems for treatment with cidofovir (CDV).  
2.1.3 J2 3T3 mouse fibroblasts (3T3 feeders)  
J2 3T3 mouse fibroblasts were originally established during cultivation of mouse embryo 
fibroblasts (Todaro and Green, 1963). They will be referred to more simply as 3T3 feeder cells 
throughout this thesis. Irradiated 3T3s were used to supplement the growth of keratinocyte 
cell lines PC08, PC09, and their derivative clonal cell lines. 3T3 feeder cells were obtained from 
the University of Cambridge, as referenced in (Stanley et al., 1989) 
2.1.4 Neonatal human epidermal keratinocytes (HEKn) 
HEKn cells are derived from neonatal foreskin and are not infected with HPV. HEKn cells 
represented a Human papillomavirus (HPV) negative control for CDV dosing studies carried out 
during this PhD. HEKn cells were purchased from Life Technologies Corporation (Carlsbad, CA).  
2.1.5 CaSki  
CaSki cell line originated from a cervical cancer that developed in a 40 year old female (Pattillo 
et al., 1977) and it has since become widely distributed within the scientific and medical 
research community. Previous studies have shown that CaSki contains 600 copies of 
concatenated HPV integrated within several chromosomal sites (2, 3, 6, 7, 11, 12, 14, 20, and 
21) (Yee et al., 1985, Mincheva et al., 1987). CaSki was obtained from the American Culture 
Collection (ATCC-LGC) (Teddington, UK) and cultured within the HPV Research Group, Cardiff 
University, by Dr Dean Bryant; DNA and RNA extracts of CaSki were used as an experimental 
positive control in several experiments carried out during this investigation. 
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2.2 Cell culture  
This section will describe cell culture conditions, preparation of cell culture reagents, and the 
protocols used to culture 3T3 feeder cells, HEKn, and PC08 and PC09. Isolation of clonal cell 
lines from PC08 and PC09 will also be described.  
2.2.1 Terminology 
The following terminologies are referred to in this section and are defined according to the 
World Health Organisation (World Health Organization, 2010). 
Primary cell culture: “A culture started from cells, tissues or organs taken directly from one or 
more organisms. A primary culture may be regarded as such until it is successfully subcultured 
for the first time. It then becomes a ‘cell line’ if it can continue to be subcultured at least 
several times”.  
Cell line: “Type of cell population with defined characteristics that originates by serial 
subculture of a primary cell population that can be banked; cloning and subcloning steps may 
be used to generate a cell line. The term cell line implies that cultures from it consist of 
lineages of some of the cells originally present in the primary culture”. 
Passage: “Transfer of cells, with or without dilution, from one culture vessel to another in 
order to propagate them, and which is repeated to provide sufficient cells for the population 
process”.  
2.2.2 Cell culture conditions 
Cell culture was carried out using aseptic technique within a class II microbiology safety 
cabinet. In all instances unless otherwise stated, cultures were incubated at 37oC and 5% 
Carbon dioxide (CO2) in a humidified incubator containing Copper(II) sulphate (CuSO4) solution 
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(Sigma-Aldrich Company Ltd, Dorset, UK). Aspirated media and reagents were discarded in 
hypochlorite solution (Presept) according to manufacturer’s guidelines (Fisher Scientific).  
2.2.3 Constituents of cell culture media 
A number of reagents were required to supplement media before being used for cell culture, 
these included: cholera toxin, epidermal growth factor (EGF), hydrocortisone, L-glutamine, 
trypsin-EDTA, and penicillin/streptomycin (PS). Constituents were prepared as shown in Table 
2.1.  
2.2.4 Preparation of cell culture media 
Media used to culture specific cell lines were prepared according to the following protocols. 
2.2.4.1 PC08, PC09, and 3T3 feeder cells 
Sterile Dulbecco’s Modified Eagle’s Medium (DMEM) was used to culture 3T3 feeder cells. 
Glasgow Minimal Essential Medium (GMEM) was used to culture PC08 and PC09 (Sigma-
Aldrich Company Ltd, Dorset, UK: #G5154). DMEM and GMEM were supplemented with the 
reagents shown in Table 2.2. Frozen aliquots of reagents were thawed prior to combining with 
GMEM or DMEM. GMEM was filter sterilised after preparation using Steritop™ vacuum filter 
cups (500ml) (Millipore EMD Millipore Corporation, Billerica, MA, USA). After filter sterilising 
GMEM, EGF was added if required; a combination of GMEM without EGF (EGF-), and GMEM 
containing EGF (EGF+) was used to culture PC08 and PC09, which will be described in latter 
sections.  
Prepared DMEM and GMEM was stored at 4 oC and warmed to 37 oC using a hot water bath 
prior to being used for cell culture. 
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2.2.4.2 HEKn cells 
Sterile EpiLife® medium (Life Technologies Corporation, Carlsbad, CA) was supplemented with 
sterile Human Keratinocyte Growth Supplement (HKGS) (Life Technologies Corporation, 
Carlsbad, CA) and used to culture HEKn cells. HKGS (5 ml, 100X) was purchased containing 
0.2% v/v bovine pituitary extract (BPE), 5 µg/ml bovine insulin, 0.18 µg/ml hydrocortisone, 5 
µg/ml bovine transferrin, and 0.2 ng/ml human epidermal growth factor. 
EpiLife® medium (500ml) contained 60 µM calcium chloride, as well as various amino acids, 
trace minerals, other organic compounds and inorganic salts. Sterile EpiLife® medium (500 ml) 
was combined with 5ml of HKGS, stored at 4oC, and warmed to 37oCin a water bath prior to 
being used for cell culture.  
2.2.5 3.2.5. Phosphate buffered saline (PBS) 
PBS is an isotonic solution and was used to rinse cells. PBS (10X) was prepared using the 
compounds shown in Table 2.3 and made up in a 1 L duran to 90% volume at pH 7.4 (using 5 M 
hydrochloric acid (HCl) or Sodium hydroxide (NaOH). The solution was diluted to 1X 
concentration within 500 ml durans using deionised water and autoclaved. PBS was cooled to 
room temperature prior to being used in cell culture.  
2.2.6 Initiating cultures from cryopreserved cells 
This section will described how cell cultures previously stored in liquid nitrogen were used to 
initiate new (starter) cell cultures in the laboratory. Cryovials (Thermo Scientific, UK) 
containing 1 ml of frozen cell cultures were taken out of liquid nitrogen storage, using 
appropriate personal protective equipment, wrapped in tissue and incubated at room 
temperature until thawed.  
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Table 2.1. Compounds used to formulate reagents for preparing cell culture media   
  
Compound Preparation details 
Cholera toxin 100 nM 
(1000X) (Sigma-Aldrich 
Company Ltd, Dorset, UK) 
 
Dissolve 0.5 mg in 0.6 ml sterile water                                                                
Make up to 60 ml with Glasgow Minimal Essential Medium 
(GMEM) (Sigma)                                                                     
Aliquot in 5 ml                                                                                                            
Store at 4 oC 
EGF (from murine 
submaxillary gland) 1 µg/ml 
(100X) (Sigma)  
Dissolve 0.1 mg in 100 ml GMEM                                                                        
Aliquot in 5 ml                                                                                                              
Store at -20 oC 
Hydrocortisone 1 mg/ml 
(2000X) (Sigma)  
Dissolve 10 mg in 5 ml 100% ethanol                                                                       
Add 5 ml sterile water                                                                                           
Aliquot in 250 µl                                                                                                         
Store at -20 oC 
L-Glutamine 200 mM (100X) 
(Sigma)  
Add 10 ml GMEM to vial (200 nM)                                                                         
Store at 4 oC 
TE (5.0 g/L porcine trypsin 
and 2.0 g/L EDTA•4Na in 
0.9% sodium chloride) (10X) 
(Sigma)   
Add 100 ml to 900 ml sterile 1X PBS                                                                     
Aliquot in 5 ml                                                                                                            
Store at -20 oC                                                 
PS (100X) (Sigma)  Aliquot in 5 ml                                                                                                            
Store at -20 oC                                                                                                                                        
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3T3 feeder cells PC08 and PC09 
Constituent Volume Constituent Volume 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma-
Aldrich Company Ltd, Dorset, 
UK) 
500 ml Glasgow Minimal Essential 
Medium (GMEM) (Sigma) 
500 ml 
Penicillin/Streptomycin (PS) 
(100X) (Sigma) 
5 ml 100X PS (Sigma) 5 ml 
Foetal Calf Serum (FCS) 
(Autogen Bioclea, Witshire, 
UK) 
50 ml 
Newborn Calf Serum (NCS) 
(Autogen Bioclear Ltd, UK) 
50 ml Hydrocortisone                     
(50 µg/ml)(Sigma) 
250 µl 
Cholera toxin (Sigma) 500 µl 
  
 
 
 
L-Glutamine (200 nM) (100x) 
(Sigma)           
5 ml 
*Epidermal Growth Factor   
(EGF) (Sigma)  
1 ml per 100 
ml GMEM 
 
Table 2.2. Preparation of DMEM and GMEM used to culture 3T3 feeder cells and PC08/PC09 
cell lines, respectively  
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Compound Weight (g) 
NaCl (Fisher Scientific, UK) 
KCl (Fisher) 
Na2HPO4 (Fisher) 
KH2PO4 (Fisher) 
80 
2 
14.4 
2.4 
 
Table 2.3. Compounds used to prepare 1 L (10X) PBS 
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2.2.6.1 3T3 feeder cells 
3T3 cells were previously cryopreserved at various cell densities, generally between 5 x 105 
and 1 x 10 cells/ml, in 1 ml aliquots. When preparing starter cultures of 3T3 feeders, 1 ml 
aliquot of 3T3 feeder cells was repeat pipetted to mix and re-suspended in a 75 cm flask 
containing 25 ml DMEM. 3T3 feeder cells were maintained in culture according to the methods 
described in the following section. 
2.2.6.2 PC08 and PC09 
PC08 and PC09 cells were previously cryopreserved at 5x105-1x107 cells/ml in 1 ml aliquots. 
When preparing starter cultures of PC08/PC09, a 1 ml aliquot was repeat pipetted to mix and 
re-suspended in 5 ml EGF- GMEM within a 6 cm tissue culture (TC) dish (BD Falcon™); 8 x 105 
irradiated 3T3 feeder cells were then used to supplement PC08 and PC09 cultures. PC08 and 
PC09 cultures were maintained in culture according to the method described in the following 
section.  
2.2.6.3 Human epidermal keratinocytes, neonatal (HEKn) 
Cryovials of HEKn cells were previously cryopreserved at >5 x 105 cells/ml in 1 ml aliquots. 
When preparing starter cultures of HEKn, a 1 ml aliquot was repeat pipetted to mix and re-
suspended in 10 ml EpiLife®medium within a 25 cm flask (Sigma-Aldrich Company Ltd, Dorset, 
UK)) and incubated. HEKn were maintained in culture according to the methods described in 
the following section. 
2.2.7 Culture of 3T3 feeder cells 
This section describes the methods used to culture, harvest, and irradiate 3T3 feeder cell 
cultures, according to the protocol used in Professor Margret Stanley’s laboratories 
(Cambridge, Uk) (Stanley et al., 1989).  
 55 
 
2.2.7.1 Seeding and harvesting cultures 
3T3 starter cultures were prepared in 75 cm flasks containing 25 ml DMEM and cryopreserved 
cell stocks of 3T3s, as previously described. Cultures were incubated until ~80% confluent; 
confluence referred to the percentage area of the base of the TC dish that was covered by a 
monolayer of cells, and was concluded via microscopic analysis. At ~80% confluence, media 
was discarded and the cell monolayer rinsed several times with 10 ml PBS. Cells were 
trypsinised using 5 ml TE and incubated for 3-5 minutes, during which time cells were viewed 
at intervals under a light microscope for cell ‘rounding’. When cells within the monolayer 
appeared more rounded/defined, cells were physically detached from the base of the flask by 
tapping the flask firmly. DMEM (5 ml) was then added to neutralise TE and cell suspensions 
were transferred from the flask to a 20 ml universal container (Sterilin™, Thermo Scientific, UK) 
and centrifuged at 1,500 rpm for 5 minutes. The supernatant was discarded and the cell pellet 
re-suspended in a known volume of DMEM and a viable cell count performed as described in 
the following section.   
2.2.7.2 Viable cell counts 
A haemocytometer (Camlab, Cambridge, UK) and separate cover slip were taken out of 
hypochlorite solution, rinsed with cold running water, and allowed to dry. Condensation was 
created on the cover-slip and counting grid by breathing onto the surface of each. The cover 
slip was placed on the counting grid with pressure applied either side to ensure a good seal; 
the presence of ‘Newton’s rings’ and inability to move the glass slide when pressed using a 
fingernail demonstrated good contact between both glass surfaces.  
Trypan blue stain (Sigma-Aldrich Company Ltd, Dorset, UK) was used to assess cell viability; 
100 µl of cell suspension was mixed with 100 µl of trypan blue. The solution was repeat 
pipetted, to ensure a single cell suspension, and 10 µl dispensed carefully to the edge of the 
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cover-slip allowing capillary action to draw the suspension underneath the slip and over the 
surface of the counting grid. The counting grid was viewed under a microscope at 100x total 
magnification and a cell counter used to record the number of unstained cells within one 
square of the grid, using the method summarised in Figure 2.1 and Figure 2.2. Cells that did 
not retain blue stain were those possessing an intact cell membrane and were considered 
viable; unstained cells within the counting grid were therefore included in the viable cell count. 
Each square of the grid was 1 mm height x 1 mm width x 0.1 mm depth which represents a 
volume of (0.1 mm3 or 0.1 µl). 0.1 µl is 1/10,000th of ml, therefore the following formula was 
used to calculate the number of cells per 1 ml of suspension: 
Viable cell count x 10,000 = number cells/ml 
In order to calculate the total number of cells in a given cell suspension, the number of cells/ml 
was multiplied by the total volume of the cell suspension.  
2.2.7.3 Passaging cultures 
Passaging cultures refers to the action of harvesting cells at a particular percentage confluence 
and re-seeding fresh TC dishes with these cells in order to maintain them in culture. Once a cell 
count had been obtained for cells harvested, 2 x 106 cells were used to seed a new 175 cm flask 
containing 25 ml DMEM. Cells were maintained in culture until confluence as previously 
described, and stored for future reference in liquid nitrogen as described in the subsequent 
section. The remaining 3T3 feeder cells underwent irradiation which will be described in the 
following section.  
2.2.7.4 Irradiating cells 
3T3 feeder cells were irradiated to sufficiently prevent cellular replication but still maintain 
secretion of extracellular matrix proteins. A Caesium-137 irradiator was used to dose 3T3  
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Figure 2.1. Microscopic image of a haemocytometer counting grid 
Having undergone trypan blue staining, unstained (viable) cells were counted within the 
square (highlighted with a circle), according to the method illustrated in Figure 2.2. This image 
was available from the Health Protection Agency (HPA), cell culture protocols.  
 
 
Figure 2.2. Overview of the cell counting technique carried out using a haemocytometer 
Cell counts were performed within the central square of a haemocytometer counting grid 
according to the principle illustrated which ensured accurate and consistent viable cell counts. 
This cell counting method was available from the Health Protection Agency (HPA), cell culture 
protocols (http://www.phe-culturecollections.org.uk/technical/ccp/cellcounting.aspx).  
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feeder cell suspensions with ionising radiation so that cells absorbed the equivalent of 60 gray 
(Gy) (time = 22 minutes). Irradiated 3T3 feeder cells were then used to supplement PC08 and 
PC09 cultures in co-culture.   
2.2.7.5 Liquid nitrogen storage 
Un-irradiated 3T3 cell suspensions with a known cell count were prepared for liquid nitrogen 
storage by centrifuging at 1,500 rpm for 5 minutes. The supernatant was discarded and cell 
pellet re-suspended in a known volume of DMEM with 5% v/v dimethyl sulphoxide (DMSO) so 
that each ml of suspension contained between 5 x 105 and 1 x 107 cells. Aliquots (1 ml) were 
prepared in appropriately labelled cryovials, stored at -80 oC for up to 48 hours within a Mr. 
Frosty™ freezing container (Thermo Scientific, UK), and then transferred to liquid nitrogen for 
long term storage.   
2.2.8 Culture of human epidermal keratinocytes neonatal (HEKn) 
This section describes the methods used to culture, passage, and harvest HEKn cell lines, 
according to the manufacturer’s guidelines (Life Technologies Corporation, Carlsbad, CA).  
2.2.8.1 Seeding and harvesting cultures 
HEKn starter cultures were prepared using cryopreserved cell stocks of HEKn in 6cm TC dishes 
containing Epilife® medium, as previously described. Cultures were incubated and media 
replenished every other day until cultures reached ~50% confluent; after this time culture 
media was replenished daily until cultures reached ~80% confluent. At 80% confluence, media 
was aspirated and cells trypsinised using 3 ml TE and incubated at room temperature for 5-10 
minutes. Cultures were viewed microscopically during incubation to inspect for cell ‘rounding’, 
when cells appeared rounded/defined TE within the dish was repeat pipetted vigorously over 
the base of the dish to physically detach HEKn cells and create a single cell suspension. Epilife® 
medium (3 ml) was added to neutralise TE and the cell suspension transferred to a labelled 
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universal container and centrifuged at 1,000 rpm for 5 minutes. The supernatant was 
discarded and the cell pellet re-suspended in a required/known volume of Epilife® medium 
and gently repeat pipette to ensure a single cell suspension. A haemocytometer was used to 
perform trypan blue viable cell counts as previously described.  
2.2.8.2 Passaging cultures 
Cultures were passaged by seeding fresh 9 cm TC dishes with 2.5 x 104 HEKn cells in 10 ml 
Epilife® medium. Cells were cultured as previously described, and stored in liquid nitrogen if 
necessary as described in the following section.  
2.2.8.3 Liquid nitrogen storage 
HEKn cell suspensions with a known cell count were prepared for liquid nitrogen storage by 
centrifuging at 1,500 rpm for 5 minutes. The supernatant was discarded and cell pellet re-
suspended in a known volume of 5% DMSO in Epilife® media so that each ml of suspension 
contained between 5 x 105 and 1 x 107 cells. Aliquots (1ml) were prepared in appropriately 
labelled cryovials, stored at -80 oC for up to 48 hours within a Mr. Frosty™ freezing container 
(Fisher Scientific, UK), and then transferred to liquid nitrogen for long term storage.   
2.2.9 Culture of heterogeneous PC08 and PC09 
This section describes the methods used to culture, passage, and harvest heterogeneous PC08 
and PC09 keratinocyte cell lines. This protocol was kindly provided by Professor Margaret 
Stanley in Cambridge University, and summarised in (Stanley et al., 1989, Freshey and 
Freshney, 2002). PC08 and PC09 were cultured to obtain sufficient cells for carrying out 
dilution cloning technique, which will be described in the subsequent section.  
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2.2.9.1 Seeding and harvesting cultures 
PC08 and PC09 starter cultures were prepared in 6 cm TC dishes containing EGF- GMEM using 
crypopreserved cell stocks of PC08 and PC09, supplemented with 8 x 105 3T3 feeders, as 
previously described. Cultures were incubated for 48 hours and replenished with EGF+ GMEM. 
Cells were viewed microscopically on a daily basis and when gaps appeared in the cell 
monolayer, cultures were replenished with 8 x 105 irradiated 3T3 feeder cells; media was 
discarded and replaced with 10 ml EGF+ media supplemented with 2 x 106 3T3 feeder cells. 
Cultures were maintained according to this method until keratinocytes reached ~80% 
confluence. When keratinocytes appeared ~80% confluent, 5 ml PBS was repeat pipetted over 
the cell monolayer to dislodge 3T3 feeder cells until 3T3 cell were no longer visible under 
microscopic examination. The remaining keratinocytes were trypsinised using 5 µl TE and 
dishes were incubated for 10-20 minutes until cells appeared ‘rounded’ when examined 
microscopically. The TE was then repeat pipetted vigorously over the base of the dish to 
physically detach keratinocytes and produce a single cell suspension. TE was neutralised by 
adding 5 ml EGF- GMEM (5 ml) and the cell suspension transferred to a labelled universal 
container and centrifuged at 1,000 rpm for 5 minutes. The supernatant was discarded and cell 
pellet re-suspended in a required/known volume of GMEM and gently repeat pipetted to 
ensure a single cell suspension. A haemocytometer was used to perform a trypan blue viable 
count of the cell suspensions, as previously described.  
2.2.9.2 Passaging cultures 
Cultures were passaged by seeding fresh 9 cm TC dishes with 10 ml EGF- GMEM seeded with 8 
x 105 PC08/PC09 keratinocytes, and ~2 x 106 3T3 feeder cells. Cultures were incubated and 
maintained as previously described; when gaps appeared in the monolayer, 9cm dishes were 
replenished with 2 x 106 3T3 feeder cells. PC08 and PC09 cultures were stored in liquid 
nitrogen if necessary, as described in the following section. 
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2.2.9.3 Liquid nitrogen storage 
Cell suspensions with a known cell count were prepared for liquid nitrogen storage by 
centrifuging at 1,500 rpm for 5 minutes. The supernatant was discarded and cell pellet re-
suspended in a known volume of FCS with 5% v/v DMSO (Autogen Bioclear, Witshire, UK) so 
that each ml of suspension contained between 5 x 105 and 1 x 107 cells. Aliquots (1ml) were 
prepared in appropriately labelled cryovials, stored at -80 oC for up to 48 hours within a Mr. 
Frosty™ freezing container (Thermo Scientific, UK), and then transferred to liquid nitrogen for 
long term storage.   
2.2.10 Deriving clonal cell lines from PC08 and PC09 
Dilution cloning was carried out to derive a selection of novel clonal cell lines from 
heterogeneous PC08 and PC09 keratinocyte cell lines. The dilution cloning protocol was 
conducted according to the method summarised for adherent cells in (Freshney, 2010).  
2.2.10.1 Serial dilution 
PC08 and PC09 keratinocyte cell suspensions were used to create a dilution series using 105, 
104, 103 and 102 cells in 5 ml EGF- GMEM within universal containers, according to Figure 2.3. 
Cultures were mixed by repeat pipetting at each step to ensure single cell suspensions, and 5 
ml of each dilution was dispensed in triplicate within 6 cm dishes and supplemented with 5 x 
105 3T3 feeder cells. Cultures were examined microscopically every 24 hours and replenished 
with EGF+ GMEM 48 hours after seeding. Cultures were viewed microscopically on a daily basis 
thereafter, and replenished with 5 ml EGF+ GMEM containing 5 x 105 3T3s feeders when gaps 
appeared in the cell monolayer, as previously described. 
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2.2.10.2 Selecting keratinocyte colonies for ring cloning. 
Colonies of keratinocytes were viewed microscopically on all dilution plates. Desirable colonies 
for ring cloning were selected when the following characteristics were visible microscopically 
which indicated that a keratinocyte colony arose from a single cell: 
1. Colony morphology appeared circular and symmetrical 
2. Colony occupied <1/4 area of 1 field-of-view at 5X magnification 
3. Colony situated >1 field-of-view distance from the location of another colony 
Colonies that grew at 103 were selected for isolation using ring cloning because colonies met 
the criteria of the characteristics previously listed. Colony positions were marked with a dot on 
the base of the TC dish using a permanent marker to identify them for ring cloning. 
2.2.10.3 Ring cloning. 
Dishes marked with colonies were prepared for ring cloning by discarding media and applying 
a sterile glass ring (Sigma-Aldrich Company Ltd, Dorset, UK) around each colony, as shown in 
Figure 2.4. In order to create a water tight seal around each glass ring, 5 ml PBS was dispensed 
in the TC dish surrounding the rings. Cells of the colony within the ring were trypsinised with 
100 µl TE and incubated for 10 minutes, then viewed microscopically for ‘rounding’. Once cells 
appeared rounded/defined, the contents of each ring was repeat pipetted to detach all of the 
cells from the base of the TC dish. Cells isolated within each ring were transferred to individual 
6 cm TC dishes; each 6 cm TC dish therefore contained a variety of clonal keratinocyte cells 
derived from PC08 and PC09. Each clonal cell line was assigned a specific identification 
comprising a letter (A-Z), the passage number, and the heterogeneous cell line (PC08 or PC09) 
from which it was derived. Clonal cell lines were maintained in 9 cm TC dishes for short-term 
culture as described in the subsequent section.  
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Figure 2.3.  Serial dilution technique 
 Stock cultures of heterogeneous PC08 and PC09 were diluted via serial dilution and plated in 
triplicate. Cultures were viewed microscopically for circular, symmetrical colonies which were 
marked for ring cloning technique.  
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Figure 2.4. Ring cloning technique  
Colonies that established on plates seeded at 103 were selected and isolated using sterile glass 
rings. Cells within each ring were trypsinised and transferred to individual 6cm TC dishes, 
resulting in the isolation and culture of a variety of clonal cell populations derived from PC08 
and PC09.  
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2.2.10.4 Clonal cell lines selected for use in this project. 
A variety of clonal cell lines were isolated from heterogeneous PC08 and PC09 during this 
investigation; each clonal cell line was found to replicate in culture at different rates. In order 
to comply with the project time-frame, and for fulfilling the objectives and investigating 
hypotheses, several of the most rapid growing clonal cell lines from PC08 and PC09 were used 
in this project.  
2.2.10.5 Short term culture of clonal cell lines. 
The most rapid growing clonal cell lines underwent short term culture (5-7 passages) according 
to the seeding, harvesting, and passaging techniques previously described for heterogeneous 
PC08 and PC09. After harvesting at each passage, 5 x 106-1 x1 07 cells were retained for DNA 
and RNA extraction as described in the following section. The slower growing clonal cell lines 
were not used for continuation in this project and were harvested and stored in liquid nitrogen 
for future reference.  
2.2.11 Calculating population doublings and doubling time  
An estimation of the growth rate of each clonal cell line was carried out during short-term 
culture by calculating population doublings (PD) and doubling time (DT). Terminology was 
obtained from World Health Organisation (WHO) (World Health Organization, 2010). PD was 
defined as an estimated measure of the total number of times the initial cell population 
doubled during one passage to 80% confluence. DT was defined as an estimated calculation of 
the mean time taken for the population of cells to double in number during culture. PD was 
calculated according to Equation 2.1, a very similar equation has been published elsewhere 
(Schaeffer, 1990). Calculation of PD and DT required the following information to be recorded 
for each passage: 
1. The number of viable  cells used to seed the dish 
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2. The number of cells harvested from each dish at ~80% confluence 
3. The time taken for each culture to reach ~80% confluence after seeding (one passage) 
The number of cells removed at ~80% confluence (NO) divided by the number of inoculated 
viable cells (Ni) represents the fold change in cell number during one passage. The fold change 
in cell number is equivalent to 2 to the power of PD (e.g. 3 population doublings for one cell = 
1 X 23 = 8 cells = 8 fold change). Mean doubling time was calculated by dividing PD by the time 
taken for each culture to reach ~80% confluence after seeding and expressed in hours. 
2.3 Nucleic acid extraction and quantification 
DNA and RNA were extracted from clonal cells that had been harvested at each passage during 
short term culture. DNA and RNA extracts were required for downstream molecular analyses 
which contributed to characterising the clonal cell lines. AllPrep DNA/RNA Mini Kit (Qiagen, 
Hilden, Germany) was used to simultaneously extract DNA and RNA according to the 
manufacturer’s instructions, as summarised in Figure 2.5.  
2.3.1 Preparing cells for extraction  
Cell suspensions of clonal cell lines were prepared during cell culture, as previously described. 
Cell suspensions containing 5 x 106-1 x 107 cells were centrifuged at 1,000 rpm for 5 minutes. 
Supernatant was poured off gently and RLT buffer containing beta-mercaptoethanol (βME) 
was added to the cell pellet depending on the number of cells present, as illustrated in Table 
2.4; 10 µl βME was required per 1 ml RLT buffer. The sample was mixed by repeat pipetting 
and transferred into cryovials for storage at -80 oC for future reference, or at 4 oC to perform 
extraction on the same day.  
RNAseZap® (Sigma-Aldrich Company Ltd, Dorset, UK) was used to spray the working area and 
equipment used in preparation for RNA extraction to destroy ubiquitous RNases which 
degrade RNA molecules. Samples were homogenised using 0.9 mm (20 gauge) needle and 
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This formula was rearranged to use PD as the subject of the formula. 
      
         
  
  
  
                
  
  
  
          
  
  
  
The base of the Log conversion was changed to the more manageable base 10. 
   
      
  
  
 
        
 
         
  
  
   
 
        
  
         
  
  
        
Equation 2.1: Equation for calculating population doublings from input and output viable cell 
numbers. 
Here, PD represents population doublings, Ni represents the number of viable cells used to 
inoculate the growth vessel and No represents the number of cells in the growth vessel at 
~80% confluence and subsequent removal. 
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syringe by aspirating and dispensing the sample repeatedly, avoiding bubble formation. The 
resulting homogenate was transferred directly to the membrane of a blue DNA spin column 
with round-bottom collection tube; sample was dispensed directly on the spin column 
membrane to prevent sample collection on the lip of the tube. The lid was closed gently to 
prevent loss of sample to the sides of the tube and centrifuged at 13,000 rpm for 30 seconds 
to allow binding of DNA to the spin column membrane. The collection tube, containing 
through-flow RNA, was retained and prepared for RNA extraction which will be described in 
the following section. 
2.3.2 RNA extraction 
Ethanol (70%) was added to RNA flow through (according to Table 2.4) and repeat pipetted 
gently to mix. A maximum volume of 700 µl of sample was transferred directly on to the 
membrane of a pink RNA spin column within a round-bottom collection tube and centrifuged 
for 15 seconds; through-flow was discarded and the collection tube re-used.  
A DNase step was then carried out to ensure absence of DNA in the sample, using DNeasy Mini 
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RW1 (350 µl) was 
added to the RNA spin column and centrifuged for 15 seconds after which through-flow was 
discarded and the collection tube re-used. A DNase mixture was then prepared by combining 
10 µl DNase with 70 µl buffer RDD (80 µl total per sample) within a sterile microcentrifuge 
tube. The solution was inverted to mix, centrifuged for a few seconds to collect the solution, 
and 80 µl dispensed directly on the RNA column membrane. The RNA spin column was 
incubated at room temperature for 15 minutes after which 350 µl RW1 was dispensed directly 
to the RNA spin column membrane and centrifuged for 15 seconds; through-flow was 
discarded and collection tube re-used.  
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Figure 2.5. Summary of DNA and RNA extraction method via Qiagen® AllPrep DNA/RNA mini 
kit 
Genomic DNA and total RNA were simultaneously purified from cell line material; DNA and 
RNA were eluted separately from one sample. Cell line material was homogenised using buffer 
provided with the kit. Firstly DNA was purified using the novel AllPrep DNA spin columns, and 
RNA purified thereafter using RNeasy mini spin columns. The extraction process involved a 
series of buffer washes and centrifugation steps resulting in RNA and DNA binding to the spin 
column membranes, which were captured during the final elution step using specific elution 
buffers. This image was available in the manufacturer’s instructions within the test kit and also 
online. 
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RLT buffer* 70% ethanol 
Cell count Volume (µl) Volume flow-through (µl) Volume ethanol (µl) 
<5 x 106 
5 x 106 - 1 x 107 
350 
600 
350 
600 
350 
600 
 
Table 2.4. Volumes of reagents involved in nucleic acid extraction  
RLT buffer was required to homogenise cell line material prior to extraction, which was 
dependent on the number of cells in the sample. Ethanol (70%) was required during RNA 
extraction and was dependent on the volume of sample through-flow. *Formulation of RLT 
buffer/βme = 10 µl βME per 1 ml RLT buffer. 
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After completing the DNase step, 500 µl RPE buffer was added directly to the spin column 
membrane and centrifuged for 15 seconds; through-flow was discarded and collection tube re-
used. This process was repeated with a 2 minute centrifugation at 13,000 rpm. The spin 
column was then carefully separated from the round-bottom tube containing through-flow 
(which was discarded) and placed into a fresh round-bottom tube. The spin column was repeat 
centrifuged for 1 minute to ensure the complete absence of through-flow and the round-
bottom collection tube was discarded and replaced with a fresh pointed collection tube. To 
elute RNA from the column membrane, 50 µl RNase-free water was added directly to the 
column membrane and centrifuged for 1 minute. RNA elution was repeated using the same 
volume of fresh RNase-free water or the existing elute.  
2.3.3 DNA extraction 
Fresh AW1 and AW2 reagents were prepared by adding 100% ethanol to each, according to 
the preparation instructions on the bottle. After preparing AW1/2, 500 µl AW1 was added 
directly to the membrane of a DNA spin column with round-bottom collection tube and 
centrifuged for 15 seconds; through-flow was discarded and collection tube re-used. AW2 (500 
µl) was added directly to the membrane of the DNA spin column and centrifuged for 2 
minutes; through-flow and collection tube were discarded and replaced with a fresh round-
bottom collection tube. The spin column was repeat centrifuged for 1 minute to ensure the 
complete absence of through-flow, and the round-bottom collection tube discarded and 
replaced with a fresh pointed collection tube. To elute DNA from the column membrane, 100 
µl EB was dispensed directly to the column membrane, incubated at room temperature for 1 
minute, and centrifuged for 1 minute. DNA elution was repeated using the same volume of 
fresh EB or the existing elute.  
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2.3.4 Nucleic acid storage  
A 5 µl aliquot of DNA and RNA extracts were prepared for immediate quantification using a 
spectrophotometer, according to the method described in the following section. The 
remaining DNA and RNA extracts were stored for future reference at -18 oC and -80 oC, 
respectively.  
2.3.5 Nucleic acid quantification 
The concentration and purity of DNA and RNA was determined using a NanoDrop™ 1000 
Spectrophotometer (NanoDrop products, Wilmington, DE, USA), according to manufacturer’s 
instructions (v3.7 user’s manual). Spectrophotometric measurements, provided a DNA and 
RNA concentration in ng/µl. The purity of DNA/RNA was assessed through the ratio of 
absorbance at 260 nm and 280 nm; a ratio of >1.8 and <2.2 was generally accepted as high 
purity RNA.  
An initialisation ‘blank’ spectral measurement was carried out to initialise the 
spectrophotometer by loading 2 µl water. To establish a new reference prior to quantifying 
DNA/RNA extracts, DNA and RNA ‘blanks’ were carried out using 2 µl of the respective 
DNA/RNA elution buffers using during nucleic extraction (EB buffer and RNase-free water). 1 
µL of DNA or RNA sample was loaded and a spectral measurement of the sample performed. 
 
2.4 Mycoplasma Detection  
A PCR-based test was used to detect Mycoplasma species (spp) in culture media retained from 
PC08, PC09, and 3T3 feeder cell cultures, at 90-100% confluence. Mycoplasma spp frequently 
contaminate cell cultures because they pass easily through filter sterilisation pores, are not 
susceptible to general cell wall targeting antibiotics (they lack a rigid cell wall structure), and 
are easily transmissible from operator to cultures and between cultures thereafter. 
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Mycoplasma spp modify the physiological aspects of the cell cultures they contaminate. Cell 
cultures were analysed prior to beginning cell culture experiments and during the period of cell 
culture (Young et al., 2010b).  
VenorGeM® Mycoplasma Detection Kit (Minerva Biolabs®, Berlin, Germany) was used to 
amplify the highly conserved 16S rRNA coding region (267 bp) from Mycoplasma species which 
are most commonly associated with contaminating cell culture systems. Amplified PCR 
products were electrophoresed and fragment sizes used to determine the presence/absence 
of Mycoplasma spp. This section will describe the method used to detect Mycoplasma 
contamination in cell cultures.  
2.4.1 Reagent preparation and rehydration 
Reagents included in the test kit were stored at 2-8 oC prior to use; Taq DNA polymerase was 
purchased separately from Minerva Biolabs® and stored at -18oC until required and on ice 
during use. Reagents were prepared according to steps 1-6 as illustrated in Table 2.5, and 
aliquotted and stored at -18 oC to avoid repeat freezing and thawing.  
2.4.2 Sample and mastermix preparation 
Media was aspirated from cell cultures at 90-100% confluence and 100 µl dispensed in sterile 
tubes. Samples were heated at 95 oC for 5 minutes using a heat block, and centrifuged for 5 
seconds at 13,000 rpm to form a pellet of cell debris. Samples were stored at 2-8 oC for PCR 
preparation immediately, or at -18 oC for future reference. The PCR master mix (MM) was then 
prepared according to Table 2.6, and stored on ice until required.  
2.4.3 PCR 
PCR tubes were labelled and 23 µl of MM dispensed in each tube followed by 2 µl of sample 
and repeat pipetted to mix. Lids were closed on tubes after mixing to prevent cross 
contamination between samples. A negative control (PCR grade water) and a positive control   
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. 
Step Lyophilised reagents Preparation details 
1 
 
 
Red cap – primer/nucleotide mix 
Yellow cap – internal control DNA 
Green cap – positive control DNA 
 
Centrifuge for 5 seconds at 13,000 rpm 
2 Red cap Add 65 µl PCR grade water (white cap) 
3 Yellow cap Add 300 µl PCR grade water (white cap) 
4 Green cap Add 300 µl PCR grade water (white cap)  
5 Red cap 
Yellow cap 
Green cap 
 
Incubate at room temperature for 5 minutes 
6 Red cap 
Yellow cap 
Green cap 
 
Vortex DNA briefly and spin for 5 seconds 
 
Table 2.5. Preparation of reagents included in VenorGeM® Mycoplasma detection Kit  
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 (‘green cap’- included in the test kit) were also prepared in the same way. PCR tubes were 
sealed tightly to prevent evapouration, loaded onto a PCR thermocycler, and PCR carried out 
for 1 cycle at 94 oC for 2 minutes, 39 cycles consisting of 94 oC for 30 seconds/55 oC for 30 
seconds/72 oC for 30 seconds, and a final hold and cool down to 4-8 oC.  
2.4.4 Agarose gel preparation and electrophoresis 
Agarose gel (1.5% w/v) was prepared using Tris/Borate/EDTA (TBE) (Life Technologies 
Corporation, Carlsbad, CA) and agarose (Life Technologies Corporation, Carlsbad, CA) 
according to Table 2.7. Molten agarose was prepared by heating agarose in a microwave until 
large bubbles formed. Molten agarose was carefully removed from the microwave with an 
oven glove and cooled slowly to 60 oC in a water bath at room temperature. Ethidium bromide 
(Sigma-Aldrich Company Ltd, Dorset, UK) was added and agarose poured into a gel plate 
containing a comb to create wells for samples. The agarose gel was left to set at room 
temperature, the comb was removed carefully when the gel had set, and the agarose gel was 
placed in to the electrophoresis tank containing 1x TBE. The first well of the gel was filled with 
10 µl 100 bp ladder (Sigma-Aldrich Company Ltd, Dorset, UK). The following wells were 
allocated for 5 µl sample PCR product combined with 5 µl loading dye (Orange G) (Sigma-
Aldrich Company Ltd, Dorset, UK) which was carefully dispensed in to each well. The voltage 
was set to 100 V for 20-30 minutes, and the gel was visualised under UV light within a 
transilluminator once electrophoresis was complete. 
2.4.5 Interpreting Results  
Amplified products were visualised within a transilluminator and band sizes determined by 
comparing with the reference ladder. The internal control DNA produced a band size of 191 bp 
on the gel which confirmed successful PCR performance. The positive control sample provided 
with the kit, produced a band size of 265-278 bp. Mycoplasma DNA within samples produced a  
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Reagent Volume n=1 (µl) 
PCR grade water 
10x reaction buffer 
Primer/nucleotide mix (red cap) 
Internal control DNA (yellow cap) 
*Polymerase (5U/μl) 
Total volume 
15.3 
2.5 
2.5 
2.5 
0.2 
23 
 
Table 2.6. Reagents required for Mycoplasma PCR mastermix  
*Polymerase was required but not included in the VenorGeM® Mycoplasma Detection Kit, and 
was purchased from Minerva Biolabs GmbH. 
 
 
Gel size  TBE volume (ml) Agarose (g) Ethidium bromide (µl) 
Small 
Medium 
Large 
100 
300 
600 
1.5 
4.5 
9 
2 
5 
10 
 
Table 2.7. Preparation of 1.5% agarose gel for electrophoresis of Mycoplasma PCR products  
 
 
Mycoplasma band size (165-278 
bp) 
Internal control band size (191 
bp) 
Interpretation 
Positive 
Negative 
Negative 
Irrelevant 
Negative 
Positive 
Mycoplasma present 
PCR inhibition 
Mycoplasma absent 
 
Table 2.8. Interpretation of PCR amplified products of Mycoplasma PCR  
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band size of 265-278 bp, which would be observed in Mycoplasma infected samples. A 
summary of band size interpretation are illustrated in Table 2.8. 
2.5 Relative gene expression  
The real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) protocol 
in use within the department of HPV Research was a modification to Roche® LightCycler 
carousel-based qRT-PCR system (Roche Applied Science, Mannheim, Germany) protocol which 
was set-up and optimised by Dr Dean Bryant. The qRT-PCR protocol was performed using 
LightCycler DNA Master SYBR Green I reagent kits and LightCycler reaction capillary tubes 
(Roche Applied Science, Mannheim, Germany) to detect PCR amplified products which were 
viewed in real-time using the LightCycler® carousel-based qRT-PCR system and associated 
software.  
qRT-PCR was carried out using RNA extracts of clonal cell lines to determine relative gene 
expression of   HPV early (E) genes, E2, E4, E5, E6, and E7, and cellular housekeeping genes, 
hypoxanthine phosphoribosyltransferase (HPRT) and TATA-box-binding protein (TBP). Relative 
HPV gene expression profiles for samples were obtained using CaSki HPV gene concentration 
standard curves (which were previously obtained by Dr Dean Bryant) and then calculating the 
relative expression ratio between HPV genes and housekeeping genes.  
Relative expression of HPV genes was carried out to characterise clonal cell lines at a molecular 
level.  
2.5.1 qRT-PCR 
This section of writing will describe the method used to perform qRT-PCR.  
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2.5.1.1 Reverse transcription polymerase chain reaction (RT-PCR) 
PCR hoods were routinely cleaned with 70% ethanol and subjected to 30 minutes UV light 
treatment before commencing. RNAseZap® (Sigma-Aldrich Company Ltd, Dorset, UK) was also 
used to spray the working area and any equipment being used when handling RNA.  
RNA extracts from clonal cell lines were subjected to RT-PCR within a designated area of the 
laboratory. RT-PCR was performed to obtain complimentary DNA (cDNA) using reagents 
provided in SuperScript III Reverse Transcriptase kit (Invitrogen, Paisley, UK) and random 
hexamer primers (Invitrogen, Paisley, UK), as shown in Table 2.9.   
Group A reagents were added to a microcentrifuge tube, heated at 65 oC for 5 minutes, and 
incubated on ice for 1 minute. An RT positive (RT+) and negative (RT-) mastermix (MM) was 
prepared using ‘group B’ reagents; each sample was prepared in duplicate using reverse 
transcriptase (RT+) and RNase free water (RT-) as an internal control for assessing the success 
of RT-PCR. ‘group B’ were combined with ’group A’ on ice and mixed by repeat pipetting. 
Samples were incubated for 5 minutes at 25 oC, 60 minutes at 50 oC, and 15 minutes at 70 oC  
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Group Reagent (n=1) 
A 
 
 
RNA sample (0.5 µg) 
1 µl random primers (200 ng) 
1 µl dNTP mix (10 mM) 
Sterile distilled water to 13 µl 
B 
 
 
4 µl 5x first strand buffer 
1 µl DTT (dithiothreitol) (0.1 M) 
1 µl RNAse-out 
*1 µl SuperScript III reverse transcriptase    
**1 µl RNase free water  
 
Table 2.9. Reagents (Group A and B) used to prepare RT mastermix  
Group A reagents were used for the initial RT step and group B reagents used in the latter step. 
*Superscript III reverse transcriptase was used in Group B reagents for preparing RT+ 
mastermix. ** RNase free water was used in Group B reagents for preparing RT- mastermix. 
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using a thermocycler. The resulting cDNA was stored at -20 oC for future reference or prepared 
immediately for real time quantitative PCR, as described in the following section. 
2.5.1.2 Real-time quantitative PCR 
The resulting cDNA was diluted 1:10 using PCR grade water. A HPV+ control sample was 
prepared using CaSki cell line DNA diluted to 1:100 using PCR grade water, and a PCR negative 
control sample prepared using PCR grade water. 
LightCycler® Capillaries were placed in LightCycler® Centrifuge Adapters within the 
LightCycler® aluminium cooling block (all from Roche Applied Science, Mannheim, Germany) in 
numerical order; the cooling block was stored at 4 oC several hours before commencing the 
protocol.  
The MM was prepared using FS DNA Master SYBR Green reagents (Roche Applied Science, 
Mannheim, Germany) and HPV specific primers or house-keeping gene primers, as illustrated 
in Table 2.10; details of forward and reverse primer sets are shown in Table 2.11.  
LightCycler® capillaries were supported in their adapters within the chilled cooling block, and 
18 µL MM and 2 µl cDNA dispensed into each capillary. Capillaries within their adapters were 
centrifuged for 3 seconds at 5k rpm to deposit the sample, and then returned to the cooling 
block in numerical order. Capillaries were taken out of adapters and stored in numerical order 
within a capillary holder and transferred to a separate laboratory to perform qPCR using 
LightCycler® quantitative real-time PCR Carousel-Based System and associated PC software.  
Capillaries were loaded into the carousel of the LightCycler® qPCR machine, and pressed down 
lightly to ensure they were fully seated. The lid was lowered gently and the specific 
programme selected using LightCycler® PC software; programme details for PCR amplification 
cycles were set according to the primer set being used (Table 2.12).  
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 Primer pair 
 
E2 E4 E5 E6 E7 HPRT TBP2 
Reagent µl per reaction 
F primer (5 µM) 2 2 2 2 2 2 2 
R primer (5 µM) 2 2 2 2 2 2 2 
*FS mix 2 2 2 2 2 2 2 
MgCl2 (25 mM) 2 1.6 1.2 1.6 2 1.6 2.4 
H20 10 10.4 10.8 10.4 10 10.4 9.6 
Template cDNA 2 2 2 2 2 2 2 
Total volume  20 20 20 20 20 20 20 
 
Table 2.10. Reagents used to prepare mastermixes of each primer set for real-time qPCR  
*FS mix was produced by adding 10 µl of reagent 1a to a full vial of defrosted reagent Ib; FS 
was stored at 4 oC within an opaque storage container for up to 1 month, according to the 
manufacturer’s instructions.  
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Primer set details 
Name 
Forward primer 
Reverse primer 
Amplified DNA 
Amplified RNA 
Reference 
Hypoxanthine guanine phosphoribosyl transferase (HPRT) 
TGACACTGGCAAAACAATGCA 
GGTCCTTTTCACCAGCAAGCT 
4982 bp (nt 133627546-133632438 of Chromosome X) 
94 bp (nt 496-589 of M31642.1) 
(Allen et al., 2008) 
Name TATA binding protein, 2nd pair of primers (TBP2) 
Forward primer TCAAACCCAGAATTGTTCTCCTTAT 
Reverse primer CCTGAATCCCTTTAGAATAGGGTAGA 
Amplified DNA 803 bp (nt 170880539-170881341 of Chromosome 6) 
Amplified RNA 122 bp (nt 1128-1224 of M55654.1) 
Reference (Minner and Poumay, 2009) 
Name 
Forward primer 
E6 
CTGCAATGTTTCAGGACCCA 
Reverse primer TCATGTATAGTTGTTTGCAGCTCTGT 
Amplified DNA/RNA 80 bp (nt 99-178 of NC001526.1) 
Reference (Wang-Johanning et al., 2002) 
Name 
Forward primer 
E7 
AAGTGTGACTCTACGCTTCGGTT 
Reverse primer GCCCATTAACAGGTCTTCCAAA 
Amplified DNA/RNA 78 bp (nt 739-816 of NC001526.1) 
Reference (Wang-Johanning et al., 2002) 
Name 
Forward primer 
E4 
AACGAAGTATCCTCTCCTGAAATTATTAG 
Reverse primer CCAAGGCGACGGCTTTG 
Amplified DNA/RNA 82 bp (nt 3362-3426 of NC001526.1) 
Reference (Roberts et al., 2008) 
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Name 
Forward primer 
E2 
TAACTGCACCAACAGGATGT 
Reverse primer TTGCATATGTCTCCATCAAACTGC 
Amplified DNA/RNA 82 bp (nt 3362-3426 of NC001526.1) 
Reference Designed in-house 
Name 
Forward primer 
E5 
CCGCTGCTTTTGTCTGTGTC 
Reverse primer GCAGAGGCTGCTGTTATCCA 
Amplified DNA/RNA 82 bp (nt 3362-3426 of NC001526.1) 
Reference Designed in-house 
 
Table 2.11. Details of qPCR primer sets used and gene products amplified   
M31642.1 = GenBank accession no. Homo sapiens HPRT mRNA.  M55654.1 = GenBank 
accession no.  Homo sapiens TBP2 mRNA. NC001526.1 = GenBank accession no.: HPV 16. 
 
 
 
Temperature (°C) Time (s) Cycles 
Initial denaturation 95 600 1 
Denaturation 95 10 
 
  
Primer annealing 58/60/62* 5 60 
Extension 72 5   
 
Temperature (°C) Rate of change (°C/s) Cycles 
Melting curve 65-95 0.1 1 
 
Table 2.12. Details of qPCR conditions for each primer set . 
Details are provided for both the qPCR reaction and the melting curve. *Annealing 
temperatures were primer pair specific. E5/E4 (58 °C), E2/E6/HPRT/TBP (60 °C) and E7 (62 °C). 
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2.5.1.3 Data analysis 
Relative expression of HPV genes was determined by quantifying clonal cell line cDNA using 
LightCycler® software and analysing data through qbasePLUS (Biogazelle Zwijnaarde, Belgium) 
according to the manufacturer’s instructions, and documented in the literature (Hellemans et 
al., 2007); absolute quantification of HPV gene expression was not performed. Data 
manipulation and analysis was carried out using qbasePLUS because this function was limited in 
LightCycler® software.  
Real-time PCR using LightCycler® system provided a Ct value (cycle threshold) translating to 
the number of cycles required for fluorescent signal to accumulate to a level where it 
intersects with the threshold (exceeds the background signal). Thresholds were calculated 
automatically in the LightCycler® software using second derivative maximum.  
HPV genes and cellular house-keeping gene concentrations were imported in to qbasePLUS 
software and used to calculate the ratio between HPV genes and cellular housekeeping genes 
to establish relative gene quantifications within each sample. Expression ratios were calculated 
using CaSki as a calibrator sample, such that expression ratios are expressed relative to CaSki 
RNA. 
 
2.6 HPV Integration Analysis 
Molecular techniques used to investigate HPV16 integration status in cell line material were 
previously optimised by Dr Rachel Raybould within the department of HPV Research.  
This section describes the protocols used to detect integrated HPV in clonal cell lines through 
two different molecular techniques. Detection of transcriptionally active HPV integrations in 
clonal cell line RNA extracts was performed using amplification of papillomavirus oncogene 
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transcripts (APOT) assay, a reverse transcription PCR-based amplification method (Klaes et al., 
1999). Detection of genomic HPV integrations in clonal cell line DNA was performed using 
detection of integrated papillomavirus sequences (DIPS) assay, an adapter ligation PCR method 
(Luft et al., 2001).  
HPV integration status was investigated to characterise clonal cell lines at a molecular level.  
2.6.1 APOT assay 
2.6.1.1 Reverse transcription polymerase chain reaction (RT-PCR)  
Clonal cell line RNA samples were subjected to RT-PCR to obtain complimentary DNA (cDNA) 
using the reagents illustrated in Table 2.13; details of primer sequences used in RT-PCR step 
and at other steps throughout APOT protocol are shown in Table 2.14.  
PCR hoods were cleaned with 70% ethanol and subjected to 30 minutes UV light treatment 
before commencing the protocol. RNAseZap® (Sigma-Aldrich Company Ltd, Dorset, UK) was 
used to spray the working area and any equipment being used when handling RNA.  
Microfuge tubes (Sigma-Aldrich Company Ltd, Dorset, UK) were set-up in duplicate for samples 
to represent a RT+ (reverse transcriptase) and RT- (RNase free water) version of each sample; 
this was carried out as an internal control for assessing the success of RT-PCR. Group A 
reagents were dispensed in microcentrifuge tubes and 1 µg RNA sample added and repeat 
pipette to mix. Samples were heated to 70 oC for 10 minutes using a thermocycler, and then 
stored on ice for 1 minute and centrifuged for 2 seconds to collect sample. Group B reagents 
were prepared as 2 separate mastermixes (MM) representing an RT+ MM and an RT- MM; RT+ 
MM contained 1 µl (200 units) of   Superscript™ II Reverse Transcriptase (Invitrogen, Paisley, 
UK), which was added last and stored on ice, and RT- MM contained 1 µl RNase free water. A 
total volume of 7 µl RT+ MM was added to each RT+ sample; this was repeated using RT- MM  
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Group Reagent Volume (μl) (n=1) 
A (dT)17-p3 primer (500 ng/µl) 
10mM dNTP 
Total volume 
1 
1 
2 
B First strand buffer 
DTT  
SuperScript II RT* 
RNase free water** 
Total volume 
4 
2 
1 
1 
8 
 
Table 2.13. Reagents used in APOT RT-PCR to obtain cDNA  
Group A reagents were prepared initially and added to RNA samples (in duplicate). Group B 
reagents were prepared in duplicate to account for an RT+ mastermix (*) and an RT- 
mastermix (**).  
 
 
Protocol Primer name Sequence 
APOT 
 
HPV 16-p1 forward 
HPV 16-p2 forward 
p3 reverse 
(dT)17-p3 reverse 
CGGACAGAGCCCATTACAAT 
CTTTTTGTTGCAAGTGTGACTCTACG 
GACTCGAGTCGACATCG 
GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT 
 
Table 2.14. Details of primer sequences used in APOT protocol 
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for RT- samples. Samples were incubated at 42 oC for 2 minutes, repeat pipetted to mix, and -
incubated at 42 oC for 1 hour, followed by 70 oC for 15minutes. The resulting cDNA was stored 
at -20 oC for future reference, or prepared immediately for primary PCR as described in the 
following section. 
2.6.1.2 Primary PCR 
The resulting cDNA samples were dispensed in 1µl aliquots in labelled microfuge tubes. A 
HPV+ control was included which consisted of CaSki cell line DNA diluted to 1:100 using sterile 
water, and a PCR negative control consisting of PCR grade water.  
Primary PCR mastermix (MM) was prepared in a microfuge tube as shown in Table 2.15. Each 
cDNA sample was combined with 24 µl MM and mixed by repeat pipetting. Taq was stored on 
ice and added last. Tubes were sealed using adhesive film (Fisher) and primary PCR carried out 
according to the conditions illustrated in Table 2.16. Primary PCR products were prepared 
immediately for nested PCR, as described in the following section. 
2.6.1.3 Nested PCR 
The resulting PCR products were dispensed in 5 µl aliquots within labelled microfuge tubes. 
Nested PCR mastermix (MM) was prepared in a microfuge tube as shown in Table 2.17; Taq 
was added last and was stored on ice prior to use. Samples were combined with 45 µl MM and 
mixed by repeat pipetting. Tubes were sealed with adhesive film and nested PCR carried out 
according the conditions illustrated in Table 2.18. The resulting nested PCR products were 
stored at 4-20 oC for future reference, or prepared immediately for gel electrophoresis as 
described in the subsequent section. 
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Reagent Concentration Volume (μl) (n=1) 
10X buffer 
dNTP 
MgCl2 
F HPV16-p1 
p3 reverse 
Taq polymerase 
Water 
Total volume 
 
10 mM 
50 mM 
10 uM 
10 uM 
5 U/µl 
 
2.5 
0.5 
0.75 
0.5 
0.5 
0.2 
19.05 
24 
 
Table 2.15. Reagents used to prepare APOT primary PCR mastermix  
 
 
Temperature (oC) Time (seconds) 
94 
94 
61 
72 
72 
180  
30  
120          30 cycles 
120  
600 
 
Table 2.16. Conditions for APOT primary PCR 
Conditions for APOT originated from the literature (Klaes et al. 1999) and were optimised 
previously by Dr Rachel Raybould during her research studies.  
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Reagent Concentration Volume (μl) (n=1) 
10X buffer 
dNTP 
MgCl2 
F HPV16-p2 
(dT)17-p3 
reverse 
Taq polymerase 
Water* 
Total volume 
 
25 mM 
25 mM 
10 uM 
10 uM 
5 U/µl 
 
5 
1 
5 
5 
5 
0.2 
23.8 
50 
 
Table 2.17. Reagents used to prepare APOT nested PCR mastermix  
* Mastermix was made up to 45 µl with water. 
 
 
APOT Temperature (oC) Time (seconds) 
Nested PCR 
 
 
 
94 
94 
67 
72 
72 
180 
30  
120        30 cycles 
120  
600 
 
Table 2.18. Conditions for APOT nested PCR 
Conditions for APOT originated from the literature (Klaes et al. 1999) and were optimised 
previously by Dr Rachel Raybould during her research studies.  
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2.6.2  DIPS assay 
2.6.2.1 Genomic DNA digestion    
Clonal cell line DNA samples underwent a digestion step to fragment DNA; DNA samples were 
prepared in duplicate to account for digestion by two restriction endonuclease enzymes, TaqI 
and Sau3AI. A HPV+ control was included using CaSki cell line DNA diluted to 1:100 wIth sterile 
water, and a PCR negative control was included using PCR grade water.  
DNA samples (1.2 µg) in duplicate were added to tubes and made up with PCR grade water to 
a total volume of 17.3 µl (for TaqI digestion), and 15.3 µl (for Sau3AI digestion).  TaqI and 
Sau3AI mastermixes (MM) were then prepared according to Table 2.19, and 4.7 µl Sau3AI 
mastermix or 2.7 µl TaqI mastermix, were combined with samples. Samples were sealed using 
adhesive film, incubated at 37 oC for 15 hours and then heat inactivated at 65 oC for 20 
minutes (Sau3AI digestion), or 80 oC for 20 minutes ( TaqI digestion). Products of digestion 
were prepared for ligation, as described in the following section. 
2.6.2.2 Preparation of TaqI and Sau3AI specific adapters 
 TaqI and Sau3AI specific adapters (25 µM) were prepared in microfuge tubes using the 
reagents shown in Table 2.20, details of adapters and primers are illustrated in Table 2.21. 
Adapter mixes were cooled from 90 oC to 4 oC over a 16 hour period using a thermocycler, and 
aliquots were stored at -20 oC. 
2.6.2.3 Ligation 
The resulting sample digestion products were dispensed in 20µl aliquots in labelled 
microcentrifuge tubes and stored on ice.  TaqI and Sau3AI mastermixes (MM) were made up 
separately in microfuge tubes according to Table 2.22, and 4µl of TaqI or Sau3I MM were   
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Mastermix Reagent Concentration Volume (μl) (n=1) 
Sau3AI 
 
 
 
Sau3AI 
Sau3AI buffer 
BSA 
Total volume 
10 U 
10X 
100X 
2.5 
2 
0.2 
4.7 
 TaqI  TaqI 
 TaqI buffer 
BSA 
Total volume 
10 U 
10X 
100X 
0.5 
2 
0.2 
2.7 
 
Table 2.19. DIPS reagents used in Sau3AI and  TaqI genomic digestion 
 
 
 
Reagent Concentration Volume (μl) 
ALI primer 
AS primer ( TaqI or Sau3AI) 
Sterile TrisHCl (pH 7.4) 
Total volume 
100µM 
100µM 
66mM 
 
25 
25 
50 
100 
 
Table 2.20. Reagents used to prepare TaqI and Sau3AI specific ligation adapters 
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 Abbreviations sequence 
DIPS control* 
(primers and 
adapters) 
DIPS_CON_1 
DIPS_CON_2 
DIPS_AP1 
TTCTCTATGTGCGTTCTCTCCCTG 
CAAACTCCAGGTCTCCAACCAG 
GGCCATCAGTCAGCAGTCGTAG 
DIPS (adapters) 
 
DIPS_AL1 
DIPS_AS Taq 
DIPS_AS SauAI 
GGGCCATCAGTCAGCAGTCGTAGCCCGGATCCAGACTTACAC
GTTG 
PO4-CGCAACGTGTAAGTCTG-NH2    
PO4-GATCCAACGTGTAAGTCTG-NH2    
DIPS** (linear 
amplification 
primers) 
 
 
 
 
 
 
DIPS_PCR1_16F1 
DIPS_PCR1_16F2 
DIPS_PCR1_16F3 
DIPS_PCR1_16F4 
DIPS_PCR1_16F5 
DIPS_PCR1_16F6 
DIPS_PCR1_16F7 
DIPS_PCR1_16F8 
ACAAAGCACACACGTAGACATCG 
AGTAATAAATCAACGTGTTGCGATTG 
TTTGGTTACAACCATTAGCAGATGC 
GTGCCAACACTGGCTGTTCAAAG 
TACCAATTCTACTGTACCTAATGCCAG 
ACTTATTGGGGTCAGGTAAATGTATTC 
AGTAGATATGGCAGCACATAATGAC 
GTTGGCAAGCAGTGCAGGTCAG 
DIPS** (nested 
PCR primers) 
DIPS_PCR2_16F1 
DIPS_PCR2_16F2 
DIPS_PCR2_16F3 
DIPS_PCR2_16F4 
DIPS_PCR2_16F5 
DIPS_PCR2_16F6 
DIPS_PCR2_16F7 
DIPS_PCR2_16F8 
CGTACTTTGGAAGACCTGTTAATGG 
GGACTTACACCCAGTATAGCTGACAG 
AATAGGTATGTTAGATGATGCTACAG 
ACAAGCAATGAACTGCAACTAACG 
GAGGTTAATGCTGGCCTATGTAAAG 
CCCTGTATTGTAATCCTGATACTTTAGG 
TGCGTGCTAGTATACAACAACAGTAAC 
TTAAACCATAGTTGCTGACATAGAAC 
 
Table 2.21. Details of primer and adapter sequences used in DIPS.  
* In control experiment, DIPS_CON_1 was used in linear PCR and DIPS_CON_2 used in nested 
PCR. ** In linear and nested PCR, 8 different sets of HPV specific primers were required to span 
the HPV16 genome; each primer was used in a separate PCR reaction.  
 
 93 
 
 
Mastermix Reagent Concentration Volumeμl (n=1) 
Sau3AI 
 
 
 
Ligase buffer 
T4 Ligase (NEB) 
Sau3AI adapter* 
Water 
Total volume 
10X 
400 U/μl 
 
 
2.4 
1 
0.48 
0.12 
4 
 TaqI Ligase buffer 
T4 Ligase (NEB) 
 TaqI adapter* 
Water 
Total volume 
10X 
400 U/μl 
 
2.4 
1 
0.48 
0.12 
4 
 
Table 2.22. DIPS reagents used in Sau3AI and  TaqI ligation reaction 
*Mastermix contained a TaqI and Sau3AI adapter final concentration of 50pmol. 
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added to each corresponding TaqI or Sau3I sample digestion product and repeat pipetted 
gently to mix. Tubes were sealed withadhesive film and the ligation reaction performed at 
room temperature for 2 hours followed by heat inactivation of ligase at 65oC for 10 minutes. 
The resulting sample ligation product was then made-up to a total volume of 40μl by adding 
16µl of sterile PCR grade water. Samples were prepared for DIPS linear amplification, as 
described in the following section. 
2.6.2.4 DIPS linear amplification 
A 1.4kb genomic loci on chromosome 21 (accession no. AP001068) was amplified using the 
ligation product of each sample to ensure DIPS assay was performing correctly. This was 
carried out using the control primers illustrated in Table 2.21 for control DIPS linear 
amplification and nested PCR steps, and then repeated using HPV16 specific primers also 
illustrated in the same table.  
PCR plates consisting of 96 microfuge wells were used to prepare samples for linear 
amplification. Plates were labelled with the sample and primer set being used and 2µl sample 
ligation product was added to wells of the plate in duplicate (accouting for sample ligation 
products derived from both TaqI and SauA3I digestions). This was set up 8 times (8 primer sets 
were required to analyse each sample product) for both TaqI and Sau3AI ligation products 
(therefore 16 in total); primer sets are shown in Table 2.21. Mastermixes (MM) were made up 
individually in microfuge tubes for each primer set as illustrated in Table 2.23; Hot Star Taq 
(Qiagen, Hilden, Germany) was added last and stored on ice. Sample ligation products were 
combined with 23µl MM and mixed gently by repeat pipetting. Plates were sealed and linear 
amplification carried out in the post PCR laboratory using a thermocycler according to the 
conditions shown in Table 2.24. The resulting linear amplification products were maintained at 
4oC in the post PCR laboratory to prevent cross contamination.  
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Mastermix Reagent Concentration Volumeμl (n=1) 
Linear PCR 
 
 
10X buffer + 15mM MgCl2 
dNTPs 
HPV_PCR1_16 (1-8)* 
Hot Star Taq 
Water 
Total volume 
1X 
10 mM (each) 
10 μM 
1 U 
2.5 
0.5 
0.5 
0.125 
19.375 
23 
Nested 
PCR 
10X buffer + 15mM MgCl2 
dNTPs 
HPV_PCR2_16 (1-8)* 
Hot Star Taq 
AP1 primer 
Water 
Total volume 
1x 
10 mM (each) 
10 μM 
1 U 
10 μM 
2.5 
0.5 
1 
0.125 
1 
17.875 
23 
 
Table 2.23. Reagents used to prepare DIPS linear and nested PCR mastermix  
*HPV specific primers used in linear and nested PCR are illustrated in Table 2.21, and were 
prepared in individual mastermixes for separate reactions.  
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DIPS Temperature (oC) Time (s) 
Linear 
amplification 
 
 
 
95 
94 
66 
72 
72 
900 
30  
30           40 cycles 
180 
420  
Nested PCR 
 
 
 
 
95 
94 
66 
72 
72 
900  
30  
30      30 cycles 
180  
420 
 
Table 2.24. Conditions for DIPS linear and nested PCR. 
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2.6.2.5  DIPS nested PCR 
Within the main laboratory, PCR plates were labelled and divided as described previously for 
linear amplification. Nested PCR mastermixes (MM) were set up individually in microfuge 
tubes according to Table 2.23, using 8 primer sets previously illustrated in Table 2.21; Hot Start 
Taq was combined with the MM last. MM (23µL) was added to the corresponding microfuge 
well of the plate and sealed using adhesive film. PCR plates were transferred to the post PCR 
laboratory and 5µl of linear amplification product for each sample was added to corresponding 
wells of the plate. Plates were resealed firmly, placed in a thermocycler, and nested PCR 
performed according to the conditions in Table 2.24. Nested PCR products were stored at at -
20oC for future reference, or prepared immediately for gel electrophoresis as described in the 
subsequent section.  
2.6.3 Identifying amplified products of DIPS and APOT  
Two gel staining and visualisation methods were utilised to detect PCR products from APOT 
and DIPS. The first method involved the addition of Ethidium Bromide (EB) (Sigma-Aldrich 
Company Ltd, Dorset, UK) directly to molten agarose containing 1X Tris-borate-EDTA (TBE) 
(Geneflow Ltd,Lichfield, UK); EB gels identified DNA bands by visualising gels under UV light 
within a transilluminator, which required the use of personal protective equipment due to the 
toxic nature of EB. The second method involved the addition of BlueView (TAE with methylene 
blue) (Sigma-Aldrich Company Ltd, Dorset, UK) directly to molten agarose containing distilled 
water, and DNA bands were visualised by the naked eye.  
Sample DNA was electrophoresed simultaneously on ethidium bromide and BlueView gels so 
that the resulting DNA band patterns could be compared. Band patterns were visualised 
initially on EB gels because band images were more enhanced under UV light exposure, and 
were used as a reference to compare with band patterns viewable on BlueView gels. Bands of 
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interest were then excised from BlueView gels rather than EB gels because exposure of DNA to 
UV light during visualisation of EB gels could adversely affect DNA, making it unsuitable for 
down-stream purification, sequencing and analysis.  
2.6.4 Gel electrophoresis: APOT amplified products 
This section of writing will describe the preparation of EB and BlueView agarose gels for 
electrophoresis of APOT derived PCR products; these protocols share a high degree of 
similarity with the protocols carried out to prepare gels for electrophoresis of DIPS derived PCR 
products, and for some parts will be referenced back to this section. 
2.6.4.1 . Preparation of ethidium bromide (EB) agarose gel 
EB gel at 1.2% w/v agarose was prepared for separating APOT PCR products using the reagents 
illustrated in Table 2.25. 
EB gels were made up in 500ml durans by dissolving agarose (Life Technologies Corporation, 
Carlsbad, CA) in 1X TBE using a microwave on full power until agarose appeared clear, froth 
disappeared, and large bubbles formed. Durans were placed in a water bath at 60 oC to reduce 
molten agarose temperature (without allowing agarose to set), after which EB was added 
carefully and swirled gently to mix. A gel plate was prepared by sealing the perimeter of the 
plate with autoclave tape and a comb fitted to produce wells within the gel. Agarose was 
gently swirled to avoid generating bubbles, poured into the gel plate, and left to cool and 
solidify on the bench top. Once the gel had solidified, combs and autoclave tape was carefully 
removed and the gel was placed in a gel tank containing 1X TBE in preparation for 
electrophoresis, which will be described in subsequent sections.   
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2.6.4.2 Preparation of BlueView agarose gel 
BlueView gels were prepared at 1.2% w/v agarose as shown in Table 2.25, via the same 
method described previously for EB gels. However, agarose was dissolved in distilled water by 
making up to 90% of the volume and the remaining 10% made up with 10X BlueView when 
agarose was molten. The solidified BlueView gel was placed in a gel tank containing 1X 
BlueView solution in preparation for electrophoresis, which will be described in the following 
section.  
2.6.4.3 Electrophoresis 
A 100bp ladder (Geneflow Ltd, Lichfield, UK) (10 µl) was loaded in to the first well of the gel as 
a reference for DNA band sizes. Nested PCR product (5 µl) was combined with 10µl loading dye 
(Orange G, Sigma) and loaded into a well of the gel. The voltage was set to 150 and 
electrophoresis carried out for half an hour (small gel) or for 1 hour (large gel). EB gel bands 
were visualised under UV light within a transilluminator; a snapshot of the band patterns were 
printed and saved. The corresponding BlueView gel bands were visualised with the naked eye 
and compared with band patterns present on the EB gel.  
2.6.4.4 Analysis of band patterns 
DNA band patterns were examined on both gels, and DNA band sizes between 250 bp and 
1050 bp were selected on BlueView gels; these DNA fragments represented possible HPV-
human fused sequences and underwent DNA purification, sequencing and analysis, which will 
be described in subsequent sections. DNA bands visualised at 250 bp and 1050 bp were 
avoided; 250 bp bands were generated due to mis-aanealing of the oligo(dT)17 primer to an 
adenosine rich region of the HPV genome, and 1050 bp bands represented episomal derived 
HPV transcripts.  
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Gel size TBE/distilled water* (ml)  Agarose (g) Ethidium bromide (µl) 10X BlueView (ml) 
Small 
Medium 
Large 
100 
300 
600 
1.2 
3.6 
7.2 
2 
5 
10 
10 
30 
60 
 
Table 2.25. Preparation of 1.2% w/v agarose gel required for separating APOT and DIPS PCR 
products via electrophoresis  
*BlueView agarose gels were prepared to 90% of the volume using distilled water and the 
remaining 10% made up with 10X BlueView after molten agarose had cooled enough to handle 
safely.  
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2.6.5 Gel electrophoresis: DIPS amplified products 
2.6.5.1 Prepartion of EB and BlueView agarose gel 
EB and BlueView agarose gels were prepared as described previously for APOT amplified 
products (Table 2.25) except that EB and BlueView gels were prepared at 2% w/v agarose 
using the reagents. 
2.6.5.2 Electrophoresis 
Electrophoresis of DIPS nested PCR products was carried out as described previously for APOT 
nested PCR products.  
2.6.6 DNA purification and elution 
Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare) was used to purify and 
concentrate DNA from PCR BlueView agarose gels.  
DNA bands selected for purification were counted and the corresponding number of 1.5 ml 
DNase-free tubes were weighed and recorded. A sterile scalpel was used to cut DNA bands 
from agarose and each slice placed in individual tubes of known weight; a new scalpel was 
used for each band slice to prevent cross contamination between samples. Tubes containing 
agarose slices were reweighed, and the weight of the agarose was calculated by subtracting 
the initial weight of the tube from the combined weight of the tube and the agarose slice. 
Capture buffer 3 (10 µl) was added per 10mg of agarose slice; if the gel slice weighed less than 
300 mg, 300 µl capture buffer 3 was added. Samples were mixed by gently inverting tubes, and 
incubated at 60 oC in a hot water bath for 15-30 minutes; samples were mixed by inversion 
every 3 minutes until the agarose appeared completely dissolved. Sample mixtures were 
visualised for a yellow/pale orange colour change, which ensured that the mix was at optimal 
pH for efficient DNA binding to the silica membrane of the GFX MicroSpin columns. Tubes 
were them centrifuged briefly for sample collection. GFX MicroSpin columns were set-up 
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within round bottom collection tubes for each sample and a maximum volume of 800µl sample 
mixture dispensed in each column. Columns were incubated at room temperature for 1 
minute, centrifuged at 16,000 x g for 30 seconds, flow through discarded, and collection tube 
reused; this process was repeated until all of the sample mixtures had been loaded, incubated, 
and centrifuged. Wash buffer 1 (500 µl) was added to each column and centrifuged at 16,000 x 
g for 30 seconds after which collection tubes were discarded and columns added to fresh 1.5 
ml DNase-free pointed bottom collection tubes. Between 10 and 50 µl of elution buffer 6 was 
added to the centre of the GFX MicroSpin membrane and incubated at room temperature for 
1 minute. Samples were then centrifuged at 16,000 x g for 1 minute to elute purified DNA. 
Purified DNA was prepared immediately for sequencing or stored at -20 oC for future 
reference.  
2.6.7 Sequencing and analysis 
The approximate concentration of purified DNA for each sample was estimated by comparison 
with a standard of known concentration included during electrophoresis. Samples were 
labelled and prepared to be sent for sequencing at the Sequencing Core, Cardiff University 
School of Biosciences; 200ng DNA in a total volume of 20µl was required, therefore sample 
DNA was diluted to 10ng/µl and a total of 20µl dispensed in DNase free microfuge tubes. DNA 
was sequenced using BigDye (Applied Biosystems,Foster city, CA) chemistry on an ABI 3130xl 
using primers previously used to carry out nested PCR (Table 2.21).  
2.6.7.1 Assessing sequence data quality  
DNA sequences for each sample were obtained from the Sequencing Core in a Microsoft Word 
file. Sequence data was imported into BioEdit Sequence Alignment Ibis Biosciences  
An Abbott company, Carlsbad, CA) and used to check the quality of the sequence data. 
Nucleotide bases were represented in capital letters, and uncalled bases were represented 
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with the letter ‘N’. Uncalled bases were compared with the frequency histogram produced 
automatically within the software and corrected in edit mode by manually replacing with the 
correct base in lower-case letters; samples containing numerous uncalled bases suggested 
poor quality sequence and were highlighted for reference. The entire sequence was saved, 
copied, and pasted into Notepad in FASTA format.  
2.6.7.2  Bioinformatics  
The algorithm BLAST (a Basic Local Alignment Search Tool) was used to compare the sequence 
to a list of sequences in the GenBank database maintained by NCBI (the National Centre for 
Biotechnology Information). In this instance it was used to align the DNA sequence obtained 
for each sample against the HPV16 reference genome and the human reference genome. This 
provided a way of identifying HPV and human fused sequences within the sample sequence, in 
order to detect integrated HPV within the human genome.  
BLAT (the BLAST-Like Alignment Tool) is an alignment tool like BLAST but works by storing an 
index of an entire genome and comparing the sequence input to this, rather than a set of 
GenBank sequences (which occurs for BLAST). In this instance, BLAT was used to analyse 
sequences found to contain HPV fused to human genome, and research the location of the 
HPV sequence within the human genome. Sequences were pasted in to the data base and the 
region of HPV and the location of integration was obtained.  
2.6.8 Primer design  
Clonal cell lines containing HPV-human fused sequences were re-explored in order to verify 
the presence of integrated HPV in samples. Primers were designed to specifically flank the 
HPV-human boundary at integration sites, and were used to interrogate samples to confirm 
that the integration events previously detected were genuine. Cross examination of samples 
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was also performed to identify whether integration loci were shared between clonal cell lines 
or whether they were unique to individual clones.  
2.6.8.1 Designing flanking primers  
PRIMER 3 was used to design primers that flank the site of HPV integration in clonal cell lines. 
Clonal cell line DNA sequences were entered in to PRIMER 3, and a variety of forward and 
reverse primer sequences (complimentary to the fused HPV-human sequence input) were 
generated. Flanking primers are illustrated in Table 2.26; primers were purchased from Sigma-
Aldrich Company Ltd, Dorset, UK.  
2.6.8.2 Rehydration and preparation of flanking primers 
Lyophilised primers were diluted according to the manufacturer’s instructions using sterile 
DNase free water to produce a 100 µM solution; 50 µl aliquots were stored at -80 oC and 
diluted to 5 µM using DNase free water when required for use.  
2.6.8.3 Touch-down PCR 
The designed flanking primers were used to interrogate the corresponding cDNA or DNA from 
which they were initially detectable. Each primer set was also used to cross-test other clonal 
cell line cDNA or DNA. Touch-down PCR was used as a one-step method for obtaining optimal 
amplification of products by varying the annealing temperature with progressive cycles to 
increase the specificity of the PCR product and prevent non-specific priming.  
Mastermix (MM) was prepared for each primer set as shown in Table 2.27; Hot-start Taq 
(Qiagen, Hilden, Germany) was stored on ice and added to the MM last. Sample cDNA/DNA at 
50 ng/µl and 15 µl MM was added to microfuge tubes and a touch-down PCR performed 
according to the conditions in.  
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Protocol Primer name Sequence 
APOT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIPS 
5D forward 
5D reverse  
11D1 forward 
11D1 reverse 
11D2 forward 
11D2 reverse 
5H forward 
5H reverse 
11H1 forward 
11H1 reverse 
11H2 forward 
11H2 reverse 
5M1 forward 
5M1 reverse 
5M2 forward 
5M2 reverse 
5M3 forward 
5M3 reverse 
5M4 forward 
5M4 reverse 
9Y forward 
9Y reverse  
13Y1 forward 
13Y1 reverse 
13Y2 forward 
13Y2 reverse 
5D forward 
5D reverse 
11D forward 
11D reverse 
5H forward 
5H reverse 
11H forward 
11H reverse 
11H1 forward 
11H1 reverse 
5M1 forward 
5M1 reverse 
5M2 forward 
5M2 reverse 
5M3 forward 
5M3 reverse 
5M4 forward 
5M4 reverse 
5M n.c. forward 
5M n.c. reverse 
5P n.c. forward 
5P n.c. reverse 
9Y forward 
9Y reverse 
13Y forward 
13Y reverse 
GCTCACACAAAGGACGGATT 
AGTGTGGAGAGGAAGACACCA 
CCATAGTACATTTAAAAGGTGATGC 
TGCCTGTATTTTTCTGGAAGG 
GCTCACACAAAGGACGGATT 
AGTGTGGAGAGGAAGACACCA 
AATTGTGTGCCCCATCTGTT  
TCATGAGGCTGAAGGAGGTT 
CACCGAAGAAACACAGACGA 
CAGAAAGCAAAAACACCAAGC 
CCTGTTAATGGGCACACTAGG 
TCATGAGGCTGAAGGAGGTT 
AATTGTGTGCCCCATCTGTT  
CCTCCACAGTCAAAGGGAAA 
CCTGTTAATGGGCACACTAGG 
CACAGTCTTAGCATCCATCTCTG 
AATTGTGTGCCCCATCTGTT 
ATCATGCGCCCACATTTT 
AATTGTGTGCCCCATCTGTT 
CGCCCACATTTTGGTTTTAT 
TAGGAATTGTGTGCCCCATC 
TGAGCTCATCCTCAGGGAAG  
TAGGAATTGTGTGCCCCATC 
TGAGCTCATCCTCAGGGAAG 
CCTGTTAATGGGCACACTAGG 
CACCCTCAAACACAGACTCG 
CACCTATAGATTTTCCACTACG 
ACAAGGTCGCTGCTTAGGG 
GCACCTATAGATTTTCCACTACG 
ACAAGGTCGCTGCTTAGGG 
TGAAATTTCTGCAAGGGTCTG 
CTCTCTGCCCACGGAAAATA 
TGAAATTTCTGCAAGGGTCTG 
CTCTCTGCCCACGGAAAATA 
ATGTTCATGGGGAATGGTTG 
CCTATGGGGCAGCATGATTA 
CTGCACAGGAAGCAAAACAA  
ATGTTCCAGGGAGAACAGGA 
CTGCACAGGAAGCAAAACAA  
ATGTTCCAGGGAGAACAGGA 
CTGCACAGGAAGCAAAACAA  
ATGTTCCAGGGAGAACAGGA 
CTGCACAGGAAGCAAAACAA  
ATGTTCCAGGGAGAACAGGA 
TGCCAGTACGCCTAGAGGTT 
CGTGCCAAATCCCTGTTTT 
AAGGATTGTGCAACAATGTG 
TGCACAAAATATGTTCGTATTCC 
ATGCACAATTGGCAGACACT  
ATCCCACCACGGTTGATTT 
TTTAACTGCACCAACAGGATG 
GTTGCCTCAATTCTGGGTGT 
 
Table 2.26. Details of flanking primer sequences designed via PRIMER 3 to interrogate clonal 
cell lines previously found to contain integrated HPV.  
n.c: abbreviation of non-contiguous; refers to fragmented sequences of integrated HPV.  
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Reagent Concentration Volume* (μl) (n=1) 
10x buffer 
dNTP 
MgCl2 
F primer* 
R primer* 
Hot-start Taq 
Water 
Total volume 
 
2 mM 
15 mM 
10 µM 
10 µM 
5 U/µl 
 
2 
2 
2 
2 
2 
0.2 
4.8 
15 
 
Table 2.27. Reagents used to prepare mastermix for touch-down PCR.  
*Details of F and R flanking primer sequences are referred to in Table 2.26. 
. Temperature 
(oC) 
Time (seconds) 
94 
94 
66-1 oC/cycle* 
72 
94 
55 
72 
72 
180 
30  
30         30 cycles 
60  
30 
30         30 cycles 
60 
600 
 
Table 2.28. Conditions for touch-down PCR.  
*The temperature for annealing in the first cycle was 5-10 oC above the melting temperature 
(Tm) of the primers (Tm values provided by Sigma-Aldrich). In the cycles thereafter, the 
annealing temperature was decreased in stages by 1 oC until the final temperature fell 2-5 oC 
below the Tm of the primers.  
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2.6.8.4 Gel electrophoresis and interpretation of results 
Touch-down PCR products were separated on a 2% w/v EB agarose gel, which was prepared as 
shown previously in Table 2.25, and electrophoresis was carried out as previously described. 
The DNA band patterns produced were analysed; to confirm amplification of the HPV-human 
integration loci, a single band would be observed for each sample with a size that correlated 
with the number of base pairs in the initial sequence of interest indicating that the selected 
sequence had been amplified. 
 
2.7 Cidofovir (CDV) dosing studies 
Cell culture and drug/compound optimisation experiments were performed to develop a CDV 
dosing protocol; optimisation experiments were carried out in collaboration with Miss Áine 
Flynn, HPV Research Group, Cardiff University. The final dosing protocol entailed treating 
vulval and vaginal clonal cell lines with cidofovir (CDV) under optimised conditions; CDV was 
purchased from Shanghai Sun-Sail Pharmaceutical Science & Technology Corporation Limited 
(Shanghai, China).  
This section describes the optimisation protocols carried out and the final CDV dosing protocol 
produced. The overall aim of the dosing regime was to assess cellular and molecular 
response(s) to CDV treatment and therefore give insight in to the mechanism(s) of action of 
CDV in VIN/VaIN disease.  
2.7.1 Preparation of CDV 
2.7.1.1 CDV assessment and formulation 
Compound verification and assessment of purity was performed by Davide Carta, Fabrizio 
Pertusati, and Karen Hinsinger (McGuigan Group, Cardiff University, Welsh School of 
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Pharmacy) using nuclear magnetic resonance (NMR). Synthesis of CDV was also carried out by 
the McGuigan Group according to the procedure outlined in the literature (Kern et al., 2002).  
Prior to preparing concentrations of CDV, stock CDV underwent repeat vortexing and warming 
to disperse the consistency and turbidity of the compound; this was carried out after verbal 
communication with colleagues of the McGuigan Group.  
2.7.2 Optimisation studies 
Optimisation studies were carried out to determine optimal experimental variables that would 
comprise the final CDV dosing protocol. This section describes the optimisation experiments 
carried out.  
2.7.2.1 CDV concentration and cell density: 96 well plates 
PC08 and PC09 clonal cell lines were cultured with irradiated 3T3 feeder cells in two 9cm TC 
dishes until ~80% confluent. Cultures were then passaged and trypan blue viable cell counts 
performed using a haemocytometer, as previously described.  Single cell suspensions were 
used to seed three 96 well plates with 5,000, 7,000, and 10,000 cells/well in triplicate using 
EGF- GMEM without being supplemented with irradiated 3T3 feeder cells, according to the 
format illustrated in Figure 2.6. PBS was dispensed in wells of the perimeter to prevent 
evaporation of cultures within central wells of the plate. A CDV dosing protocol was then 
carried out as illustrated in Figure 2.7. Plates were incubated for 24 hours to allow cells to 
attach to the base of each well. After 24 hours (day 1) media was aspirated gently from wells 
of plate 1, which represented an initial cell count without CDV treatment; a rubber tube 
connected to an air suction pump was used to aspirate media, taking care not to disrupt the 
cell monolayer. Aspirated media was diverted into a discard bottle containing hypochlorite 
solution (Presept). Cells were then washed with PBS and trypsinised using 5 µl TE and 
incubated for 5-10 minutes. During incubation cells were visualised  
 109 
 
 
 
 
Figure 2.6. 96 well plate format for optimisation of cell density and CDV concentration 
Wells were inoculated with 5, 000, 7, 000, and 10, 000 cells/well in triplicate which were 
subjected to different concentrations of CDV prepared in GMEM (0, 1, 10, and 100 µM) and a 
no dose control. 
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Day 1 
(24 hours) 
Strip + count 
        replenish media 
        (CDV/no dose control) 
+72 hours 
::::: 
::::: 
::::: 
::::: 
::::: 
::::: 
::::: 
::::: 
::::: 
 Day 0  
(Seed) 
1 
2 
3 
Day 4 
(96 hours) 
Day 7 
(168 hours) 
        replenish media 
       (CDV/no dose control) 
Strip + count 
        replenish media 
       (CDV/no dose control) 
Strip + count 
+72 hours 
 
Figure 2.7. Dosing regime carried out for optimisation of cell density and CDV concentration 
in 96 well plate format.  
Wells of plates 1, 2, and 3, were seeded on day 0 and incubated for 24 hours. After 24 hours 
(day 1) cells were stripped from plate 1 and cell viability assessed by performing viable cell 
counts, and the first dose of CDV applied to wells of plates 2 and 3 by replenishing with EGF+ 
GMEM supplemented with 0, 1, 10, and 100 µM CDV and incubated for 72 hours. After 72 
hours (day 4) plate 2 was stripped and cell viability assessed, and the second dose of CDV was 
applied to wells of plate 3 and incubated for 72 hours. After 72 hours (day 7) plate 3 was 
stripped and the final assessment of cell viability performed.  
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microscopically for cell rounding, and wells were repeat pipetted to physically detach cells. The 
resulting cell suspensions were transferred from each well into individual, labelled 1ml tubes 
and combined with 5 µl GMEM to neutralise TE; plate 1 was then discarded. Media was also 
aspirated and discarded from wells of plates 2 and 3 in the same way, and replenished with 
EGF+ GMEM supplemented with 0, 1, 10, and 100 µM CDV and re-incubated for 72 hours. 
After 72 hours (day 4), media was aspirated from wells of plate 2 and viable cell counts 
performed as described previously; plate 2 was then discarded. After 72 hours (day 7), media 
was aspirated from wells of plate 3 and viable cell counts performed as described previously, 
plate 3 was then discarded.  
2.7.2.2 Cell density: 6 cm TC dishes 
To cultivate sufficient cell numbers for optimising cell density in 6cm TC dishes, PC08 and PC09 
clonal cell lines were cultured with irradiated 3T3 feeder cells in four 9cm TC dishes until ~80% 
confluent. Cultures were then passaged and trypan blue viable cell counts performed as 
previously described. The resulting clonal single cell suspensions were used to seed 6cm TC 
dishes in triplicate with 1 x 105, 5 x 105, and 1 x 106 cells (nine 6 cm TC dishes in total) using 
EGF- GMEM, without supplementing with 3T3 feeder cells. Cultures were replenished with 
EGF+ GMEM at 24 hours (day 1), viewed microscopically to analyse cell/colony morphology 
and assess percentage confluence, and re-incubated for an additional 72 hours. After 72 hours 
(day 4) cells were viewed microscopically to analyse cell/colony morphology and assess 
percentage confluence for the final time.  
2.7.3  Developing the final CDV dosing protocol  
A preliminary CDV dosing protocol was designed prior to the final CDV dosing protocol to 
ensure that a dose response was detectable under the conditions. The preliminary CDV dosing 
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protocol is illustrated in Figure 2.8. After performing this protocol, the time points for 
assessing cell viability were modified and the final CDV dosing protocol was devised. 
2.7.3.1 Final CDV dosing protocol  
The final CDV dosing protocol was carried out as shown in Figure 2.9. TC dishes (A-E) were set 
up in duplicate to account for two separate down-stream applications, i. viable cell counts, and 
ii. DNA and RNA extraction. When viable cell counts had been carried out, the remaining cell 
suspensions were prepared for apoptosis analysis via flow cytometry, which will be described 
in the following section. 
To cultivate sufficient cell numbers for the dosing protocol, each PC08 and PC09 clonal cell line 
was cultured with irradiated 3T3 feeder cells in eight 9 cm TC dishes until ~80% confluent. 
Cultures were then passaged and viable cell counts performed using a haemocytometer, as 
previously described. Five 6cm TC dishes (A-E) in duplicate (10 dishes in total) were set up and 
the resulting clonal single cell suspensions of PC08 and PC09 were each used to seed dishes 
with 5 x 105 cells in 5ml of EGF- GMEM, without supplementing with 3T3 feeder cells, and 
incubated for 24 hours.  
After 24 hours incubation, cells of dish A were viewed microscopically and an initial viable cell 
count was carried out to assess cell viability using a haemocytometer as previously described; 
dish A was then discarded. The remaining cell suspensions were prepared for analysis of 
apoptosis via flow cytometry. Cells of duplicate dish A was prepared for DNA and RNA 
extraction, according to the method previously described, and then discarded. Cells of dish D 
and E were viewed microscopically, media was aspirated and replenished with 5ml EFG+ 
GMEM supplemented with 10µM CDV, and Dish D and E were incubated for 12 hours and 36 
hours respectively. Cells of dish B and C were prepared in the  
 113 
 
 
 
 
 
Figure 2.8. The preliminary CDV dosing protocol 
Dishes A-E were seeded with 5x105 cells and incubated for 24 hours. After 24 hours an initial 
cell viability reading of dish A was carried by counting viable cells using a haemocytometer; 
dishes D and E were treated with GMEM supplemented with 10µM CDV (CDV treated), and 
dishes B and C were replenished with GMEM only (no treatment). Dish B (no treatment) and D 
(CDV treated) were incubated for a further 24 hours and assessed for cell viability. Dish C (no 
treatment) and E (CDV treated) were incubated for a further 48 hours and assessed for cell 
viability.  
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Figure 2.9. The final CDV dosing protocol 
Dishes were seeded with 5x105 cells and incubated for 24 hours. After 24 hours, an initial 
reading of plate A was carried out to assess cell viability and extract DNA/RNA; plates D and E 
were treated with GMEM supplemented with 10µM CDV (CDV treated), plates B and C 
replenished with GMEM only (no treatment control), and all plates incubated for a further 12 
hours. After 12 hours, plates B (no treatment control) and D (CDV treated) were assessed for 
cell viability, and DNA/RNA extracted. After 36 hours, plates C (no treatment) and E (CDV 
treated were assessed for cell viability and DNA/RNA extracted. Nb. After cell viability counts, 
remaining cell suspensions underwent preparation for flow cytometry (apoptosis analysis).  
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same way, replenishing with 5ml EGF+ GMEM and incubating for 12 and 36 hours respectively.  
After 12 hours incubation with 10µM CDV, cells of dish B were viewed microscopically and 
prepared for a viable cell count and cell suspensions retained for flow cytometry. Cells of 
duplicate dish B were prepared for DNA and RNA extraction. Both dishes were discarded. Dish 
D cell cultures were prepared in the same way, representing 12 hours incubation without CDV 
treatment,    
After 36 hours incubation with 10µM CDV treatment, cells of dish C were viewed 
microscopically and prepared for a viable cell count and cell suspensions retained for flow 
cytometry. Cells of duplicate dish C were prepared for DNA and RNA extraction. Both dishes 
were discarded. Dish E was then prepared in the same way, representing 36 hours incubation 
without CDV treatment.  
 
2.8 Detection and quantification of apoptosis 
During the CDV dosing protocol, CDV treated and untreated cells were retained and 
underwent apoptosis analysis using annexinV-Cy5/7-aminoactinomycin D (7-AAD) staining 
(eBioscience, Incorporated, San Diego, CA.) and flow cytometry. Stained cells were analysed 
for signs of apoptosis by detecting fluorescence absorptions of AnnexinV-Cy5 and 7-AAD 
between 650-670 nm and 543-625 nm, respectively, using Accuri™ Flow Cytometer C6 (BD 
Biosciences, USA) according to the manufacturer’s instructions.  
Reagents used to prepare cells were stored on ice for the duration of the experiment. Once 
cell suspensions had been prepared, they were immediately transported on ice to Accuri™ C6 
flow cytometer (BD Biosciences, Belgium) for analysis.  
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2.8.1  Cell preparation and staining  
Clonal cell lines were were cultured and dosed with CDV according to the dosing regime 
previously described. Cells were then trypsinised, resuspended and trypan blue viable cell 
counts performed. Cells suspensions were centrifuged at 12,000 rpm for 5 minutes and 
supernatant discarded gently. The cell pellet was resuspended in 1 ml staining buffer (Life 
Technologies), transferred to a microfuge tube and re-centrifuged. 1X annexinV-Cy5 binding 
buffer (Life Technologies) containing 1/100 of stock AnnexinV-Cy5 solution (Life Technologies) 
and 1µg/ml 7-AAD (Life Technologies) was made up in 50 µl total volume and used to 
resuspend cells. Tubes were tapped gently to ensure that cells were resuspended, and 
incubated at room temperature in the dark for 5 minutes. After incubation, AnnexinV binding 
buffer containing 1µg/µl of stock AnnexinV-Cy5 solution was prepared in a total volume of 150 
µl and used to resuspend cells. Cells were centrifuged at 12, 000 rpm for 5 minutes. After 
centrifugation, cells were resuspended in 100 µl AnnexinV binding buffer containing 1 µg/µl of 
stock AnnexinV-Cy5 solution and transferred to miniFACS tubes (BD Biosciences, Belgium). 
Tubes were transferred immediately on ice for flow cytometry analysis.   
2.8.2  Flow cytometry  
The Accuri C6 flow cytometer was operated according to manufacturer’s instructions and 
laboratory standard operational procedure within the department of Haematology, Cardiff 
Univeristy, School of Medicine. Prior to running cell suspensions through the system, the 
machine was initialised and prepared for a series of washing cycles. Samples were run 
separately at medium speed until 50,000 cells had been counted; gating, speed settings and 
cell count limits were selected using the software icons. Once a sample had been processed it 
was discarded and the machine prepared for one washing cycle using water for 30 seconds; a 
30 second water rinse was carried out between samples to clean the tubes and prevent carry-
over of the previous sample. At the end of use and the machine required preparation for the 
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next user, the machine was prepared for another series of washing cycles and the machine left 
on. If the software and machinery was not required, an extended wash was performed prior to 
closing down the software and shutting off the machinery.  
2.9  Whole transcriptome sequencing and analysis 
RNA sequencing of the transcriptome is a recently developed method which enables accurate 
and complete transcript profiling of cells (Wang et al., 2009). Whole Transcriptome Analysis Kit 
was used to convert the full set of RNA transcripts expressed within a cell into a cDNA library 
for sequencing analysis on the Applied Biosystems SOLiD™ Sequencing system, as described in 
manufacturer’s instructions (Applied Biosystems, CA, USA). RNA sequencing was carried out 
out by Dr James Colley and colleagues at Wales Gene Park (Cardiff University), supported by 
additional funding from the Tom Owen Scholarship fund.  
The basic principles of SOLiD™ transcriptome sequencing comprised 3 stages, i. sample 
preparation, ii. substrate preparation, and iii. SOLiD analyser barcoding. Each stage was carried 
out as follows: 
I. Sample preparation. A mate-paired library was created by sheering sample DNA to a 
specified size and ligating adapters to the ends to produce 2 DNA fragments at a 
known distance apart in the target sample. The resultant mate-paired library 
comprised millions of unique molecules which represented the entire target sequence.  
II. Substrate preparation. Mate-paired libraries underwent emulsion PCR to hybridise 
libraries to beads; libraries were then clonally amplified. Bead enrichment was carried 
out to capture beads containing amplified library templates, which were then 
covalently attached to a glass slide. 
III. Barcoding on SOLiD™ analyser. Template beads bound to the glass slide were 
combined with universal sequencing primer, ligase, and a pool of fluorescently labelled 
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probes (4 dyes representing 4/16 dinucleotide sequences). A complimentary probe 
was hybridised to the template sequence and ligated, after which fluorescence was 
measured and the dye cleaved off for further reactions. A new primer was hybridised 
off-set by 1 base and the ligation cycle repeated; this primer reset process was 
repeated for 5 rounds to provide dual measurement of each base separated by several 
cycles, to increase sequence accuracy.  
The resultant raw sequence data underwent down-stream analysis in conjunction with Dr 
Peter Giles and Dr Kevin Ashelford at Wales Gene Park (Cardiff University), according to the 
flow chart illustrated in Figure 2.10. 
2.9.1 Statistical and data analysis  
2.9.1.1  Quality control of RNA and sequence data 
Concentration and quality of cell line RNA extracts was assessed using Nanodrop 2000 
spectrophotometer and Agilent to ensure RNA was suitable for SOLiD™ sequencing, as 
previously described. Data yield and mapping success of the resulting SOLiD™ sequence data 
was prepared for all samples to ensure transcript data quality was sufficient for down-stream 
gene expression analysis.  
2.9.1.2 Quantification of gene expression 
RPKM values (Reads per Kilobase exon Model per million mapped reads) (Mortazavi et al., 
2008) the common method for quantifying expression levels for RNA-sequence datasets, were 
calculated for individual transcripts using in-house software. To define the transcript locations 
used in the analysis, the RefSeq gene model RefGene, as provided by the UCSC human 
reference hg19 site, was used along with the gene model for HPV16 downloaded from NCBI 
(accession no: NC_001526). Integrative Genomics Viewer (IGV) was used to visualise mapped 
transcript reads to reference these reference genomes.  
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Figure 2.10. Summary of SOLiD™ sequencing and data analysis.  
Clonal cell line total RNA extracts underwent SOLiD™ Whole Transcriptome sequencing and 
the resultant raw data analysed. Raw data in the form of transcript reads underwent quality 
control (QC) to ensure data was suitable for down-stream analysis. Transcripts were then 
mapped to the human and HPV genomes; this provided an estimation of mapping yield and 
success to determine whether sequence data was suitable for further down-stream analyses. 
Sequence data was then subjected to i. gene expression analysis, and ii. differentially 
expressed gene (DEG) analysis followed by over-representation analysis (ORA) and gene 
ontology (GO). Gene expression was assessed by converting sequence data to reads per KB per 
million reads (RPKM values), the common method for quantifying gene expression in this 
instance. Transcripts were then visualised through IGV and mapped to the RefSeq gene model 
RefGene, as provided by the UCSC human reference hg19 site, along with the gene model for 
HPV16, downloaded from NCBI (NC_001526). As part of DEG analysis, corrected p-values were 
filtered for transcripts presenting with a high degree of confidence as being significantly 
different between 2 data sets. This data was filtered by FDR multiple testing correlation and a 
cut-off of p<0.05 applied. ORA GO analysis was then applied to the significantly expressed 
(p<0.05) transcripts to sort them in to different GO categories; GO ORA identified changes in 
expression for a number of genes in an ontology group and allowed a selection of genes to be 
identified as having some differential expression which all map to the same category.  
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2.9.1.3 Quality control of transcript count data  
To check any issues with the underlying transcript data distributions for each sample, the 
smallest value, lower quantile, median, upper quantile, and largest value, were calculated and 
illustrated in a box plot for easy visual representation using R statistical software. MvA plots 
were also produced using R statistical software to check samples for irregularities in transcript 
data in a pairwise comparison with other samples.  
2.9.1.4 Identification of differentially expressed genes (DEG) using edgeR  
To identify differentially expressed genes in response to CDV treatment, edgeR 
analysis (Robinson et al., 2010) was carried out on normalised transcript count data. The 
resultant p-values were corrected for multiple testing and false discovery issues using the false 
discovery rate (FDR) method (Benjamini and Hochberg, 1995). This provided a list of significant 
transcripts found to be over or under-expressed after treatment with CDV. Heat maps of 
significant transcripts were constructed using R statistical software in order to reveal patterns 
within the dataset which could be visualised more easily.  
2.9.1.5 Over representation analysis (ORA) of gene transcripts against Gene Ontology (GO) 
annotations 
GO ORA was carried out using goseq method (Young et al., 2010c) to standardise the 
representation of significant gene transcripts using a controlled vocabulary of terms. 
Transcripts were grouped into associated functions (GO ID and term) which were then 
categorised under 3 general themes, 1. Biological processes (BP), 2. Molecular functions (MF), 
and 3. Cellular component (CC). GO ORA of the top 500 significant gene transcripts was carried 
out against GO annotations and the resulting data was corrected for multiple testing and false 
discovery using the FDR method.  
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3 Phenotypic characterisation of short term vulval 
intraepithelial neoplasia (VIN) and vaginal intraepithelial 
neoplasia (VaIN) cell cultures 
3.1 Results 
Heterogeneous cell lines PC08 and PC09 were derived in a pilot study from tissue biopies of 
VIN III and VaIN III; PC08 and PC09 were cultured for 19 and 21 passages respectively. 
Cryopreserved cell stocks of early passage PC08 and PC09 were revived and used to produce a 
selection of clonal cell lines, which will be described in this Chapter. Early passage PC08 and 
PC09 were selected because they were closely related to the parental biopsy tissue from which 
they were explanted and so provide a good representation of neoplastic disease in vitro. The 
clonal cell lines were used in a series of preliminary experiments to optimise cell culture 
conditions (described in Chapter 4). Clonal cell lines also underwent short-term culture for 5-7 
passages during which time they were characterised; characterisation was carried out to 
determine whether the individual lines differed from one another and whether they were 
stable with regard to morphology, growth rates and HPV gene expression.  
This chapter describes phenotypic characterisation of early passage PC08 and PC09, and clonal 
cell lines during short-term culture; PC08 and PC09 cell culture records over 19 and 21 
passages are also included from the pilot study (kindly provided by Dr Ned Powell). Phenotypic 
characterisation refers to the observable characteristics of the cells and was carried out by 
examining cell cultures microscopically to assess cell and colony morphology (shape and 
appearance). Exploring cell and colony morphology was important because it gave an 
indication of the health of the cells, allowed an initial assessment of potential cell culture 
contaminants, and allowed differences in cell and colony characteristics to be identified among 
clonal cell lines.  
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Characterisation also included estimation of the total number of population doublings (PD) 
over the entire cell culture period, and doubling time (DT) at each passage, which were defined 
previously. Investigation of the growth characteristics was important because it accurately 
showed how robust the clonal cell lines were in culture, identified potential growth rate 
variants amongst the clonal cell lines, and also gave an indication of the health of the cells 
when linked to morphology.   
3.1.1 Aims and objectives 
The central aim was to derive a series of clonal cell lines from heterogenous (parental) cell 
lines and phenotypically characterise them during short-term culture; this comprised assessing 
morphology and growth characteristics.  
The following objectives structured this section of work: 
1. Revive crypreserved heterogenous cell lines (PC08 and PC09) and maintain for 1 
passage in culture. 
2. Isolate clonal cell lines from PC08/PC09 and maintain in short-term culture for 5-7 
passage. 
3. Assess cell and colony morphology for each clonal cell line during short-term culture. 
4. Investigate the rate of cell proliferation for each clonal cell line during short-term 
culture (through calculating doubling time (DT)). 
5. Investigate rate of cell proliferation through calculating DT in PC08 and PC09 using 
historical cell culture records. 
3.1.2 Study sample. 
Phenotypic characterisation was carried out for: 
i. Passage (P) 2 PC08 and PC09 cultures initiated from cryopreserved cell stocks at 
P1.  
 123 
 
ii. P4 clonal cell lines isolated from P3 PC08 and PC09 cultures. 
iii. Clonal cell lines (>P4) that underwent short term culture (5-7 passages). 
Growth characteristics were assessed in: 
i. A selection of clonal cell lines (>P4) during short term culture (5-7 passages). 
ii. Heterogeneous PC08 and PC09 using cell culture records originating from the 
previous pilot study (19 and 21 passages). 
3.2 Early passage PC08 and PC09 cell cultures 
3.2.1 Morphological characteristics 
Early passage heterogeneous PC08 and PC09 cell lines were fastidious in culture which was 
very challenging and labour intensive.  Initial cultures of P2 PC08 and PC09 were highly 
contaminated with dermal fibroblasts from the original biopsy tissue, as shown in Figure 3.1; 
fibroblasts originated from the biopsy tissue where they generate connective tissue in the 
dermis of the skin. Fibroblasts overpopulated both cultures quickly and were problematic 
because they restricted keratinocyte establishment and growth. During initial stages of P2 
cultures, fibroblasts were discouraged by growth with 3T3 feeder cells and were removed by 
washing vigorously with phosphate buffered saline (PBS). This did not appear to affect the 
growth of 3T3 feeder cells or keratinocytes and fibroblasts were not transferred into future 
cultures.  
PC09 established and grew quicker than PC08.  Both cell lines grew well amongst a background 
of irradiated (non-proliferating) 3T3 feeder cells, as illustrated in Figure 3.2; 3T3 feeder cells 
did not possess a characteristic cell shape and it was not difficult to distinguish between 
keratinocyte colonies and 3T3 feeder cells under microscopic examination.  Colonies of 
keratinocytes were roughly circular in shape and contained a population of polygonal 
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keratinocytes that tessellated (i.e. polygonal shaped keratinocytes covered the base of the TC 
dish in an interlocking manner, without gaps or overlapping) as shown in Figure 3.3.  
Keratinocyte colonies grew outwards as a result of peripheral cell division causing surrounding 
3T3 feeder cells to dislodge from the monolayer, forming a ‘ridge’ on the periphery of 
expanding keratinocyte colonies as illustrated in Figure 3.4.  This was also evident when 
expanding keratinocyte colonies in close proximity converged. 
3.2.1.1 Main findings 
Culturing of early passage (P2) PC08 and PC09 was labour intensive and problematic 
particularly during the initial stages of P2 cultures. PC09 appeared to establish more rapidly in 
culture than PC08. Nevertheless both heterogeneous cell lines grew in culture at early passage 
and were considered suitable for dilution cloning to isolate a selection of clonal cell lines.  
3.2.2 A selection of colony morphologies exist in early passage heterogeneous 
PC08 and PC09 cultures  
Two types of colony variants were observed in P2 PC08 and PC09 cell cultures, as illustrated in 
Figure 3.5; type 1 contained laterally growing keratinocyte cells forming ‘flat’ colonies, and 
type 2 contained differentiating keratinocyte cells forming colonies that appeared to resemble 
‘peaks’. By comparison type 2 colonies were smaller than type 1, and were more frequently 
observed at lower cell densities.  For example, post seeding where cultures approached ~40% 
confluence, type 1 colonies were predominant over type 2 colonies, and once cultures 
exceeded ~40% confluence type 1 colonies dominated cultures.  
3.2.2.1 Main findings 
Heterogeneous PC08 and PC09 early passage (P2) cell cultures comprised colonies 
representing 2 different morphological variants which appeared to be related to percentage 
confluence of the cell culture.   
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Figure 3.1. Dermal fibroblast contamination in P2 PC08 and PC09 heterogeneous cultures 
A. P2 PC09 cell culture in 6 cm TC dish and, B.  P2 PC08 cell culture in 6 cm TC dish (100x total 
magnification).  The cultures consisted of 3T3 feeder cells (blue arrow), which did not display 
characteristic cell shape, and fibroblasts (red arrow) which demonstrated elongated 
morphology.   
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Figure 3.2. Morphological characteristics of P2 PC09 and 3T3 feeder cells in culture  
A. A background of irradiated 3T3 feeder cells (50x total magnification) used to support 
keratinocyte cell cultures in 6 cm TC dish.  Irradiated 3T3s were not capable of replicating and 
did not demonstrate characteristic cell morphology.  B.  One keratinocyte colony (circled in 
red) surrounded by 3T3 feeder cells in 6 cm TC dish (50x total magnification).  Keratinocyte 
colonies were roughly circular in shape, and were easily distinguishable next to 3T3 feeder 
cells.  C.  One keratinocyte colony (circled in red) consisting of approximately 10 dividing 
keratinocyte cells (100x total magnification) with surrounding 3T3 feeder cells in 6 cm TC dish. 
D. One keratinocyte colony (circled in red) consisting of approximately 20 dividing 
keratinocytes (320x total magnification) with surrounding 3T3 feeder cells in 6 cm TC dish.   
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Figure 3.3. Characteristic morphology of P2 PC09 keratinocyte cells within a colony 
 A. Keratinocyte colonies surrounded by 3T3 feeder cells in 6 cm TC dish (50x total 
magnification). The red circle highlights an area of laterally growing keratinocytes within a 
colony which has been magnified as shown in B.  B.  Characteristic polygonal morphology and 
tessellating pattern of keratinocytes within a colony (100x total magnification).  
  
A 
 B 
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Figure 3.4. Characteristics of 3T3 feeder cells surrounding expanding keratinocyte colonies in 
P2 PC09 cultures 
A. One keratinocyte colony containing lateral keratinocytes (circled in red) in 6 cm TC dish (50x 
total magnification).  3T3 feeder cells formed a ‘ridge’ (blue arrows) on the periphery of 
expanding keratinocyte colonies, which eventually detached from the base of the dish and into 
media suspension.  B. Convergence of two lateral keratinocyte colonies (circled in red) formed 
a 3T3 feeder cell ‘ridge’ (blue arrows) in 6 cm TC dish (50x total magnification).  C. Multiple 
converging keratinocyte colonies in 6 cm TC dish; two of which were larger and contained 
lateral keratinocytes (circled in red) and two of which were considerably smaller and contained 
differentiating keratinocytes that resembled ‘peaks’ (circled in yellow) (50x total 
magnification).    
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Figure 3.5. Variation in keratinocyte colony morphology in P2 PC08 cell cultures  
An example of type 1 (circled in red) and type 2 colonies (circled in yellow) identified in PC08 
cultures in 6 cm TC dishes. Type 1 colonies contained lateral keratinocytes that appeared ‘flat’ 
and were significantly larger than ‘type 2’ colonies which contained differentiating 
keratinocytes, resembling ‘peaks’ (50x total magnification).   
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3.3 Clonal cell lines  
3.3.1 Overview of clonal cell lines isolated from PC08 and PC09  
In the literature, previous investigations to derive cell lines from VaIN and VIN biopsy tissue 
have been documented to evaluate early stages of neoplasia (Hietanen et al., 1992), and to 
analyse HPV16 transcription patterns (Grassmann et al., 1996). However, isolation and 
characterisation of clonal cell lines with VIN and VaIN origin have not previously been achieved 
or documented. 
In this study a selection of clonal cell lines were isolated from early passage (P2) 
heterogeneous PC08 (VIN) and PC09 (VaIN) cells lines. Early passage (P2) rather than later 
passage PC08 and PC09 were used because they were likely to be more representative of the 
original biopsy tissue from which they were explanted, and so were likely to be good models of 
neoplastic disease in vitro. When selecting a suitable in vitro model for assessing response to 
drug treatment, it is ideal that the cells being treated comprise of a homogeneous cell 
population so that response to treatment can be assessed without interference from multiple 
cell types. The clonal cell lines isolated in this study consisted of homogeneous cell populations 
which could be used as in vitro experimental systems of vulval and vaginal neoplastic disease, 
to investigate response to CDV treatment and potentially other therapeutic agents in the 
future.   
3.3.1.1 Clonal cell lines isolated from PC08 and PC09 
To produce the P2 cultures, cryopreserved P1 PC08 and PC09 cell lines were thawed and used 
to seed 6 cm TC dishes with 3T3 feeder cell support. To isolate clonal cell lines, P2 PC08 and 
PC09 were allowed to reach ~80% confluence then trypsinised and used for dilution cloning in 
9 cm TC dishes (in triplicate). Well dispersed keratinocyte colonies arose on TC dishes seeded 
with 103 cells (P3) and were selected for ring cloning. Cells isolated within each ring were 
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trypsinised and transferred to individual 6 cm TC dishes. Each resulting clonal cell population 
was assessed independently in culture.  
Twelve clonal cell lines were isolated as shown in Table 3.1. Each clonal cell line was given a 
letter of identification; PC08 clonal cell lines = M-X, and PC09 clonal cell lines = A-L. Each letter 
was linked with the parental heterogeneous cell line, therefore clonal cell lines were referred 
to as M08-X08, and A09-L09.  
After initial isolation, 2/12 PC08 clones and 11/12 PC09 clones survived. Due to the relatively 
poor success for PC08, a second attempt was made to isolate more clonal cell lines; higher 
passage (P5) cryopreserved cell stocks of PC08 and PC09 were set up in culture at P6 and 
dilution cloning was carried out in the same way. Two clonal cell lines (Y08 and Z08) were 
isolated from P8 PC08 and only Y08 survived culture after initial isolation. Overall, 10 clonal cell 
lines from PC09 and 3 clonal cell lines from PC08 survived initial isolation and were maintained 
in culture. With regard to the project time-frame and due to the fastidious nature of the cell 
cultures thus far, for PC08 and PC09 the 3 clonal cell lines that established and reached 
confluence most rapidly after initial isolation were selected and underwent short-term culture 
of between 5 and 7 passages; these were PC08 clonal cell lines M08, P08, and Y08, and PC09 
clonal cell lines A09, D09, and H09.  The remaining clonal lines were maintained in culture and 
achieved between 1 and 4 passages; at each passage they were stored in liquid nitrogen for 
future reference but were not included in future analyses constituting this project.  
Clonal cell lines M08, P08 and Y08, were cultured for 5 passages which lasted 63, 63, and 51 
days, with an estimated total number of population doublings (PD) during this time of 25.0, 
24.0, and 23.7, respectively.  Clonal cell lines A09, D09, and H09, were cultured for 7 passages 
which lasted 84, 86, and 84 days, with an estimated 36.2, 38.5, and 33.5, respectively.    
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Biopsy 
tissue 
Heterogeneous 
cell line 
Clonal 
cell line 
Survival 
post 
isolation 
Short term culture 
(passage) 
Total time in 
culture 
(days) 
Total 
PD 
Start Finish 
Vulval PC08 M 
N 
O 
P 
Q 
R 
S 
T 
U 
V 
W 
X 
Y 
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23.7 
Vaginal PC09 A 
B 
C 
D 
E 
F* 
G 
H 
I 
J 
K 
L 
 
 
 
 
 
 
 
 
 
 
 
 
5 
5 
5 
5 
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5 
5 
5 
5 
5 
5 
11 
8 
7 
11 
8 
 
6 
11 
5 
9 
9 
9 
84 
 
 
86 
 
 
 
84 
36.2 
 
 
38.5 
 
 
 
33.5 
 
Table 3.1. Isolation and short-term culture of clonal cell lines derived from PC08 and PC09  
The 3 most rapid clonal cell lines to establish from PC08 and PC09 were selected for short-term 
culture (5-7 passages) during which time they were characterised phenotypically and growth 
characteristics also assessed. The star (*) highlights clonal cell line F which was discarded 
immediately due to fungal contamination, and the dash (-) denotes colonies that were isolated 
and given ID but did not survive when cultured independently.  
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3.3.1.2  Main findings 
Clonal cell lines were successfully isolated from heterogeneous PC08 and PC09 cell lines. PC09 
produced more lines that survived the cloning procedure and proliferated.  
3.3.2 Morphological characteristics  
Once clonal cell lines had been isolated and transferred to TC dishes for their first initial 
passage, they were viewed daily microscopically to assess cell and colony morphology and 
allowed to reach ~80% confluence.  
Microscopic images of clonal cell lines derived from PC08 (M, P and Y) and PC09 (A, B, C, D, E, 
G, H, I, J, K and L) are shown at first passage after isolation in Figure 3.6, Figure 3.7, and Figure 
3.8. During this initial passage, variations in keratinocyte size and tessellation patterns within 
the cell monolayer were visible for each clonal cell line.  
3.3.2.1 Main findings  
Variations in keratinocyte cell morphology and tessellation patterns in the monolayer were 
observed between clonal cell lines after initial isolation and remained unchanged for the 
length of time each clone was maintained in culture. Also, morphological differences were 
observed between clonal cell lines which confirmed that they are distinctly different (clonal). 
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Figure 3.6. Morphology of clonal cell lines isolated from PC08 at first passage post isolation 
Clonal cell lines were cultured in 6 cm TC dishes and images taken at 80% confluence (100x 
total magnification); initial cultures of clonal cell lines M08 and P08 were at P4, and Y08 at P8. 
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3.3.2.1.1.1  
3.3.2.1.1.2  
3.3.2.1.1.3  
3.3.2.1.1.4  
 
 
 
 
 
 
 
 
 
 
 
3.3.2.1.1.5  
 
Figure 3.7. Morphology of clonal cell lines A09-G09 isolated from PC09 at first passage post 
isolation  
Clonal cell lines were cultured in 6 cm TC dishes and images taken at 80% confluence (100x 
total magnification). Initial cultures of clonal cell lines A09-L09 were at P4.   
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Figure 3.8. Morphology of clonal cell lines H09-L09 isolated from PC09 at first passage post 
isolation  
Clonal cell lines were cultured in 6 cm TC dishes and images taken at 80% confluence (100x 
total magnification). Initial cultures of clonal cell lines A09-L09 were at P4.   
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3.3.3 Keratinocyte morphology correlates with growth during culture 
Cell morphology and tessellation pattern appeared to vary amongst clonal cell lines in culture.  
The association between keratinocyte morphology and the number of population doublings 
for each clonal cell line during the period of culture, was assessed by correlating cell 
morphology (Figure 3.6, Figure 3.7, and Figure 3.8) and cell culture data presented (Table 3.1).  
Clonal cell lines M08, P08 and Y08, and A09, D09, H09, J09, K09 and L09,  all demonstrated 
relatively smaller, tightly tessellating polygonal keratinocytes and were passaged most 
frequently in culture (between 5-7 passages were performed). Clonal cell lines B09, C09 and 
E09, demonstrated relatively larger keratinocytes with a more loosely forming tessellation, and 
were passaged 3-4 times during culture. Clonal cell lines G09 and I09 lacked typical polygonal 
keratinocyte morphology, with cells of varying size and shape (particularly enlarged cytoplasm) 
and and no obvious tessellation pattern; G09 was passaged twice and clone I passaged once 
over the culture time period.  Clonal cell lines comprising relatively smaller keratinocytes 
appeared to proliferate more rapidly during this initial passage.  
3.3.3.1 Main findings 
A relationship was identified between the morphology of keratinocytes and a crude estimate 
of the rate of proliferation during the first passage in culture.  It appears that the morphology 
of clonal keratinocytes is linked to their rate of proliferation, and supports the suggestion that 
there are distinct differences among the lines. Rates of proliferation were confirmed more 
accurately through assessment of doubling time (DT), which will be described in the following 
section. 
3.3.4 Time in culture and population doubling time 
Cells were consistently seeded at 8 x 105 cells in 9 cm TC dishes and passaged when 80% 
confluence was reached (with the exception of one occasion when passage was delayed due to 
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contamination of feeder cells), hence the number of population doublings was consistent 
across the culture series; values for cell counts, population doubling and doubling times are 
included in Appendix I. Population doubling times were calculated to assess the rate of 
proliferation for clonal cell lines M08, P08, and Y08, and A09, D09, and H09.  The DT at each 
passage is illustrated in Figure 3.9. 
The DT values for all clonal cell lines appeared to be fairly stable during short-term culture, 
with a trend for doubling time to decrease for all cell lines except D09, for which doubling time 
appeared to increase; this suggested that rate of cell proliferation increased with duration in 
culture for all clonal cell lines excluding D09. However, anomalous DT values were obtained at 
the third passage for M08 and P08, fourth passage A08 and H09, and fifth passage for D09 
(highlighted with red star symbol in Figure 3.9). This problem was related to the 3T3 feeder 
cells which were found to be contaminated prior to irradiation and could not be used. This 
resulted in delayed passage of the clonal lines. Excluding these anomalies, the mean doubling 
times are shown in Table 3.2  
3.3.4.1 Main findings 
The DT decreased with time in culture for all clonal cell lines except D09, showing all clones 
(excluding D09) exhibited increased rate of cell proliferation during culture.  
 
3.4 Historical PC08 and PC09 cell culture records 
3.4.1 Time in culture affects PD and DT 
PC08 and PC09 were cultured for 17 and 19 passages over 101 and 129 days respectively, as 
described previously.  During this time it was calculated that PC08 achieved a total of 96.7 
population doublings and PC09 achieved 111.6 population doublings. Mean doubling times for 
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PC08 and PC09 were 1.1 and 1.2 days respectively. Variation of doubling time with passage 
number is shown in Figure 3.10. 
There appeared to be a trend for shorter doubling times with increasing passage number. 
There was no significant difference between the mean doubling times for the PC08 and 09 cell 
population (T Test, 2 tailed, unpaired samples with unequal variances: P = 0.21). The mean 
doubling times for the heterogeneous populations were however significantly shorter than for 
the clonal populations (Table 3.2). 
3.4.1.1 Main findings 
The mean doubling times for PC08 and PC09 were 1.1 and 1.2 days and were significantly 
shorter than for clonal cell lines. Doubling times in PC08 and PC09 appeared to decrease with 
time in culture showing that rate of cell proliferation increased with time in culture.  
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Figure 3.9. Doubling time versus passage in clonal cell lines M08, P08 and Y08, and A09, D09 
and H09. 
‘Passage’ illustrated on the x axis refers to the number of times the clonal cell line had been 
passaged since being derived from the parental line. The red star highlights anomalous DT 
values which were a result of delayed passage due to contamination of 3T3 feeder cells. 
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Clonal cell line 
             
Mean DT 
(days) 
                               
Linear regression (R2) 
Comparison with parental 
population (PC08/PC09)    
(P values) 
M08                      
P08                       
Y08                        
A09                           
D09                                                          
H09 
1.69      
1.77      
1.81      
1.76      
2.23       
1.88 
0.4                            
0.59                           
0.52                          
0.81                          
0.38                          
0.83 
0.00028                      
0.00260                      
0.00051                      
0.03735                        
0.01933                       
0.02276 
 
Table 3.2. Mean doubling times for clonal cell lines derived from PC08 and PC09 in short-
term culture  
Doubling times were calculated without including the starred values in Figure 3.9. R2 values 
were calculated by linear regression, without including the starred values in Figure 3.9. 
Doubling times were also compared (T Test, 2 tailed, unpaired, unequal variances) with the 
doubling times for the parental heterogeneous cultures (PC08 and PC09). 
 
 
 
 
            
 
Figure 3.10. Doubling time versus passage number for heterogeneous PC08 and PC09 cell 
lines 
R2 values were calculated by linear regression and linear regression lines are shown for 
extended passage. 
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3.5  Discussion 
The main conclusions of the experiments described in this chapter were: 
1. Early passage (P2) heterogeneous cell cultures of PC08 (VIN) and PC09 (VaIN) were 
successfully revived and cultured.  
2. Early passage (P2) heterogeneous cell cultures produced colonies with diverse 
morphologies. 
3. Clonal cell lines were successfully isolated from heterogeneous PC08 and PC09 cell 
lines. 
4. Differences were observed in cell and colony morphology between keratinocytes of 
clonal cell lines. 
5. For 5/6 clones, rate of cell proliferation (assessed as DT), increased with increasing 
passage number. 
6. For heterogeneous PC08 and PC09 cultures, rate of cell proliferation also increased 
with increasing passage number. 
7. Rate of cell proliferation was significantly different between PC08/PC09 and clonal cell 
lines. 
Clonal cell lines were isolated, assessed in terms of morphology and growth characteristics, 
and intended for use as an in vitro experimental culture system representing VIN and VaIN.   
3.5.1 Morphology of cultures and isolation of clonal cell lines 
Early passage cultures of PC08 and PC09 were fastidious in culture and this was thought to be 
because cultures were only 1 passage away from their parental biopsy tissue. Colony 
morphology variants observed at these early passages might be expected in 
primary/secondary cell cultures as cultures include a variety of cell types reflecting the 
composition of the epithelia.  Colonies were identified which resembled ‘peaks’ under 
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microscopic analysis, and these were thought to represent differentiating epithelial cells. 
Colonies of laterally growing cells were also observed in the monolayer, and their morphology 
appeared more similar to transformed cells such as CaSki and SiHa. Laterally growing 
keratinocytes dominated over differentiated keratinocytes when cultures became more 
confluent, and this observation suggested that cells conferring a selective growth advantage 
eventually replace cells within the culture population.  
The data show that very early passage (P2) PC08 and PC09 cultures were slow growing, 
contaminated with fibroblasts, and included cells with diverse morphologies, which is a 
common feature of explanted early passage cell lines (Stanley, 2002). Nonetheless, several 
lines were derived by single cell cloning from the parental population. Laterally growing 
keratinocytes that produced ‘flat’ colonies appeared more likely to produce lines capable of 
sustained growth, while colonies that formed peaks, were perhaps more likely to differentiate 
and grew less well.  
Early cultures of PC09 established better than PC08 and a higher proportion of PC09 single cell 
isolates survived cloning. These observations may suggest that the heterogeneous PC09 
population may have included a greater proportion of cells with a ‘more transformed’ 
phenotype than was present in PC08. Alternatively the differences between PC08 and PC09 
might relate to their distinct anatomical origins (vaginal and vulval) and that they were 
biopsied from two different women; hence individual genetic factors might contribute to how 
well the resulting cell lines established and grew in culture. To try to increase the number of 
PC08 clones available, the dilution cloning was repeated using higher passage cells. The 
rationale for using higher passage cells was that during culture, heterogeneous cell 
populations undergo selection for cells most suited to growth in culture. Therefore PC08 
heterogeneous cells of higher passage might be able to thrive better in culture and therefore 
increase the success rate of dilution cloning. This repeat was not as successful as expected, and 
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in hindsight there was not a great difference in passage number between the first attempt (P1) 
and the repeat (P5) (only 4 passages higher).  
Morphology and growth of clonal cell lines was initially assessed post isolation. Clonal cell 
cultures that comprised enlarged cells, lacked polygonal morphology and tessellation patterns, 
and took longer to reach ~80% confluence during first passage; G09 and I09 in particular 
exhibited these features. Previous studies have reported the morphology of senescent 
keratinocytes (Kang et al., 2000, Rheinwald et al., 2002). Cellular senescence was first 
described by Hayflick (Hayflick, 1965), and defined as viable and metabolically active cells that 
exhibit permanent arrest of cell proliferation, which occurs in response to various stressors 
(Campisi and d'Adda di Fagagna, 2007, Loughran et al., 1996). Keratinocytes undergoing 
cellular senescence are irregularly shaped (not polygonal), with enlarged cytoplasm, and 
reduced cellular organelle density.  Freshly isolated cultures of G09 and I09 could have become 
growth arrested through senescence due to the stress inflicted on cells post cloning in a 
culture environment, resulting in the morphological phenotype and limited proliferative 
potential previously described.  
3.5.2 Growth characteristics  
There were significant differences between the mean doubling times for the parental 
heterogeneous cell populations and the clonal lines derived from them, with the clonal lines 
showing doubling times approximately 50-100% longer than the parental cell lines. There are 
several possible reasons for this, including loss of cellular diversity within the culture 
environment or selection of slow growing clones.  Heterogeneous cell populations comprise a 
diverse selection of cells, all of which respond differently to the external cell culture 
environment. The likelihood of a cell arising with a growth advantage over other cells is 
increased in a diverse (heterogeneous) population of cells, and these might then quickly 
overpopulate the culture. In clonal cell lines, cells respond similarly because they are identical 
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and this reduces the likelihood of cells with a selective growth advantage arising and might 
therefore limit rate of change within a cell population.  This might be the best explanation for 
why PC08 and PC09 doubled more frequently than the clonal cell lines. Selection of slow 
growing clones appears less likely, given that the most rapidly growing clones were selected, 
and doubling time appears fairly consistent between clones. The difference could also have 
been caused by differences in the handling of the cell cultures, but this appears unlikely as 
heterogeneous and clonal lines were cultured according to standardised protocols. 
Both the heterogeneous and 5/6 of the clonal populations showed a tendency for doubling 
time to reduce with increasing passage number. This is consistent with selection of faster 
growing clones with increasing time in culture. The behaviour of clone D09, which showed the 
opposite trend, is more difficult to explain but might be attributed to changes in expression of 
HPV encoded genes which will be discussed in later chapters.  
3.5.3 Strengths and weaknesses 
The clonal lines have several strengths as potential models of VIN and VaIN. They were derived 
from early passage heterogeneous cell lines explanted from biopsy tissue, and are likely to 
provide a good in vitro representation of vulval and vaginal neoplastic disease because they 
still closely represent the physiology of the human tissue from which they were derived. At 
these very early passages, cells have not had sufficient time to accumulate genetic 
modifications which occur as a result of selective pressures through long-term cell culture 
process. Additionally the clonal cell lines provide a homogeneous population of cells which can 
be used experimentally; identical cells comprise the cell culture model and cellular response is 
therefore consistent i.e. results should not be influenced by selection of subclones from within 
a heterogeneous population. The majority of documented studies that have investigated HPV 
related disease and potential therapeutics have used immortalised cell lines as an 
experimental system, such as CaSki, SiHa and HeLa (Divya and Pillai, 2006, De Schutter et al., 
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2013). Immortalised cell lines are either derived directly from late metastatic tumours or have 
established in long-term culture and undergone selective pressures conferring growth 
advantages resulting in cell transformation. Hence immortalised cell lines can lack biological 
relevance especially in relation to early neoplastic disease. The clonal cell lines isolated during 
this study originated from grade III VIN and VaIN biopsy tissue and have replicated successfully 
during short-term culture; this has not been accomplished or documented previously and is 
therefore novel.  
Only one previous study has reported successful derivation of cell lines from VIN (Grassmann 
et al., 1996); the HPV16 positive KG line was derived using an explant procedure from a VIN3 
lesion and was used in organotypic raft culture to investigate the activity of the HPV P670 
differentiation dependent promotor. The heterogeneous line was cultured for >80 population 
doublings and was described as an immortalised line, however no further publications have 
reported use of this line. Similarly a single publication has reported isolation of keratinocyte 
lines from vaginal lesions (Hietanen et al., 1992); two cell lines, UT-DEC-1 (HPV33) and UT-DEC-
2 (HPV16), were derived from VaIN 1 and 2 lesions. Both lines grew for >24 passages and were 
described as potentially immortal, but no further publications describing use of these lines 
have been identified. By contrast, the HPV16 positive W12 cell line derived by Margaret 
Stanley in 1989 (Stanley et al., 1989) from a low grade cervical lesion has provided the basis for 
numerous insights into the biology of HPV infection and the significance of viral integration in 
particular (Pett and Coleman, 2007); the W12 heterogeneous population has given rise to 
several defined clones with distinct integration events (Gray et al., 2010). 
The experiments described above do have several limitations. During short-term culture, 
confluency was determined under microscopic analysis, and clonal cell lines were passaged at 
80% confluence which is the simplest and most common method described in the literature. 
However it must be acknowledged that this is a subjective measure. 
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A further limitation was the somewhat crude method used for calculation of doubling time. 
Doubling times can be more accurately determined by analysis of the log phase of a fully 
defined growth curve based on multiple replicates of daily cell counts from seeding to plateau 
phase (Freshney, 2005a), however this was not appropriate here where the main aim was to 
study multiple lines over an extended period of culture.   
Clonal cell populations can be obtained in several ways. For cells that are usually in suspension 
(e.g. blood cells) FACS can be used to directly isolate single cells. In this study these methods 
were not suitable due to the adherent nature of keratinocytes and their sensitivity to cell 
density i.e. at low cell densities cell survival was reduced as a result of cell density dependent 
regulation of growth, and as a result dilution cloning was performed according to a 
standardised protocol (Freshney, 2010). This process creates single cell suspensions and allows 
single cells to divide and replicate to form colonies in TC dishes; colonies are then isolated and 
transferred to separate vessels. The limitations of this technique included the possibility of 
cells establishing in close proximity on the base of the TC dish and then replicating and cell 
types combining, which would form a colony comprising two different cell types. To ensure 
that the colonies selected were those that arose from a single cell, single cell suspensions were 
seeded at a variety of cell densities, and the exclusion criteria listed in Methods and Materials 
implemented when selecting individual colonies for isolation.    
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4 Preliminary cell culture and optimisation studies  
4.1 Results 
Clonal cell lines were derived from PC08 (vulval) and PC09 (vaginal) heterogeneous cell lines, 
as described in Chapter 3.  The clonal cell lines were intended for use as in vitro experimental 
models of HPV related vulval and vaginal neoplastic disease; specifically for assessing 
responses to cidofovir (CDV) treatment described in Chapters 7 and 8. Before they could be 
used for CDV dosing studies, clonal cell line cultures were assessed during short-term culture 
(between 5 and 7 passages) to identify phenotypic and molecular characteristics of each clonal 
cell line, as described in Chapter 5 and 6.  
Prior to characterisation and CDV dosing studies, a series of preliminary studies were 
performed using early passages of two clonal cell lines. Firstly to optimise the growth 
conditions for short-term culture of clonal cell lines, and secondly to determine key 
parameters within the culture system that might affect growth of cells and expression of HPV 
oncogenes. The aim of these experiments was to ensure that clonal cell lines could be used 
dependably for investigating response to CDV.  
In culture, keratinocytes are often supplemented with irradiated 3T3 feeder cells (this is 
referred to as co-culture i.e. culturing mixed cell types together). 3T3s are thought to provide 
extracellular proteins to support the growth of keratinocytes and provide paracrine factors 
that enhance epithelial cell survival (Parkinson and Yeudall, 2002, Alitalo et al., 1982, 
Rheinwald and Green, 1975) and therefore clonal cell lines were prepared in co-culture with 
3T3 support. It has been suggested that specific 3T3 clones support growth better than others 
(i.e. the J2 clone), and that 3T3s should not be used beyond passage 20, as extended culture 
results in selection for fast-growing variants that do not survive as long after irradiation and 
are inferior as feeders (Stanley, 2002). The clonal cell lines isolated during this project were 
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novel, thus to optimise the co-culture system, the effect of irradiated 3T3 passage number on 
the time taken for clonal cell lines to reach 100% confluence was investigated. The main aims 
of this experiment was to determine a passage limit past which 3T3s would no longer be useful 
for supplementing clonal cells in culture.  
The next experiment investigated the effects of growing clonal cell lines without 3T3 feeder 
cells. This was undertaken because for CDV dosing studies, a mixed population of cells would 
be undesirable and this could potentially confound cell counts and quantification of nucleic 
acids. This experiment investigated whether clonal cell lines could establish and grow 
independently without co-culture with 3T3 feeder cells.  
Published studies suggest that CDV may affect expression of HPV oncogenes, E6 and E7 (Amine 
et al., 2009, Abdulkarim et al., 2002). To explore this, the effect of clonal cell confluence on E6 
and E7 expression was investigated. The outcome would then guide the standardisation of 
percentage confluence to be used in future cell culture experiments. 
Lastly, cell cultures were also examined for Mycoplasma infection. Mycoplasma species are the 
smallest free-living prokaryotic microorganisms. Contamination of cell culture is a common 
and serious problem (Young et al., 2010a) causing biochemical and metabolic changes in 
infected cell lines resulting in altered physiology and metabolism of nucleoside analogues 
(Taylor-Robinson and Bebear, 1997). Mycoplasma detection was carried out to ensure that 
cultures were uncontaminated. 
4.1.1 Aims and objectives 
The central aim was to optimise and assess variables within the novel cell culture systems to 
standardise the cell culture process for the rest of the project.  
The following objectives structured this section of work:  
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1. Investigate whether the passage number of irradiated 3T3 feeder cells affects the 
establishment and growth of clonal cells in co-culture.  
2. Assess whether clonal cell lines could establish and grow adequately without 
irradiated 3T3 cells. 
3. Investigate whether confluence of clonal cell lines affects HPV oncogene expression. 
4. Assess whether presence/absence of 3T3 feeders affects HPV oncogene expression. 
5. Examine cell cultures for Mycoplasma contamination.  
4.1.2 Study sample 
Clonal cell lines M08 and D09 established and replicated most rapidly after initial isolation, as 
described in chapter 4, and were therefore used to carry out the preliminary studies at 
passage (P) 6.   Irradiated 3T3 feeder cells at P≤20 were used to supplement M08 and D09 in all 
instances except for when variability in 3T3 passage number was being assessed (P17, 22, 29, 
and 36 were used).  
4.1.3 Passage number of 3T3 feeder cells affects the growth of clonal cell lines  
The effect of 3T3 passage number on the growth of clonal cell lines in co-culture was 
investigated by exploring how long it took for cultures to reach 100% confluence in co-culture 
with irradiated 3T3 feeder cells of variable passage.  3T3 feeder cells were prepared in culture 
in four rounds at P17, 22, 29 and 36, and stripped and irradiated as previously described. 
Irradiated 3T3 feeder cells (2 x 106) were then used to supplement D09 and M08 cultures in 9 
cm tissue culture (TC) dishes seeded with 8 x 105 cells. Cultures were viewed microscopically 
twice daily until cultures reached 100% confluence.  
The relationship between time taken for D09 and M08 to reach 100% confluence and 3T3 
passage number is shown in Figure 4.1. There was clearly a strong positive correlation 
between 3T3 passage number and time taken to reach confluence for both cell lines. There 
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were also substantial differences in the morphology of cultures observed microscopically. 3T3s 
at higher passages (P29 and 36) tended to detach from the base of the dish more easily. This 
was identified by the presence of increased numbers of 3T3 cells in media suspension and 
‘gaps’ observed in the cell monolayer under microscopic analysis (summarised in Table 4.1).  
4.1.3.1 Main findings  
This experiment clearly established that there was a relationship between the passage number 
of the 3T3 cells and keratinocyte proliferation. From this, a passage limit for irradiated 3T3 
feeders was established for co-cultures in future experiments.  
4.1.4 Clonal cell lines can establish and grow independently  
In order to investigate whether clonal cell lines could be cultured effectively in the absence of 
3T3 feeder cells, M08 was prepared in culture at 8 x 105 in 9 cm TC dishes, with and without 
3T3 feeder cells (in duplicate). Cultures were analysed microscopically on a daily basis until 
cells reached 100% confluence; cell morphology was also assessed during this time.  
Cultures of M08 supplemented with 3T3 feeder cells appeared to establish better within the 
first 48 hours of culture in comparison to cultures of M08 without 3T3 feeder cells. However, 
cells with and without 3T3 feeder cells reached 100% confluence in a comparable time frame 
(10 days). With and without 3T3 feeder cells, the keratinocytes maintained polygonal 
morphology, however keratinocytes tended to establish and replicate as circular colonies in a 
background of 3T3 feeder cells whereas colony formation was less defined in cultures without 
3T3s (Figure 4.2).    
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Figure 4.1. Time taken for clonal cell lines M08 and D09 to become confluent in co-culture 
with 3T3 feeder cells of varying passage  
M08 and D09 at P6 were seeded with 8 x 105 cells in 9 cm TC dishes with 2 x 106 irradiated 3T3 
feeder cells at P17, 22, 29 and 36. The time taken for keratinocytes to reach 100% confluence 
was assessed microscopically. Cultures were prepared in triplicate; microscopic analysis of 
triplicate cultures showed that replicates for each condition reached confluence on the same 
day (error bars are not shown).  
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Clonal 
cell 
line 
3T3 
passage 
no. 
Time to 
confluence 
(days) 
Observations during culture 
D 17 8 3T3s attached and few in suspension 
22 9 3T3s attached with increased numbers of cells in 
suspension with increasing time in culture 
29 11 3T3s establish poorly and detach easily with increased 
numbers of cells in suspension and ‘gaps’ in the monolayer 
36 11 3T3s establish poorly and detach easily with increased 
numbers of cells in suspension and ‘gaps’ in the monolayer 
M 17 9 3T3s attached and few in suspension 
22 10 3T3s attached with increased numbers of cells in 
suspension with increasing time in culture 
29 11 3T3s establish poorly and detach easily with increased 
numbers of cells in suspension and ‘gaps’ in the monolayer 
36 13 3T3s establish poorly and detach easily with increased 
numbers of cells in suspension and large ‘gaps’ in the 
monolayer 
 
Table 4.1. Microscopic observations of clonal cell lines M08 and D09 supplemented with 
irradiated 3T3 feeder cells of varying passage 
M08 and D09 at P6 were seeded with 8 x 105 cells in 9 cm TC dishes with 2 x 106 irradiated 3T3 
feeder cells at P17, 22, 29 and 36. Co-cultures were examined microscopically and 
observations recorded throughout culture upon reaching 100% confluence. Cultures were 
prepared in triplicate and the same observations were made in each replicate.  
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Figure 4.2. Morphology of M08 keratinocytes in culture with and without 3T3 feeder cell 
support  
M08 at P6 was seeded with 8 x 105 cells in 9 cm TC dishes with or without 2 x 106 irradiated 
3T3 feeder cells and no feeder cells. A. M08 cells grown with 3T3 feeder cells at 100% 
confluence, and B. M08 cultures without 3T3 feeder cells at ~80% confluence (100x total 
magnification). 
 
  
A
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4.1.4.1 Main findings   
Clonal cell cultures proliferated independently of co-culture with 3T3 feeder cells.. This 
suggested that clonal cell lines without co-culture with 3T3 feeder cells could be used for 
future drug treatment and response experiments.  
4.1.5 Confluence of clonal cell lines affects HPV oncogene expression  
The effect of confluence on E6 and E7 expression in M08 was analysed at 50%, 75%, 100% and 
100% + 1 week confluence whilst in co-culture with and without 3T3 feeder cells. Cells were 
maintained in culture until the desired degree of confluence was reached, and then trypsinised 
and nucleic acids extracted. RNA was used for qRT-PCR and relative E6 and E7 expression 
values were obtained according to the methods previously described. 
The effect of cell density on mRNA levels for HPV oncogenes E6 and E7 is shown in Figure 4.3. 
Examples of real time fluorescent traces and melt curves are shown in Appendix II. There was 
no significant difference in mRNA levels for HPV E6 and E7 in cultures with and without 3T3 
feeder cells, as shown in Figure 4.4. 
4.1.5.1 Main findings  
Expression of E6 and E7 was clearly affected by cell density, with highest expression observed 
in cells at approximately 75% confluence. This demonstrated the importance of 
standardisation of culture conditions when analysing oncogene expression. In subsequent 
experiments cells were passaged consistently at ~80% confluence. There was no significant 
difference between relative expression ratios of E6 and E7 in M08 cultures supplemented with 
and without 3T3 feeders at 75% confluence (E6: p = < 1.1821., E7: p = < 0.9223, at p < 0.05, 2-
tailed t-test). 
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Figure 4.3. Effect of percentage confluence on mRNA levels of E6 and E7 in P6 clonal cell line 
M08  
M08 co-cultures containing irradiated 3T3 feeder cells were investigated using qRT-PCR to 
determine relative E6 and E7 mRNA levels when cultures reached 50%, 75%, 100%, and 100% 
plus 1 week confluence. Expression was normalised to stable house-keeping genes TBP2 and 
HRPT. Expression was quantified relative to CaSki cDNA as a standard. Cultures were prepared 
in triplicate and error bars denote the standard deviation. 
 
 
 
 
 
 
Figure 4.4.  Mean relative quantification ratios of E6 and E7 mRNA levels in P6 clonal cell line 
M08 cultured with and without 3T3 feeders at 75% confluence. 
M08 cultures with and without irradiated 3T3 feeder cells underwent qRT-PCR to determine 
relative E6 and E7 expression levels. Cultures were prepared in triplicate. There was no 
significant difference between E6 and E7 mRNA levels in clonal cell line M08 cultures 
supplemented with and without 3T3 feeders (E6: p = < 1.1821, E7: p = < 0.9223, at p < 0.05, 2-
tailed t-test). 
0 
0.02 
0.04 
0.06 
0.08 
0.1 
0.12 
0.14 
50 75 100 100 + 1 week 
R
e
la
ti
v
e
 q
u
a
n
ti
fi
c
a
ti
o
n
 (
Q
R
) 
ra
ti
o
 
Percentage confluence (%) 
E7 
E6 
 E7 E6 
Without  feeders 0.056217 0.054881 
With  feeders 0.059026 0.040682 
 157 
 
Mycoplasma contamination 
3T3 feeder and clonal cell line cultures were examined by PCR for Mycoplasma contamination, 
as previously described. An example of the data generated is shown in Figure 4.5. 
4.1.5.2 Main findings  
Mycoplasma contamination was not detected in any of the cell cultures tested. 
 
4.2 Discussion   
The main conclusions of these preliminary studies were: 
1. There was a clear relationship between the passage number of the 3T3 feeder cells 
used to constitute the feeder layer and keratinocyte proliferation assessed as time 
taken to reach confluence. 
2. Keratinocytes did proliferate in the absence of feeder cells. 
3. mRNA levels for HPV E6 and E7 were affected by cell density. 
4. mRNA levels for HPV E6 and E7 at 75% confluence was not affected by the presence or 
absence of 3T3 feeders in culture. 
5. Cultures were free from Mycoplasma contamination. 
These experiments provided useful information to guide the planning of future experiments. 
On the basis of this data it was decided that keratinocytes would usually be prepared using co-
culture with 3T3s at less than P22, but would not be used in CDV dosing studies to avoid using 
multiple cells in culture (particularly since the presence/absence of 3T3s in culture did not 
appear to affect HPV E6 and E7 expression levels). Passaging cultures would also be 
standardised to ~80% confluence.  
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Figure 4.5. Mycoplasma testing using VenorGeM® PCR 
Clonal cell cultures M08 and D09, 3T3 feeder cell cultures, and test kit positive and negative 
control samples underwent PCR, electrophoresis on a 1.5% ethidium bromide agarose gel, and 
were visualised using a UV transilluminator. The test kit negative control and positive control 
generated band sizes of 191 bp and 265-278 bp, respectively. Each sample included an internal 
control that generated a band size of 191 bp, which confirmed successful PCR; samples with an 
absent band at 191 bp indicated PCR inhibition. Mycoplasma species DNA within samples (i.e. 
samples that were contaminated with Mycoplasma) also generated a band size of 265-278 bp 
with or without a 191 bp internat control band. All cell culture samples generated amplicons of 
191bp confirming that the PCR had worked and samples were not contaminated with 
Mycoplasma.  
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4.2.1 Cell culture with and without 3T3 feeder support  
Some of the data on the effects of culture with 3T3s were difficult to interpret; the time taken 
for M08 cells to become confluent with P36 3T3s was 13 days, while without 3T3s, cultures 
reached confluence in 10 days. This suggests that the presence of late passage 3T3s was more 
detrimental to the growth of keratinocytes than their complete absence. 3T3s produce 
extracellular matrix proteins such as basal lamina glycoproteins which may promote 
keratinocyte cell attachment and growth (Alitalo et al., 1982, Rheinwald and Green, 1975), 
although Peehl and colleagues (Peehl and Ham, 1980) suggest that keratinocyte cells do not 
necessarily require co-culture with 3T3 feeder cells to grow effectively.  The use of epidermal 
growth factor (EGF) as a media supplement might contribute to enhancing the growth of 
keratinocytes cultures that are not supported by 3T3 feeder cells (Rheinwald and Green, 1977), 
and clonal cell lines in this study were supplemented with GMEM containing EGF.  
The data suggested that the M08 cell line could be cultured effectively without feeder cells. 
However, the potential convenience of culture without feeder layers had to be balanced 
against the potential effects on the cultures. Using W12 cells, a naturally HPV transformed cell 
line derived from a cervical intraepithelial neoplasia, Dall et al. have previously shown that 
culture without feeder cells for 15 to 25 population doublings may promote HPV episome loss 
via induction of stress response pathways (Dall et al., 2008). However, as the planned drug 
treatment studies would only involve short term culture without feeders, episome loss 
appeared an acceptable risk.  
4.2.2 The effect of confluence on HPV oncogene expression 
The effect of confluence on E6 and E7 emphasised the importance of comparing cell cultures 
of the same percentage confluence, particularly in CDV dosing studies where HPV oncogene 
expression is investigated, in order to avoid bias and produce reliable results. The effects of 
confluence on expression of HPV E6 and E7 have previously been investigated by Wechsler et 
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al. (Wechsler et al., 2012). HPV16 genomes were transformed into the NIKS keratinocyte line 
to generate clones which in organotypic raft culture phenocopied low and high-grade 
squamous intraepithelial lesions (LSIL and HSIL). In monolayer culture, the LSIL-like clones did 
not appear to continue to divide effectively post 100% conﬂuence and showed reduced E6 and 
E7 expression, which suggested that they were sensitive to contact inhibition. However, the 
HSIL-like clones displayed an increase in E6 and E7 when they reached confluence and 
continued to divide. This demonstrates the importance of standardisation of culture 
conditions. Considering that the M08 and D09 cells both showed reduced E6 and E7 mRNA in 
cells at confluence, and appeared to show contact inhibition, it might also suggest that despite 
being derived from high grade lesions (VIN3 and VaIN3) they may be more representative of 
low grade disease. This could be confirmed by organotypic raft culture of these lines, but these 
experiments were not undertaken during this project.  
4.2.3 Mycoplasma infection and cellular metabolic activity 
Mycoplasma testing confirmed that the cell lines were not infected. It was especially important 
to perform this testing as mycoplasma infection can affect the metabolism of nucleoside 
analogues, such as Cidofovir, which is used in treatment of VIN. Bronckaers et al. 
demonstrated that several nucleoside analogues are degraded to their inactive base forms by 
Mycoplasma hyorhinis encoded thymidine phosphorylase in MCF-7 breast carcinoma cells 
(Bronckaers et al., 2008). The mycoplasma encoded enzyme dramatically reduced the 
cytostatic activity of the compounds causing a reduction in the formation of active metabolites 
and/or reduced drug incorporation into nucleic acids in infected cells compared with 
uninfected cells.  
4.2.4 Strengths and weaknesses  
The strengths of the preliminary studies were that all experiments were performed in 
replicates, and the results generated were highly consistent between replicates and between 
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clonal cell lines M08 and D09, which originated from different anatomical sites (vulval and 
vaginal respectively). Although the data output was not entirely quantitative, the analyses 
identified important parameters to guide design of future experiments.  
There were some weaknesses in the experimental design; clonal cell lines M and D were 
selected for preliminary studies because they were the most rapid clonal cell lines to establish 
and replicate in culture after being isolated. Early passage keratinocytes were slow growing in 
culture, as previously described in chapter 3, and using the first clonal lines to establish meant 
that the project time frame could be optimised and the preliminary studies could be carried 
out before a variety of clonal cell lines were available. However, picking the most rapid 
growing clonal cell lines for use in these studies introduced selectivity in to the experiment 
because these cell populations were those with genetic traits that conferred a cellular growth 
advantage, and might not be fully representative of the other clonal lines. Selectivity was 
unavoidable in this instance as the preliminary data had to be completed before clonal cell 
lines were characterised to ensure that the cell culture environment was optimal for future 
experiments. 
The preliminary studies considered percentage confluence of cell cultures as a standard for 
assessing variables within the culture system, and also as a variable under investigation.  
Confluence was determined under microscopic analysis, which is the simplest, most common 
method described in the literature, although it is subjective. This subjectivity was considered a 
weakness, however this technique is commonly accepted as a method of determining 
confluence.  
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5 Molecular characterisation  
5.1 Results 
Clonal cell lines were characterised at a molecular level by investigating HPV integration status 
and HPV gene expression over a range of passages during short-term culture. DNA, but not 
RNA, from heterogeneous PC08 and PC09 was also available from the previous pilot study 
(kindly provided by Dr Ned Powell) and underwent limited HPV integration analysis.  
HPV integration status was investigated using two PCR based assays, 1. Detection of Integrated 
Papillomavirus Sequences (DIPS), and 2. Amplification of Papillomavirus Oncogene Transcripts 
(APOT). DIPS detected genomic integrated HPV and APOT explored whether HPV integrants 
were actively transcribed. E2 PCR was also performed to confirm disruption to E2, by Dr Rachel 
Raybould (HPV Research Group, Cardiff University). Incorporation of historical PC08 and PC09 
was useful for assessing the origin of HPV integrants detected in clonal cell lines previously 
derived from PC08 and PC09, i.e. to assess whether HPV integrated loci were present in the 
parental cell line or induced as a result of clonal cell line isolation and cell culture. HPV 
integration status was explored for several reasons, i. to determine whether distinct HPV 
integration profiles were present in the clonal cell lines, ii. to determine when integration of 
HPV occurred (before or after isolation in vitro), and iii. to explore whether the cell culture 
process can induce integration of HPV. It has been suggested that integration of HPV into the 
host genome can cause activation of endogenous proto-oncogenes or inactivation of tumour 
suppressor genes (Einstein et al., 2002, Ferber et al., 2003a, Ferber et al., 2003b, Couturier et 
al., 1991). Hence the exact sites of integration were identified to see if they coincided with 
known oncogenes or tumour suppressor genes. 
HPV gene expression was also investigated during short-term culture to fulfil the objective of 
characterising clonal cell lines at a molecular level. Relative expression of HPV genes E2, E4, E5, 
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E6 and E7, was assessed at each passage using qRT-PCR to obtain transcription profiles for 
each clonal cell line. HPV gene expression was also explored because CDV has previously been 
shown to affect expression of HPV oncogenes E6 and E7 (Abdulkarim et al., 2002). Since clonal 
cell lines were intended for use as an in vitro experimental system for future CDV dosing 
protocols, it was necessary to assess the stability of E6 and E7 expression over a succession of 
passages in culture.  
5.1.1 Aims and objectives 
The central aim was to characterise clonal cell lines during short-term culture at a molecular 
level; this involved investigating HPV integration status and relative HPV gene expression. The 
following objectives structured this section of work: 
1. Investigate integration of HPV in to the host DNA (genome) in all clonal cell lines at 
early and late passages of short-term culture. 
2. Investigate transcriptionally active HPV integrants in all clonal cell lines at early and 
late passages of short-term culture. 
3. Investigate if there is a link between genes disrupted by HPV integration and 
carcinogenesis (through researching gene function). 
4. Investigate relative HPV gene expression in all clonal cell lines at each passage of short-
term culture. 
5.1.2 Study sample 
5.1.2.1  HPV integration status 
DNA and RNA extracts of earliest and latest passages of clonal cell lines M08 (P5 & 9), P08 (P5 
& 9), Y08 (P9 & 13), A09 (P5 & 11), D09 (P5 & 11) and H09 (P5 & 11) underwent DIPS and APOT 
analysis, respectively. DNA of heterogeneous PC08 (P19) and PC09 (P21) also underwent DIPS 
analysis.  
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5.1.2.2 HPV relative gene expression  
RNA extracts of all passages of clonal cell lines M08 (P5 - 9), P08 (P5 - 9), Y08 (P9 - 13) A09 (P5 - 
11), D09 (P5 - 11) and H09 (P5 - 11) underwent qRT-PCR and gene expression analysis.  
5.1.2.3 E2 PCR 
DNA extracts of earliest and latest passages of clonal cell lines M08 (P5 & 9), P08 (P5 & 9), Y08 
(P9 & 13), A09 (P5 & 11), D09 (P5 & 11) and H09 (P5 & 11), and heterogeneous PC08 (P19) and 
PC09 (P21), underwent E2 PCR. 
5.2 HPV integration status 
HPV integration was determined using several different assays. DIPS ligates adapters to 
common restriction endonuclease cut sites in the HPV and human genome. PCR with adapter 
specific primers is then used to amplify HPV:human DNA fusions (Luft et al., 2001). APOT 
amplifies HPV mRNAs in order to detect and differentiate HPV:human fusion transcripts (Klaes 
et al., 1999). E2 PCRs are a series of overlapping PCRs that cover the entire E2 gene (Collins et 
al., 2009). Missing fragments indicated disruption or loss whilst complete coverage of E2 
suggested the presence of episomal HPV, integrated HPV with intact E2, or HPV genomes 
integrated as concatamers (as observed in the CaSki cell line) (Meissner, 1999). 
5.2.1 E2 disruption 
DNA extracts of PC08, PC09, and clonal cell lines, underwent PCR amplification of the HPV E2 
gene as described by Collins and colleagues (Collins et al., 2009). The results of E2 PCRs are 
summarised (along with DIPS data) in Table 5.1. In all clonal cell lines, E2 PCR data was 
consistent at early and late passage. E2 was intact in PC08 and its derivative clonal cell line 
Y08, which suggested the presence of episomal HPV or integration of full length, possibly 
concatenated, HPV. E2 was not amplified in clonal cell line M08 which suggested E2 disruption 
due to integration of HPV into the host genome. In P08 a truncated E2 fragment was 
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produced; sequencing of this fragment revealed a section of E2 spanning nt 2201 to 3147 had 
been deleted (Figure 5.1). PC09 and its derivative clonal cell lines A09, D09, and H09 all 
contained intact E2 which suggested the presence of episomal HPV or integration of full 
length, possibly concatenated, HPV.  
5.2.1.1 Main findings 
E2 PCR data suggested that clonal lines representing integrated and potentially episomal HPV 
infections had been isolated. E2 PCR data was consistent in early and late passage (which were 
independent samples), validating the status of E2 in each clonal cell line.  
5.2.2 Genomic integration loci 
DIPS was performed using DNA extracts of PC08, PC09, and clonal cell lines, to detect genomic 
HPV integration. The resulting sequence data underwent BLAST and BLAT analysis, as 
previously described, to identify the site of integration in the human genome and also the 
region of the HPV genome that was disrupted. All integration and non-contiguous events 
detected by DIPS were confirmed by PCR and sequencing using primers that flanked the host 
viral junction. Viral disruption and genomic integration loci that were detected in PC08, PC09, 
and clonal cell lines are shown in Table 5.1. Integrated HPV was detected in M08 and Y08 but 
not in P08 or heterogeneous PC08, which suggests that these events occurred during culture 
or were present at undetectable levels in heterogeneous PC08. HPV integration was also 
detected in heterogeneous PC09 and D09 and H09, but not in A09. Integration loci were 
different in each clonal cell line, and were consistent at early and late passage; an additional 
integration loci was detected in late passage of H09. 
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Biopsy Cell line Passage 
no. 
E2 PCR Viral disruption (ORF) Integration loci Orientation 
PC08 Hetero.  19 Intact Not detected - - 
M08 5 Disrupted nt 1194 (E1) 3q28 Antisense  
9 Disrupted nt 1194 (E1) 3q28 Antisense 
P08 5 Disrupted nt 2201-3147 (E1-E2) None NA 
9 Disrupted nt 2201-3147 (E1-E2) None  NA 
Y08 9 Intact nt 2116 (E1) 3p21.31 Antisense 
13 Intact nt 3167 (E2) 3p21.31 Antisense 
PC09 Hetero. 21 Intact nt 6033 (L1) 2q36.1 Sense 
A09 5 Intact Not detected - - 
11 Intact Not detected - - 
D09 5 Intact nt 5003 (L2) 18p11.31 Antisense 
11 Intact nt 5003 (L2) 18p11.31 Antisense 
H09 5 Intact nt 2490 (E1) 11p15.3 Sense 
11 Intact  nt 2490 (E1) 11p15.3 Sense 
11 intact nt 1848 (E1) 22q12.3 Antisense 
 
Table 5.1. Genomic integration loci determined by DIPS and E2 PCR, for PC08, PC09 and 
clonal cell lines at early and late passages 
‘None (non-contiguous)’ refers to viral disruption causing non-contiguous (fragmented) HPV 
sequence. The percentage consensus of sequence data with NCBI database was >95% for all 
samples. ‘Hetero.’ denotes the heterogeneous cell population, and ‘nt’ specifies the nucleotide 
number in the HPV16 genome. 
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Figure 5.1. Disruption to E2 detected in P08  
A.  A schematic representation of wildtype (no disruption) and clonal cell line P08 HPV16 E1 
and E2 amplicon.  In wildtype, forward (F) and reverse (R) primers span 2070-3263 bp 
producing a fragment with a total size of 1193 bp. In P08, primers spanning the same region 
produced a fragment with a total size of 247 bp and sequencing identified an absent region 
between 2201-3147 bp. B. Gel electrophoresis image of amplicons generated using forward (F) 
and reverse (R) primers flanking E1 and E2 in P08, producing a fragment of 247 bp in size.  
Amplicons for Y08 and heterogeneous PC08 are also illustrated at 1193 bp, consistent with 
wildtype (no disruption). Gel electrophoresis image was kindly provided by Dr Rachel Raybould 
and adapted for this illustration.  
A. 
B. 
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5.2.2.1 Main findings 
DIPS analysis suggested that a selection of integrated and episomal HPV existed in the clonal 
cell lines. Genomic integration loci were different in each clonal cell line.. Integration loci were 
consistent at early and late passage and this validated the integration events identified in 
independent samples of each clonal cell line. As integration was not detected in 
heterogeneous PC08, this might highlight limitations of DIPS as a technique or indicate that 
HPV integration may have occurred during culture. An additional genomic integration loci was 
detected in clonal cell line H09 at late passage which might indicate that HPV integration was 
induced during short-term culture.  
5.2.3 Transcriptionally active integration loci 
APOT was performed using RNA extracts of clonal cell lines to explore whether genomic 
integration loci were actively transcribed. RNA was not available for heterogeneous PC08 or 
PC09 and as such these were not tested. The resulting sequence data underwent BLAST and 
BLAT analysis, as previously described and integrated and episomal transcripts were identified. 
Electrophoresed APOT fragments and the resulting sequenced transcripts for clonal cell lines 
are shown in Table 5.2 and Figure 5.2. Four different transcript patterns were detected in the 
clonal cell lines investigated (Figure 5.3):  
 Type 1: integrated transcript consisting of E7-E1 fused directly to human sequence. 
 Type 2: integrated transcript consisting of E7-E1 spliced to E4 fused to human 
sequence. 
 Type 3: episomal transcript consisting of E7-E1 spliced to E4. 
 Type 4 transcripts: episomal transcript consisting of E7-E1 spliced to E4-E5.  
HPV integrated transcripts were detected in D09, H09, M08 and Y08; HPV episomal transcripts 
were detected in A09 and P08. Different integrated transcripts were identified in each clonal  
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Biopsy Cell 
line 
Passage 
no. 
Viral disruption (ORF) 
(type) 
Integration loci Orientation 
PC08 M08 
 
5 nt 880 (E1) (type 1) 3q28 Antisense 
9 nt 880 (E1) (type 1) 3q28 Antisense 
P08 
 
5 NA (type 3) NA (episomal) 
9 NA (type 3) NA (episomal) 
Y08 
 
9 nt 882 (E1) (type 1) 3p21.31 Antisense 
13 nt 882 (E1) (type 1) 3p21.31 Antisense 
PC09 A09 
 
5 NA (type 3) NA (episomal) 
11 NA (type 3) NA (episomal) 
11 NA (type 4) NA (episomal) 
D09 
 
5 nt 3716 (E4) (type 2) 18p11.31 Sense 
11 nt 3716 (E4) (type 2) 18p11.31 Sense 
H09 
 
5 nt 882 (E1) (type 1) 5q11.2 Sense 
11 nt 882 (E1) (type 1) 5q11.2 Sense 
11 nt 3494 (E4) (type 2) 1p36.13 Antisense 
 
Table 5.2. APOT derived transcripts (integrated and episomal) detected in clonal cell lines at 
early and late passages  
‘NA’ denotes instances where episomal transcripts were detected. The percentage consensus 
of sequence data with NCBI database was >98% for all cell lines.  ‘Nt’ specifies the nucleotide 
number within the HPV16 genome. 
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Figure 5.2. APOT amplified transcripts of early and late passage clonal cell lines 
Amplicons were electrophoresed on a 2% w/v agarose gel for early and late passages of clonal 
cell lines A09 (P5 & 11), D09 (P5 & 11), H09 (P5 & 11), M08 (P5 & 9), P08 (P5 & 9), and Y08 (P9 
& 13). 
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Figure 5.3. Schematic representation of transcript types detected via APOT for clonal cell 
lines  
Four transcript types were detected for clonal cell lines; types 1 and 2 are integrated 
transcripts since they contain human sequence, and types 3 and 4 are episomal since they did 
not contain human sequence. Type 1 transcripts tend to arise when HPV integration disrupts 
HPV genes E2/E4, and type 2 when integration disrupts HPV genes L2/L1.  represents 
splicing within a transcript. 
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cell line, and were consistent at early and late passage; however H09 had acquired an 
additional integrated transcript at late passage.  
To confirm the presence of integrated transcripts in each clonal cell line, flanking primers were 
designed, using PRIMER 3 software, to span the HPV-human junction of each integration site 
detected by APOT. The clonal cell line cDNA used for APOT was investigated using these primer 
sets to confirm the presence of specific integrated transcripts; PCRs were also performed using 
integrant-specific primers to investigate whether these integrated transcripts were present in 
clonal cell lines derived from the same parental heterogeneous cell line (PC08 or PC09). 
Amplified fragments for each clonal cell line are illustrated in Figure 5.4. The electrophoresis 
image shows that the flanking primers amplified the expected fragment in the relevant clonal 
cell lines. When the primer sets were used for PCR with other clones from the same 
heterogeneous line (e.g. D09 primers with H09 cDNA) an amplicon was not produced. This 
validated the results of the APOT analysis, and also confirmed that integrated transcripts were 
unique to each individual clonal cell line. An additional integrated transcript was detected in 
late passage H09 which might indicate that a HPV integration event occurred during short-
term culture. 
5.2.3.1 Main findings 
APOT analysis showed that integrated HPV was present in several of the lines and suggested 
that episomal HPV in others. Integrated transcripts were distinct in each clonal cell line, 
confirming that they represent independent clones. Integrated transcripts were consistently 
detected at early and late passage, which were independent samples and were confirmed 
using flanking primers. An additional integrated transcript was detected in one clonal cell line 
which might indicate that an integration event was acquired during culture. 
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Figure 5.4. Confirmation of integrated transcripts identified by APOT using flanking primers 
for HPV-human integration loci  
Unique primer sets were designed to interrogate HPV-human fused sequences within each 
sample. Amplicons of various sizes (see below) were therefore expected depending on the 
location of the primers during the design process. Amplicons were electrophoresed on 2% 
agarose gels, and fragment sizes for each clonal cell line and passage number were confirmed 
as follows: D09 at P5 (177 bp) and P11 (200 bp, 177 bp), H09 at P5 (161 bp) and P11 (168 bp, 
176 bp), M08 at P5 (152 bp, 150 bp, 164 bp, 155 bp), and Y08 at P9 (153 bp) and P13 (153 bp, 
110 bp).  
  
ladder 
  177        200         177        161        168         176        152         150        164      155        153        153        110  
    bp         bp           bp          bp          bp           bp          bp           bp          bp        bp          bp          bp          bp 
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5.2.4 Host genes disrupted by integration  
BLAST searches were used to identify host cell genes that were disrupted by HPV integration 
(Table 5.3). The functions of these genes were as follows: 
LEPREL1, also known as P3H2, encodes a member of the prolyl 3-hydroxylase subfamily of 2-
oxo-glutarate-dependent dioxygenases. These enzymes play a critical role in collagen chain 
assembly, stability, and cross-linking by catalyzing post-translational 3-hydroxylation of proline 
residues. Mutations in this gene are associated with nonsyndromic severe myopia with 
cataract and vitreoretinal degeneration, and downregulation of this gene may play a role in 
breast cancer (http://www.genecards.org/cgi-bin/carddisp.pl?gene=LEPREL1). LEPREL1 
expression has been reported to be down-regulated in breast cancer cell lines due to hyper-
methylation of CpG islands around exon 1 (Shah et al., 2009). Loss of collagen is an early event 
in the development of some epithelial cancers (Ikeda et al., 2006).  
CDCP1 encodes a transmembrane protein which contains three extracellular CUB domains and 
acts as a substrate for Src family kinases. The protein plays a role in the tyrosine 
phosphorylation-dependent regulation of cellular events that are involved in tumor invasion 
and metastasis (http://www.genecards.org/cgi-bin/carddisp.pl?gene=CDCP1). CDCP1 is up-
regulated in colon cancer (Scherl-Mostageer et al., 2001) and increased expression correlates 
with poor prognosis in lung cancer patients (Ikeda et al., 2009). 
TGIF1 encodes a member of the three-amino acid loop extension (TALE) superclass of atypical    
homeodomains. TALE homeobox proteins are highly conserved transcription regulators. The 
TGIF1 protein binds to a previously characterized retinoid X receptor responsive element from 
the cellular retinol-binding protein II promoter. In addition to its role in inhibiting 9-cis-retinoic 
acid-dependent RXR alpha transcription activation of the retinoic acid responsive element, the 
protein is an active transcriptional co-repressor of SMAD2 and may participate in the  
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Clonal 
cell line 
Passage 
no. 
Integration loci (chromosome and gene) 
DIPS APOT 
M08 
 
5 3q28.7 LEPREL1 3q28.7 LEPREL1 
9 3q28.7 LEPREL1 3q28.7 LEPREL1 
P08 
 
5 NA (episomal) NA (episomal)  
9 NA (episomal) NA (episomal) 
Y08 
 
9 3p21.31 CDCP1 3p21.31 CDCP1 
13 3p21.31 CDCP1 3p21.31 CDCP1 
A09 
 
5 NA (episomal) NA (episomal)  
11 NA (episomal) NA (episomal) 
11 NA (episomal) NA (episomal)  
D09 
 
5 18p11.31 TGIF1 18p11.31 TGIF1 
11 18p11.31 TGIF1 18p11.31 TGIF1 
H09 
 
5 11p15.3 MICAL2 5q11.2 no gene 
11 11p15.3 MICAL2 5q11.2 no gene 
11 22q12.3 LARGE 1p36.13 CLCNKB 
 
Table 5.3. Comparison of integration loci detected via DIPS and APOT  
The location of HPV integration within the host cell chromosome and the gene disrupted are 
shown for each clonal cell line. H09, highlighted in yellow, illustrates discrepant DIPS and APOT 
integration loci.  
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transmission of nuclear signals during development and in the adult. Mutations in this gene 
are associated with holoprosencephaly type 4, which is a structural anomaly of the brain 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=TGIF1). SMAD proteins are tumour 
suppressors that inhibit cell proliferation and are reported to be down-regulated in colorectal 
cancer (Xie et al., 2003). TGIF1 has been found to be expressed in several cancers (oesophagus, 
stomach, liver and leukaemia) (Hamid et al., 2008, Nakakuki et al., 2002, Borlak et al., 2005). 
TGIF1 located at 18p11.3 is a region commonly involved with head and neck squamous cell 
carcinoma (van den Broek et al., 2007, Noutomi et al., 2006). Reis and colleagues carried out 
detailed mapping of tumoural and non tumoural tissue through a Brazilian head and neck 
cancer project and found that TGIF1 transcripts were expressed (Reis et al., 2005). Expanding 
on this head and neck cancer project, Matizonkas-Antonio and colleagues studied the 
expression of TGIF1 transcripts and found that gain or loss of function might play a role in oral 
cancer cell differentiation (Matizonkas-Antonio et al., 2011).  
MICAL2 (microtubule associated monooxygenase, calponin and LIM domain containing 2) is a 
protein-coding gene, associated with visceral leishmaniasis, and prostate cancer 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=MICAL2). The MICAL2 gene product acts 
as a cytoskeletal regulator and is involved in axon guidance. The development of the nervous 
system is an invasive process and it is thought that overexpression of MICAL2 may contribute 
to invasiveness in prostate cancer (Ashida et al., 2006). 
LARGE is one of the largest genes in the human genome and encodes a glycosyltransferase 
which participates in glycosylation of alpha-dystroglycan, and may carry out synthesis of 
glycoprotein and glycosphingolipid sugar chains. Mutations in this gene cause MDC1D, a novel 
form of congenital muscular dystrophy with severe mental retardation and abnormal 
glycosylation of alpha-dystroglycan (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=LARGE). 
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CLCNKB encodes a member of the family of voltage-gated chloride channels. Chloride channels 
have several functions, including the regulation of cell volume, membrane potential 
stabilization, signal transduction and transepithelial transport. This gene is expressed 
predominantly in the kidney and may be important for renal salt re-absorption. Mutations in 
this gene are associated with autosomal recessive Bartter syndrome (a congenital kidney 
condition) (http://www.genecards.org/cgi-bin/carddisp.pl?gene=CLCNKB). 
5.2.4.1 Main findings 
The genes disrupted by HPV integration were in most cases previously documented to be 
associated with carcinogenesis. 
5.3 Relative expression of HPV genes 
Relative expression of HPV genes E2, E4, E5, E6 and E7 were assessed and normalised to stable 
house-keeping genes TBP2 and HRPT, which are constitutively expressed in keratinocyte cells. 
Expression was quantified relative to CaSki cDNA as a standard.  Relative expression of HPV 
genes was investigated using RNA extracted from clonal cell lines at each passage during short-
term culture. RNA was reverse transcribed to cDNA prior to performing qPCR and analysis, as 
previously described. Relative expression levels of house-keeping genes, TBP2 and HPRT, were 
analysed initially to ensure that expression levels were of equivalent difference for each 
passage of short-term culture; an example is illustrated for A09 in Figure 5.5.  
Each clonal cell line exhibited unique patterns of E gene expression, as shown in Figure 5.6; 
examples of real-time fluorescent traces are presented in Appendix III. In all clonal cell lines, 
unless found to be completely absent, transcripts of E2, E6, and E7 tended to be stable over a 
range of successive passages in culture, however E4 and E5 expression fluctuated more 
frequently, particularly in D09 and Y08, and were completely absent in clonal cell line M08. E2, 
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Figure 5.5. Mean relative expression ratios of house-keeping genes TBP2 and HPRT in A09 
Mean relative expression of HPRT was normalised to TBP2, and vice versa, at a range of 
passages during short term culture. Expression was calculated relative to standards produced 
for CaSki cell line. Error bars signify standard deviation.  
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Figure 5.6. Relative expression of HPV E2, E4, E5, E6, and E7 during short-term culture of 
clonal cell lines 
Relative expression was investigated in clonal cell lines at a range of passages: M08 (P5-9), P08 
(P5-9), Y08 (P9-13), A09 (P5-10), D09 (P5-10), and H09 (P5-10). Expression is relative to CaSki; a 
value of 1 indicates the same level of expression detected in the CaSki cell line. No data 
signifies that transcripts were not detected for a particular gene. Error bars signify standard 
deviation.  
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E6, and E7 were expressed at low levels relative to CaSki in all clonal cell lines except for D09, 
where E2, E4, E6 and E7 were expressed at higher levels than in CaSki.  
5.3.1.1 Main findings 
The clonal cell lines exhibited diverse patterns of HPV gene expression over multiple passages 
in culture. This reinforces the suggestion that the clones are distinct from one another. HPV 
oncogenes E6 and E7 were expressed in all clonal cell lines, but E2 expression was absent in 
2/6 lines (M08 and P08) and mRNA for E4 and E5 was undetectable in M08. Expression of HPV 
encoded genes was relatively stable in 4/6 lines but was less stable in lines Y08 and D09. 
 
5.4 Summary of HPV integration and expression profiles 
This section will bring together HPV integration status and relative gene expression patterns to 
create an overview for each clonal cell line.  
5.4.1 Heterogeneous PC08 and PC09 
PC08 cell line: E2 was found to be intact and no integration was detected. This data suggested 
that PC08 contained episomal HPV only, or an integrated HPV which was not detectable by 
APOT or DIPS.  
PC09 cell line: E2 was found to be intact and genomic integration was detected. This data 
suggested that PC09 contained either a mixed population of episomal and integrated HPV, or 
contained only integrated HPV, but with an intact E2 gene. The later scenario is consistent of a 
break site in the L1 region identified by DIPS (Table 5.1).    
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5.4.2 Clonal cell lines M08, P08 and Y08 
M08: E2 was found to be disrupted which was confirmed by absent expression of E2. 
Consistent genomic integration and integrated transcripts were also detected. This data 
suggested that M08 contained integrated HPV only. HPV E6 and E7 expression appeared stable 
during short-term culture at levels approximately half those present in the CaSki cell line. E4 
and E5 expression was absent, which is consistent with the breaksite detected by DIPS at nt 
1194 in the E1-E2 region upstream of E4 and E5. This data indicated that clonal cell line M08 
could be used as a suitable in vitro experimental model for integrated HPV in vulval neoplastic 
disease in future CDV dosing experiments.  
P08: HPV was initially believed to be episomal in this line, as integration was not suggested by 
DIPS or APOT analysis. This suggested that P08 could be used as a suitable in vitro 
experimental model for episomal HPV in vulval neoplastic disease in future CDV dosing 
experiments. However E2 PCRs later established that the E2 ORF was disrupted. Sequencing of 
the truncated E2 PCR product revealed a deletion of the E2 ORF from nt 2201 to 3147. This 
was consistent with the absence of E2 expression in qRT-PCR analyses (which were also 
conducted towards the end of the project). HPV E6 and E7 expression appeared stable during 
short-term culture at levels approximately half those observed in CaSki. E4 mRNA levels were 
approximately 1/10 of levels in CaSki, while E5 mRNA levels were over 10 fold higher.  
Y08: E2 was found to be intact and E2 expression was detected, however consistent genomic 
integration and integrated transcripts were also detected. This suggested that clonal cell line 
Y08 contained either a full length, possibly concatenated insertion, or a mixed population of 
episomal and integrated HPV. HPV E6 and E7 expression appeared stable during short-term 
culture at levels approaching 1/10 those of CaSki. However, E4 and E5 appeared to fluctuate 
markedly between passages, and for this reason Y08 was not considered for use as an in vitro 
model, since it exhibited characteristics which suggested molecular instability.  
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5.4.3 Clonal cell line A09, D09, and H09 
A09: E2 was found to be intact and E2 expression was detected. Genomic integration and 
integrated transcripts were not detected, however episomal transcripts were identified. This 
data suggested that clonal cell line A09 contained episomal HPV only. HPV E2, E6, and E7 
expression appeared stable during short-term culture at levels similar to CaSki; E4 and E5 
expression was also detected which is consistent with the presence of episomes. This data 
indicated that clonal cell line A could be used as a suitable in vitro experimental model for 
episomal HPV in vaginal neoplastic disease in future CDV dosing experiments.  
D09: E2 was found to be intact and E2 expression was detected. Consistent genomic 
integration and integrated transcripts were also detected. This data suggested that clonal cell 
line D09 contained either a full length, possibly concatenated, insertion or a mixed population 
of episomal and integrated HPV. HPV E2 and E7 expression appeared stable during short-term 
culture, however expression levels were higher than observed in CaSki. Additionally E4 
expression was detected which is consistent with episomal HPV. E4 and E6 levels showed a 
possible trend to increase with time in culture. E5 expression levels were very low or absent. 
Clonal cell line D was not considered for use as an in vitro model of mixed episomal/integrated 
HPV in vaginal neoplastic disease because it exhibited unstable molecular characteristics at 
levels comparable with CaSki (which is a cell line derived from a late metastatic tumour) and 
therefore considered to be a poor representation of neoplasia. 
H09: E2 was found to be intact and E2 expression was detected. Genomic integration and 
integrated transcripts were detected although integration loci were inconsistent; interestingly 
at late passage an additional genomic integration and integrated transcript was detected, 
however the genomic and transcript loci were inconsistent. This data suggested that clonal cell 
line H09 contained either a full length, possibly concatenated, insertion or a mixed population 
of episomal and integrated HPV. HPV E6 and E7 expression appeared stable during short-term 
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culture at similar levels to those in CaSki. E2 expressed at approximately 1/10 of the level of 
CaSki.  E4 and E5 were also found to be expressed which is consistent with the presence of 
episomes. This data indicated that clonal cell line H could be used as a suitable in vitro 
experimental model for mixed episomal/integrated HPV in vaginal neoplastic disease in future 
CDV dosing experiments. 
5.4.3.1 Main findings 
Stable M08, P08, A09 and H09 were selected for use as in vitro models of neoplastic disease 
for future CDV dosing studies, and comprised a selection of naturally occuring HPV integrated 
and episomal infected clonal cell lines representing vulval and vaginal neoplasia.  
  
5.5 Discussion 
The main conclusions of these investigations were: 
1. Different patterns of HPV integration were identified among clonal cell lines; 
i. E2 PCRs suggested integration had occurred in M08 and possibly in P08. 
ii. DIPS identified genomic insertion of HPV in heterogeneous PC09, and clonal 
cell lines M08, Y08, D09 and H09. 
iii. APOT identified human:HPV fusion transcripts in M08, Y08, D09 and H09. 
2. There was consensus between E2 PCR, DIPS, and APOT in all clonal cell lines except 
H09. 
3. The majority of genes found to be disrupted through HPV integration had previous 
association with carcinogenesis. 
4. Different patterns of HPV gene expression were identified in different clonal cell lines. 
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The main aim of the experiments described in this chapter was to determine whether the 
clonal cell lines showed different patterns of HPV integration state and gene expression. A 
secondary aim was to investigate the stability of these characteristics in short-term culture, 
over at least five passages. The isolation of clonal cell lines with different patterns of 
integration and gene expression meant that they could be used to model a range of naturally 
occurring HPV infections, and that integration state and HPV gene expression could potentially 
be correlated with response to drug treatment. 
5.5.1 Relationships between integration and gene expression 
The data also allows some observations to be made on the relationships between HPV 
integration and gene expression. In some cases the relationship was straight forward to 
interpret. For example, in M08 the absence of E2, E4 and E5 transcripts was consistent with 
the presence of integration disrupting the E1 gene at nt 1194 resulting in loss of transcription 
of downstream ORFs. Similarly in P08, DIPS identified a deletion of the E1-E2 region which 
included the E2 qRT-PCR amplimer, which is consistent with detection of E4 and E5 transcripts 
but absence of E2. However the data for other lines was more ambiguous; for Y08, full length 
E2 was amplifiable and E2, E4 and E5 were transcribed, however integration in E1 was also 
consistently detected by both DIPS and APOT. This data was suggestive of the presence of 
episomes or concatenated full length insertion of HPV, or a mixed infection with both 
episomes and integrants. There are examples of all of these possibilities in other cell lines; the 
CaSki cell line contains integrated full length concatenated HPV (Meissner, 1999) while the 
W12 cell line can contain episomal or integrated HPV, or a mixture of both (Pett et al., 2006).  
There is a widely accepted model of cervical carcinogenesis in which E2 loss, attributable to 
viral integration, leads to upregulation of the E6 and E7 oncogenes (Pett and Coleman, 2007). 
It was notable therefore that an inverse relationship was not observed between E2 and E6/E7 
expression in cultured cells. In fact the highest levels of E2 mRNA were in clonal line D09, 
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which also showed the highest levels of E6 and E7 expression. This suggests that in cultured 
cells this relationship does not hold true. Likewise there was no obvious correlation between 
HPV integration and gene expression; the A09 line was the only line showing no evidence of 
viral integration, and E6/E7 mRNA levels were similar to the other clonal lines. This may 
suggest that E6/E7 has been upregulated by other means in the A09 line, although it should be 
noted that the relationship between integration and HPV gene expression has been challenged 
in at least one publication (Hafner et al., 2008) 
5.5.2 HPV integration during culture 
Since integration analyses were not performed on early passage heterogeneous PC08 and 
PC09, it is not clear whether these integration events already existed in the heterogeneous 
populations and were selected out of it, or whether integrants were induced through the cell 
culture process. The data are possibly more consistent with the presence of the integrated 
clones in the parental heterogeneous population and selection during the dilution cloning 
step. This is because the integrated transcripts were detected in the very earliest passages and 
confirmed again at latest passage. The identification of new integration events in later passage 
cultures, as seen in H09 where a new integration event at 1p36.13 was identified in at P11, 
demonstrates that integration during the culture process is possible. The additional integration 
event in H09 at P11 was detected by both DIPS and APOT however the loci were inconsistent 
as previously described. Flanking primers were designed to span the HPV-human fused 
transcript detected in H09 at P11 only, and applied to cDNA from H09 at P5 and P11. The 
integrated transcript was detectable at P11 only.  
Intact E2 was also detected at early and late passage of H09, suggesting the presence of 
episomal HPV. Since H09 appears to have acquired an integration event which was confirmed 
in late passage only, integration of HPV may have occurred during short term culture which 
suggests that culturing cells might have induced episomal HPV to integrate in to the host DNA. 
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5.5.3 Gene disruption and link to carcinogenesis  
The genes disrupted via HPV integration were researched to identify previous literature which 
might suggest a role in promoting or enabling cell proliferation, providing cells with a selective 
growth advantage and possibly resulting in cell immortalization. Several of the genes disrupted 
had some reported association with cancer, but this was often when overexpressed rather 
than disrupted.  
5.5.4 Non-random integration events  
According to DIPS and APOT assays, HPV integration disrupted LEPREL1 (specifically at 3q28.7) 
in clonal cell line M08. Over the past few decades studies have shown that HPV integration 
occurs within regions of fragile sites (FS) and in cluster formations at chromosome loci which 
might reflect chromosomal regions that are generally unstable (Wentzensen et al., 2004).  
Schmitz and colleagues provided further support for a clustering of HPV integration sites in 
chromosomal ‘hot spot’ regions, of which 3q28 LEPREL1 was described (Schmitz et al., 2012).  
Thus, detection of integration also at LEPREL1 in M08 might contribute to supporting the 
theory of non-random integration of HPV within FS that is described in the literature.   
5.5.5 Order of assays and integration status of P08 
It is important to note that the assays were not performed in the same order in which the data 
is presented. APOT and DIPS were performed early in the project, and E2 PCRs were developed 
and applied towards the end of the project. Similarly, the E2 specific qRT-PCR assays were not 
developed and applied until the latter phases of the project. This was because a published E2 
primer set was initially used  (Roberts et al., 2008), however it was later noted that this primer 
set was located within the region of the E2 ORF that overlapped with the E4 ORF, and this 
primer set actually amplified cDNA corresponding to both E2 and E4. A second primer set was 
hence designed corresponding to the upstream region of the E2 ORF; this primer set is specific 
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to the E2 sequence only and is referred to in this thesis as “E2” while the original E2/E4 primer 
set is referred to as “E4”. 
This is highly relevant to the integration state of P08 as data from the assays performed first 
(DIPS and APOT) both suggested that HPV was episomal in this clone, i.e. no evidence for 
integration was found. Therefore for the majority of this project, P08 was thought to contain 
episomal HPV. When the E2 PCRs were performed it became apparent that P08 contained a 
truncated E2 gene with a 1077bp deletion from nt 2070 to 3147 (illustrated previously in 
Figure 5.1). This region covers the upstream region of the E2 gene including the E2 specific 
qRT-PCR amplimer. This finding was consistent with the qRT-PCR data derived using the newer 
primer sets which showed complete absence of E2 in P08 but detectable E4 (at 1/10 the levels 
detectable in CaSki).  
These findings changed the assessment of the integration state of HPV in P08. E2 is a 
multifunctional protein (McBride, 2013).  It is the main transcriptional regulator for many 
papillomaviruses (Phelps and Howley, 1987) but also has other essential functions in the viral 
life cycle. E2 initiates replication by loading the E1 helicase on to the viral origin of replication 
(Sanders and Stenlund, 2000, Mohr et al., 1990), and is also involved in genome partitioning by 
joining viral genomes to host chromosomes (Bastien and McBride, 2000, Ilves et al., 1999, 
Lehman and Botchan, 1998, Skiadopoulos and McBride, 1998). E2 is also almost certainly 
required for productive viral DNA replication (McBride, 2013). It therefore seems very unlikely 
that the truncated E2 present in P08 would be consistent with stable replication and 
maintenance of episomal HPV. This question could be resolved by Southern blotting extracted 
DNA and probing with full length HPV sequences as described by Alazawi and colleagues 
(Alazawi et al., 2002). Unfortunately time constraints prevented this experiment from being 
undertaken but would be informative future work. 
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5.5.6 Strengths and Weaknesses 
The data illustrate several of the strengths and weaknesses of the assays employed, which can 
be summarised as follows: 
The E2 PCR assay is quick and relatively simple to perform and uses only a small quantity of 
DNA (Collins et al., 2009). However it can only conclusively show integration when the 
integration event results in disruption of the E2 sequence and no full length E2 is present, 
either as a full length insertion or as episomes. 
The APOT assay is useful to identify transcriptionally active integration events (Klaes et al., 
1999), but it is complex, labour intensive and expensive. It also doesn’t identify 
transcriptionally silent integrants or integration events that occur too far from a relevant 
restriction site, i.e. the assay depends on there being a restriction site within a PCR amplifiable 
range of the integration site.  APOT will identify integrated HPV, but detection of integrants 
does not rule out the presence of episomal HPV (i.e. a mixed population of integrated and 
episomal HPV). 
The DIPS assay is useful to identify the exact sites of chromosomal integration and can identify 
transcriptionally silent integration events (Luft et al., 2001). It shares several of the limitations 
of APOT; it is relatively complex and labour intensive, will not identify integration sites that are 
too distant from restriction sites used in the initial digestions, and identification of integrated 
HPV does not exclude the presence of episomal HPV. 
Nevertheless a combination of these molecular based assays (E2 PCR, APOT and DIPS) are 
sensitive and have been reported in the literature to determine HPV integration status.  
5.5.7 Discrepencies between APOT and DIPS 
APOT and DIPS failed to detect the same integration loci in clonal cell line H09, with several 
possible explanations.  
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Multiple integration loci might exist within cells, and therefore DIPS or APOT might detect the 
most frequently occurring (or dominant) integration event. It is therefore plausible that a 
‘dominant’ genomic integrant detected via DIPS is not transcriptionally active and therefore 
not detectable via APOT. Similarly, the ‘dominant’ integrated transcript detectable via APOT 
may not have been a ‘dominant’ genomic integrant and therefore not detectable via DIPS. 
However in H09, 2 integration loci were detectable in the same sample which does not support 
this theory unless both integrants were equally dominant.  
There are limitations associated with both assays, as previously discussed. Both assays depend 
on there being a restriction endonuclease site within a PCR amplifiable range of the integration 
site for it to be detected. It could be that one integrant but not the other was detectable in 
each assay.   
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6 Optimisation of cidofovir (CDV) dosing protocol 
6.1  Results 
A selection of clonal cell lines were characterised previously. Of these, clonal cell lines M08 and 
P08 (vulval), that represented integrated and episomal states of HPV infection with stable E6 
and E7 expression, were used to optimise the CDV dosing protocol. A series of optimisation 
experiments were carried out, which will be described in this chapter, with the primary 
objective of establishing a final CDV dosing protocol. The final CDV protocol was used to assess 
cellular and molecular response to CDV treatment using several clonal cell lines as 
experimental models of vulval and vaginal neoplastic disease, which will be described in 
chapter 7.   
Initially, optimisation experiments were performed using cells cultured in 96 well plates, which 
required fewer cells, smaller volumes of reagents, and was a less labour and resource intensive 
method of obtaining replica data sets. Experiments were then translated to 6 cm diameter TC 
dishes, which would ultimately be used, in order to generate a sufficient quantity of cells for 
downstream analyses. 
Previous studies have evaluated the effects of CDV in HPV positive cell lines through dosing 
cells with 10 µM CDV (Amine et al., 2009).  Thus cell viability was assessed in M08 and P08 cell 
culture models using a range of CDV concentrations surrounding this value.  The fraction of 
cells that survived CDV treatment was also determined, and the concentration of CDV causing 
inhibition of 50% of the cell population (or inhibitory concentration = IC50) was also calculated. 
The confluence of cell cultures seeded at a variety of cell densities was also assessed over a 
period of 4 days.  The seeding density was optimised so that cultures would establish during 
the first 24 hours but would not exceed >80% by the final day of the experiment; this ensured 
that cells were proliferating for the entirety of the dosing protocol.   
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6.1.1 Aims and objectives 
The central aim was to design and optimise a dosing protocol through establishing suitable 
CDV dosing parameters.  
The following objectives structured this section of work: 
1. Investigate whether seeding cell density affects response to CDV treatment.  
2. Investigate whether 10 µM CDV dose will result in reduced growth, ideally 
approximating IC50. 
3. Explore the potential for scaling-up culture vessels from 96 well plates to 6cm TC 
dishes. 
6.1.2 Study sample 
Clonal cell lines M08 and P08 at P8 were cultured for optimisation studies. Cultures were not 
supplemented with irradiated 3T3 feeders in order to maintain a homogeneous cell population 
to accurately assess dose response, which was previously justified in chapter 4.  
 
6.2 Optimisation in 96 well plate format 
6.2.1 Cell density did not affect the toxicity of CDV  
A 7 day (168 hour) dosing regime was set up in 96 well plates. The aim of this initial dosing 
regime was to analyse dose response using a range of seeding cell densities (5,000, 7,000 and 
10,000 cells/well) combined with a range of CDV concentrations (1, 10, and 100 µM). Cultures 
were treated with CDV at 24 hours (day 1) and 96 hours (day 4). Response to CDV was 
assessed at 96 hours (day 4) and 168 hours (day 7) by performing trypan blue viable cell 
counts.  
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Error! Reference source not found.Figure 6.1 illustrates M08 viable cell counts on days 0, 4 
and 7 of the dosing protocol. Viability cell counts were mostly inversely proportional to CDV 
concentration at all seeding cell densities. This suggested that, within the range examined, 
response to CDV was not dependent on the number of cells being dosed. 
The surviving fractions on day 7 were plotted against CDV concentration in Figure 6.2, and data 
was linearised by Log transformation; the IC50 was then calculated from the resulting linear 
regression equations using the formula in Equation 6.1 (where is Y = 0.5, M is slope, and C is 
constant). 
The surviving fraction was around 0.5 using 10 µM CDV for all seeding cell densities (Table 6.1). 
The IC50 was more variable, falling at approximately 10 µM at seeding densities of 5,000 and 
10,000 cells/well; however the IC50 was four fold higher for cell cultures seeded at 7,000 
cells/well.  
6.2.1.1 Main findings 
 
Within the range investigated, surviving fraction after treatment with CDV was affected by 
seeding cell density. IC50 for CDV was close to 10 µM on the final day for cultures seeded at 
5,000 and 10,000 cells, except for cultures seeded with 7,000 cells/well.  
 
6.3 Optimisation in 6 cm diameter TC dish format 
6.3.1 Seeding cell density affected time taken to reach confluence 
Preliminary dosing studies were also performed in 6 cm diameter TC dish format.  The 
advantage of culturing cells in a larger vessel, were the generation of greater quantities of cells 
which would be useful for down-stream analyses in later experiments to assess molecular  
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Figure 6.1. Viable cell counts of clonal cell line M08 with CDV  
M08 cultures were prepared by seeding a 96 well plate with (A) 5,000 cells/well, (B) 7,000 
cells/well, (C) 10,000 cells/well and carrying out x2 CDV doses of 0, 1, 10 and 100 µM CDV at 
24 hours and 96 hours of a 168 hour regime. Response to CDV was assessed by viable counts 
performed at 96 hours and 168 hours. The embedded key shows [CDV].  Error bars signify 
standard deviation. 
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Figure 6.2.  Surviving fraction vs. [CDV] at 168 hrs (day 7) for clonal cell line M08  
Correlation of Log transformed cell surviving fraction and CDV concentration in M08 cultures 
seeded at (A) 5,000 cells/well, (B) 7,000 cells/well, and (C) 10,000 cells/well. Linear regression 
equations have been included in the format of          
y = -0.32x - 0.0015 
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Equation 6.1. The formula used to derive IC50 values from linear regression equations. 
 
 
 
 
 
Cells seeded (cells/well) Surviving fraction at 10 µM IC50 (µM) 
   5,000 0.46 7.63 
7,000 0.56 44.51 
10,000 0.54 16.46 
 
Table 6.1. Surviving fraction of M08 cells at 10 µM and IC50 of CDV at 168 hours (day 7) at 
varying seeding densities   
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Response(s) to CDV.  The aim of this experiment was to determine optimal seeding cell density 
for cultures in a 6 cm TC dish, so that cultures would establish within the first 24 hours but not 
exceed >80% confluence before the end of the experiment. 
The seeding densities required for a 6 cm TC were guided by scaling from the relative surface 
area of 1 well of a 96 well plate, to a 6 cm plate. M08 was used to seed 6 cm TC dishes in 
triplicate at 1x105, 5x105, and 1x106, and maintained in culture for 96 hours. Cultures were 
viewed microscopically 24 hours (day 1) after cell establishment and at the end of the 
experiment at 96 hours (day 4), to assess keratinocyte/colony morphology and percentage 
confluence.  
Dishes seeded at 1x105 established poorly during the first 24 hours and ‘craters/gaps’ were 
observed in the monolayer and cells were present in media suspension; cultures reached 40% 
confluence after 4 days. Plates seeded at 5x105 established after 24 hours and reached ~80% 
confluence after 4 days without any unusual observations within the cell monolayer. Dishes 
seeded at 1x106 established after 24 hours, however by day 4 cell cultures were already 100% 
confluent.  
6.3.1.1 Main findings 
The experimental format was scaled up to 6 cm TC dishes and a seeding density of 5x105 in 6 
cm TC dishes was selected for the final CDV dosing protocol. Cells established well after 24 
hours and reached the required percentage confluence of ~80% in the desired time-frame (4 
days).  
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6.4 Preliminary CDV dosing protocol  
Based on the previous optimisation studies, a preliminary CDV dosing protocol was devised 
lasting 72 hours and consisting of cultures seeded at 5x105 in 6 cm TC dishes, as described and 
illustrated previously in Figure 2.8. A time period of 72 hrs rather than 96 hours was selected 
to avoid any chance of cells reaching confluence. A single 10 µM CDV dose was given 24 hours 
after seeding. Trypan blue viable cell counts and cell morphology were assessed 24 and 48 
hours after dosing. The preliminary protocol was performed to ensure that response to CDV 
could be detected under similar conditions intended for use in the final CDV dosing protocol.   
6.4.1 Response to CDV: cell viability 
Viable cell counts of M08 and P08 decreased slightly 24 hours after seeding, as shown in Figure 
6.3. In both M08 and P08, viable cell counts were lower in the CDV dosed arm compared to the 
no dose control. At 24 hrs post treatment in M08, cell numbers were reduced by 
approximately two thirds in the CDV treated plates, while for P08 they were reduced by 
approximately half. There was a statistically significant difference 24 hours after treatement 
for M08 and P08 (M08 and P08: p = >0.0001 at p < 0.05 using 2-tailed t-test). After 48 hours of 
CDV treatment, viable cell counts increased in M08 but continued to decrease in P08; for both 
lines at this time point, there was a statistical significance between treated and untreated 
samples (M08 and P08: p = >0.0001 at p < 0.05 using 2-tailed t-test). There were some notable 
differences between the cell lines; especially that despite the same number of cells being used 
for the initial inoculum, higher cell counts were recorded in M08 at 72 hours in both the 
treated and untreated samples. 
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Figure 6.3. Cell viability counts of M08 and P08 during preliminary CDV dosing protocol. 
M08 and P08 were seeded at 5x105 in 6 cm TC dishes in duplicate. Cultures were treated with 
10 µM CDV 24 hours after seeding (as indicated in figure). An initial viable cell count was 
performed 24 hours after seeding. Viable cell counts were also performed 24 and 48 hours 
after cultures were treated with and without CDV. Error bars signify standard deviation. A 
statistically significant difference was found 24 and 48 hours after CDV treatment in M08 and 
P08 (M08 and P08, 24 hrs: p = > 0.0001., 48 hrs: p = > 0.0001 (at p < 0.05 (2-tailed t-test)). 
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6.4.1.1 Main findings 
A response to CDV treatment was identified by reduced viable cell counts at 24 and 48 hours 
after treatment in both cell lines, which were shown to be statistically significant. At both time 
points CDV treatment appeared to reduce viablilty by approximately 50-70%.  
6.4.2 Response to CDV: cell morphology 
Cell cultures of M08 and P08 were viewed microscopically 24 hours after being treated with 
and without CDV (Figure 6.4 and Figure 6.5). Keratinocytes of M08 appeared enlarged at 24 
and 48 hours post CDV dose when compared to no dose controls. Keratinocytes of P08 
appeared enlarged and resembled ‘fried egg’ morphology within the monolayer at 24 and 48 
hours after CDV treatment which was not observed in no dose control cultures. ‘Craters’ were 
also visible in the cell monolayer 48 hours after CDV treatment in P08.  
6.4.2.1 Main findings 
Keratinocyte morphology of M08 and P08 was obviously different in response to CDV 
treatment when compared to no dose controls. Keratinocytes became enlarged, more 
noticeably 48 hours after CDV treatment in both cell lines.  
 
6.5 Discussion 
The main conclusions of these experiments were that: 
1. Within the range investigated, seeding density did affect response to CDV. 
2. 10 µM was an appropriate dose, as it approximated an IC50 dose at 7 days (i.e. it 
produced a quantifiable response). 
3. The experiments were scaled up to higher volumes, and appropriate seeding densities 
were determined.  
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M08 
No dose              10µM CDV 
               
           
 
Figure 6.4. Morphology of M08 during preliminary CDV dosing protocol 
Cultures of M08 were visualised at 50x total magnification 24 and 48 hours after being dosed 
with and without CDV.  
  
24 hrs  24 hrs 
48 hrs 48 hrs 
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P08 
No dose              10µM CDV 
            
            
 
Figure 6.5. Morphology of P08 during preliminary CDV dosing protocol. 
Cultures of P08 were visualised at 50x total magnification 24 and 48 hours after being dosed 
with and without CDV. Red circles highlight enlarged cells which resembled ‘fried egg’ 
morphology, and blue arrows point to ‘craters’ observed in the monolayer which might 
represent areas where keratinocytes have detached from the monolayer.   
  
24 hrs 24 hrs 
48 hrs 48 hrs 
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4. In 6 cm TC dishes 10 µM CDV reduced viable cell counts by 50-70% at 24 and 48 hrs. 
These experiments provided useful information to develop variables constituting the final CDV 
dosing protocol in this experimental cell culture system. 
The IC50 doses calculated from the experiments conducted in 96 well plates were consistent for 
the wells seeded with 5000 and 10000 cells (7.63 and 16.46 µM) but a higher value was 
obtained for the wells seeded with 7000 cells. From Figure 6.2B, it seems that a slightly 
different dose response relationship was seen compared to the Figure 6.2A and C, with less 
effect at lower concentration and more effect at higher concentrations. Given that values 
closer to 10 µM were found in the other two experiments, it seems likely that this higher IC50 
may be anomalous. 
The results of the initial experiments conducted in 6 cm plates suggested that it was possible 
to scale the experiments up to larger volumes. This was required to produce sufficient material 
(nucleic acids) for downstream analysis in the final protocol. These experiments also 
demonstrated the importance of optimising seeding density, because at lower densities cells 
displayed altered morphology while cultures at higher densities reached confluence within the 
experimental timeframe (which was undesirable as it would impose an artificial limit on 
proliferation and could alter gene expression patterns). These studies also determined the 
optimal seeding density to be used in the final study. A density of 5x105 cells in 6 cm TC dishes 
was selected since it provided sufficient cell numbers for successful establishment and growth, 
without becoming over-confluent by the final day of the dosing experiment (earlier preliminary 
cell culture studies (chapter 4) had demonstrated that cells seeded at too low a cell density 
exhibited cell density-dependant growth inhibition identified by detachment of cells from the 
monolayer during the first 24 hours of culture and poor growth thereafter).  
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The time period for this study was reduced from 168 hours in the initial experiments, to 96 
hours and then further to 72 hours. This was considered necessary to avoid any chance of cells 
reaching confluence. It also accounted for the desired experiments to follow (to investigate 
molecular effects of CDV) which would have a shorter time course. For example, for 
transcriptional responses to be detected cultures would be assessed 12-24 hours after dosing.  
Additionally, a relatively high seeding cell density would be required to provide sufficient 
cellular material, which would be inconsistent with longer time courses. The shorter time 
course also allowed treatment with a single dose of CDV rather than multiple doses. 
The first attempt at dosing M08 and P08 in 6 cm TC plates showed that 10 µM CDV was 
effective in reducing viable cell count. There were some differences in the data obtained with 
96 well plates and 6 cm plates; these related mainly to the time taken to achieve a quantifiable 
effect. In 96 well plates (Figure 6.3) it did not appear that 50% inhibition was achieved within 
24-48 hours post dosing, whereas this effect was evident in the larger plates (Figure 6.3).  
The data shown in Figure 6.3 also confirmed earlier indications that M08 was the more 
vigorously growing of the two clonal cell lines examined. This is perhaps consistent with the 
subjective impression from Figure 6.4 that the morphology of P08 is more variable and that 
CDV dosing appeared to have a more visible effect in this line. 
6.5.1 Strengths and weaknesses 
The strengths of these experiments were that growth conditions were optimised to direct the 
development of a dosing protocol, without haphazard investigation. The optimisation and 
dosing experiments performed were conducted in two cell lines in a variety of formats with 
largely consistent results. The weaknesses include the small number and coverage of CDV 
concentrations in optimisation, and in hindsight the range of concentrations could have been 
spread more evenly around the 10µM concentration.  
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More detailed growth curves, again with a greater range of concentrations, would have 
allowed more exact IC50 calculations to be performed. However for the purpose of determining 
an appropriate concentration to investigate CDV mechanism of action, these experiments 
were adequate. 
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7 Response to CDV in clonal cell lines 
7.1 Results 
A series of cell culture and CDV optimisation studies were previously performed to develop a 
final dosing protocol, which will be described in this chapter.  A selection of clonal cell lines, 
which comprised integrated and episomal versions of HPV with neoplastic vulval and vaginal 
origin, underwent the dosing protocol. Response to CDV treatment was investigated to give 
insight in to the molecular mechanism(s) of action of CDV in these clonal cell lines, which might 
be indicative of response to CDV observed in clinical disease.   
Our current understanding is limited as only a few studies have specifically investigated the 
mechanism of action of CDV in HPV related anogenital disease.  CDV has previously been 
shown to be specific to cells containing HPV when normal neonatal foreskin keratinocytes 
were compared to non-tumourigenic d-2C HPV16-transformed keratinocytyes (Johnson and 
Gangemi, 1999). CDV has been found to reduce E6 and E7 transcription although this effect 
was modest (50% reduction in E6/E7 transcripts at 3 days post treatment with 10µg/ml CDV) 
and based on experiments performed using semi-quantitative RT-PCR in the HEP2 cell line 
which was derived from an HPV18 positive head and neck squamous cell carcinoma 
(Abdulkarim et al., 2002). The authors demonstrated nuclear accumulation of p53 after CDV 
treatment and suggested that reduced E6/E7 expression revived tumour suppressor pathways 
that regulate the cell cycle resulting in G2/M blockage and accumulation of HPV positive cells 
in S phase. There was no increase in apoptotic cell death and the absence of apoptosis in 
response to 10µg/ml CDV was confirmed by TUNEL assay. A more recent study examined the 
effect of CDV treatment on E6 protein levels using western blots and suggested that following 
6 days of treatment with an unspecified dose of CDV E6 levels were reduced (although the 
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degree of reduction was not quantified) (Amine et al., 2009). The same authors also suggested 
that treatment with CDV did result in apoptosis in HPV positive cells. 
These studies have used immortalised cell lines as investigational models of HPV related 
disease. HPV infected immortalised cell lines such as CaSki (Pattillo et al., 1977), SiHa (Friedl et 
al., 1970) and HeLa (Gey et al., 1952, Jones et al., 1971), originate from metastatic tumours 
and have accumulated a selection of mutations and rearranged genomic structures (Meissner, 
1999) contributing to a cell phenotype which proliferates uncontrollably and poorly represents 
disease seen clinically. In contrast, this project focused on the action of CDV in the treatment 
of neoplastic disease using the relatively early passage HPV16 positive VIN3/VaIN3 clonal cell 
lines. These lines resemble precancerous neoplasia better than alternative immortal models as 
they were derived from neoplastic biopsies and are used at early passages. 
The primary objective of this chapter was to determine whether the action of CDV currently 
described in the literature, was reproducible in clonal cell culture models.  Other attributes of 
the clonal cell lines that might affect response to CDV treatment were also considered (i.e. 
anatomical origin of cell lines (vulval or vaginal) and HPV integration status (episomal or 
integrated)).  An initial assessment of cell death, without distinguishing between cell apoptosis 
or necrosis, was performed through manual trypan blue viable cell counts and microscopic 
analysis of cell morphology.  To specifically investigate induction of apoptosis as a mechanism 
of cell death, cell populations were assessed for apoptosis markers using fluorescence-
activated cell sorting (FACS) and annexin V/7-Aminoactinomycin D (7-AAD) staining, and the 
percentage of cells engaged in early and late apoptosis assayed by flow cytometry. Apoptosis 
data was not generated through flow cytometry due to the adherent nature of keratinocytes 
that caused problems for flow cytometry machinery which was currently in use for 
haemopoetic (non adherent) cells (kindly provided by Haematology department, University 
Hospital of Wales); repetitions were carried out but the problem persisted and an alternative 
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option was not performed due to the project timeframe.  Relative expression of HPV 
oncogenes E6 and E7 was investigated using qRT-PCR.  
The results were assessed to determine whether there were differences in response between 
cells from the two different anatomical sites (vulva vs. vagina) and to investigate whether HPV 
integration status (episomal or integrated) might affect response to CDV. Whole transcriptome 
sequencing via RNA-Seq of CDV treated and untreated cell lines was also performed. This 
allowed differential gene expression to be determined using the complete set of gene 
transcripts within a cell, thereby eliminating the selectivity of analysing specific gene 
transcripts; transcriptome sequencing is described in chapter 8. 
7.1.1 Aims and objectives 
The central aim was to determine whether the action of CDV currently described in the 
literature was reproducible in the clonal cell culture models, thereby giving insight in to the 
molecular mechanism(s) of action of CDV in neoplastic disease.  
The following objectives structured this section of work: 
1. Investigate whether CDV treatment will result in fewer viable cells. 
2. Investigate whether a more marked effect will be seen in HPV16 infected clonal cell 
lines compared to HPV negative HEKn cell line. 
3. Investigate whether fewer viable cells may be a result of cellular apoptosis. 
4. Investigate whether HPV oncogene expression will decrease in response to CDV 
treatment. 
5. Explore whether there is a difference in dose response between vulval and vaginal 
clonal cell lines, and cell lines containing integrated and episomal HPV. 
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7.1.2 Study sample 
Clonal cell lines derived from VaIN 3; A09 (HPV16 episomal) and H09 (HPV16 integrated), and 
clonal cell lines derived from VIN3; M08 (HPV16 integrated) and P08 (HPV16 status 
unconcluded (chapter 5) were prepared for the CDV dosing study at P11 in both experiments. 
Neonatal human epidermal keratinocytes (HEKn) at P3 were also prepared for the CDV dosing 
study, representing a HPV negative primary keratinocyte cell line. Clonal cell cultures were not 
supplemented with irradiated 3T3 feeders to maintain a homogenous cell population for 
accurate assessment of dose response, as justified in chapter 4. 
7.2 The final CDV dosing protocol 
The final CDV dosing protocol was carried out as previously described and illustrated in Figure 
2.9 and described in chapter 6. To summarise, the protocol was carried out in 6 cm TC dishes 
seeded with 5x105 cells (in duplicate).  The protocol lasted 2.5 days (60 hours) and consisted of 
1 CDV dose using 10 µM CDV which was given 24 hours after seeding.  Response to CDV was 
assessed in treated cultures and in no dose controls 12 and 36 hours after dosing.  
Cells underwent down-stream analyses (experiment 1 and 2), as summarised in the flow-chart 
(Figure 7.1).  In experiment 1, cell cultures were viewed microscopically to assess changes in 
cell morphology, trypsinised and trypan blue viable cell counts taken (in triplicate) to give an 
indication of cell death (without distinguishing between cell apoptosis or necrosis). FACS and 
cytometric assay was then performed to investigate the percentage of cells undergoing 
apoptosis. In experiment 2, cell cultures were also viewed microscopically at each time point. 
Cells were rinsed with PBS and lysed directly from the cell monolayer using RLT buffer and 
beta-mercaptoethanol (βME) (without trypsinisation), and DNA and RNA extraction performed 
simultaneously. RNA was used to assess HPV E6 and E7 oncogene expression via qRT-PCR. RNA 
was also used to perform SOLiD™ RNA sequencing, which will be described in chapter 8. 
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Figure 7.1.  Overview of down-stream analyses performed using cells after CDV dosing  
Following the CDV dosing protocol, down-stream analyses (experiment 1 and 2) were 
performed using clonal cell lines M08, P08, A09 and H09 at P11. Cell cultures were analysed 
microscopically to assess keratinocyte morphology, viable cell counts were performed, and 
fluorescence-activated cell sorting (FACS) were performed to investigate apoptosis 
(experiment 1). Duplicate cell cultures were also analysed microscopically to assess cell 
morphology, and lysed for nucleic acid extraction. RNA extracts were quantified and used to 
investigate relative expression of HPV oncogenes (E6 and E7) using qRT-PCR, and also 
underwent RNA-sequencing.  
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7.3 Response to CDV 
Response to CDV treatment was assessed through trypan blue viable cell counts, 
morphological analysis of keratinocytes, and investigating relative expression of HPV 
oncogenes (E6 and E7) as previously described.   
7.3.1 CDV reduces the number of viable cells  
At all time points during two independent repeats of the CDV dosing protocol, treated and 
untreated cells were rinsed with PBS and trypsinised to obtain single cell suspensions, and 
trypan blue viable cell counts performed using a haemocytometer; triplicate viable cell counts 
were performed and combined.   
A reduction in mean viable cell count was seen in response to CDV treatment in all clonal cell 
lines and in HEKs.  The surviving fraction of cells 12 and 36 hours after 10µM CDV treatment 
for clonal cell lines and HEKs are illustrated in Figure 7.1.  Twelve hours after being treated 
with CDV, 50% and 59% of cells remained viable in vulval lines M08 and P08 respectively, 85% 
and 89% in vaginal lines A09 and H09 respectively, and 60% in HEKs. Thirty six hours after 
being treated with CDV, the number of viable cells remained relatively stable in M08 (2% 
decrease), but increased by 9% in P08. In vaginal lines A09 and H09, the number of viable cells 
had decreased by 13%. The number of viable cells remained relatively stable in HEKs (2% 
decrease).  After 12 hours of treatment, there was a significant difference between surviving 
fraction of vulval cell lines (M08 and P08) and vaginal cell lines (A09 and H09) (p = 0.0194 at p < 
0.05 (2-tailed t-test)).  There was no significant difference between surviving fraction of vulval 
and vaginal lines 36 hours after treatment (p = 0.2514). After 12 hours of treatment, surviving 
fractions of vulval lines with HEK lines were not found to be significantly different (p = 0.3061), 
and vaginal lines with HEK lines were found to be significantly different (p = 0.0061), at p < 
0.05. After 36 hours of treatment, vulval lines and HEKs were not found to be significantly 
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different (p = 0.7493), and vaginal lines with HEKs were found to be significantly different (p = 
0.0332).  
Viable counts at all time points of the dosing study, for untreated cells, were used to create 
growth curves for clonal cell lines and HEKs (Figure Figure 7.2). From this, the growth of M08 
and H09 appeared to be more rapid than A09 and P08, followed by HEKs. Viability counts 24 
hours after seeding were also much lower than the initial seeding cell density (= 5x105 cells) in 
A09 and P08.   
7.3.1.1 Main findings 
A reduction in viable count was seen in response to CDV in all cell lines. Surviving fractions 12 
hours post CDV treatment showed a more considerable response to  10µM CDV in vulval clonal 
lines (M08 and P08) than vaginal lines (A09 and H09), which was statistically significant, 
suggesting that vaginal lines are less sensitive to the effects of CDV treatment.  After an 
additional 24 hours in CDV, the surviving fraction of cells for M08 remained relatively stable, 
but increased in P08, and decreased the same percentage in A09 and H09.  The difference in 
survival fraction of A09 and H09 suggested that these vaginal lines were more sensitive to CDV 
24 hours after treatment than vulval lines. In terms of comparison with HEK (HPV negative), 
after 12 hours of treatment, survival fractions of vulval and HEk lines were not significantly 
different, but vaginal and HEK lines were; this was reflected at 36 hours also. This suggested 
that HPV negative HEK lines were also sensitivie to CDV treatment, with a response that was 
more comparable with the vulval lines.  
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Table 7.1. Survival fractions at 12 and 36 hours after treatment with CDV. 
Mean viable cell counts of P3 HEKs, P 11 vulval cell lines (M08 and P08), and P11 vaginal cell 
lines (A09 and H09), were used to calculate the surviving fraction of cells at 12 and 36 hours 
post treatment. The surviving fractions illustrated are calculated from the mean viable counts 
(in triplicate) from 2 separate CDV dosing experiments. Surviving fractions of vulval cell lines 
and vaginal cell lines were significantly different 12 hours after treatment at p < 0.05 (2-tailed 
t-test (p=0.0194)), and were not significantly different 36 hours after treatment (p=0.2514). 
After 12 hours of treatment, surviving fractions of vulval and vaginal lines in comparison to 
HEK lines were not found to be significantly different and not significantly different, 
respectively (vulval: p = 0.3061., vaginal: p = 0.0061). After 36 hours of treatment, vulval and 
vaginal lines with HEKs were not found to be significantly different and found to be 
significantly different, respectively (vulval: p = 0.7493., vaginal: p = 0.0332).   
 
  
 
Cell line 
Surviving fraction  
Difference 12 hrs 36 hrs 
M08 
P08 
A09 
H09 
HEKs 
0.51 (51%) 
0.59 (59%) 
0.85 (85%) 
0.89 (89%) 
0.6 (60%) 
0.49 (49%) 
0.68 (68%) 
0.72 (72%) 
0.76 (76%) 
0.62 (62%) 
-0.02 (-2%) 
0.09 (9%) 
-0.13 (-13%) 
-0.13 (-13%) 
0.02 (2%) 
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Figure 7.2. Viability cell counts at each time point of the CDV dosing protocol  
Mean viable cell counts of untreated P3 HEKs and P11 clonal cell lines M08, P08, A09, and H09, 
at 24, 36, and 60 hours; data was calculated from triplicate cell counts of 2 separate CDV 
dosing experiments. Error bars signify standard deviation.    
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7.3.2 CDV affects keratinocyte morphology 
HEKs and clonal lines were examined microscopically to assess keratinocyte morphology in two 
independent repeats of the CDV dosing protocol. Keratinocyte morphology of M08 (Figure 7.3, 
Figure 7.4), P08 (Figure 7.5, Figure 7.6), A09 (Figure 7.7, Figure 7.8), H09 (Figure 7.9Figure 
7.10), and HEKS (Figure 7.11, Figure 7.12), at 12 and 36 hours after CDV treatment (and no 
dose control) are shown. Figure 7.13, taken from (Li et al., 2012), is included to illustrate the 
morphological appearance of apoptosing keratinocytes. Treatment with CDV had a distinct 
effect on keratinocyte morphology, with larger cytoplasmic compartments, and more rounded 
keratinocytes lacking tessellation pattern in the monolayer; this effect was not evident for 
HEKS (Figure 7.11, Figure 7.12).  For vulval cell line M08, the effect was evident at 12 hours 
post treatment and was increased at 36 hours (Figure 7.3, Figure 7.4). These effects were less 
visible in the P08 cells, with an increased effect observed 12 hours after treatment which 
reverted to relatively smaller (but still enlarged) cells after 36 hours (Figure 7.5, Figure 7.6). In 
the vaginal A09 keratinocytes, a less distinct effect on keratinocyte morphologically was 
observed at 12 hours but more so 36 hours (Figure 7.7, Figure 7.8). The same trends were 
more visible in H09 where large polymorphic keraintocytes were observed 12 hours after CDV 
treatment and more considerably 36 hours after treatment (Figure 7.9, Figure 7.10). 
7.3.2.1 Main findings 
CDV appeared to distinctly affect keratinocyte morphology of clonal cell lines but a distinct 
effect was not observed in HEKs. Morphological changes did not appear to be consistent with 
apoptosis. Changes in morphology became more considerable with increasing time after CDV 
treatment in M08 and H09. In P08, substantial changes to keratinocyte morphology were 
observed 12 hours after treatment that appeared to revert after 36 hours.  In A09, 
morphological changes in response to CDV treatment were mostly apparent 36 hours after 
treatment. 
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Figure 7.3. Morphology of M08 during CDV dosing protocol (experiment 1) 
Cultures of M08 at P11 were visualised at 320x total magnification under light microscopy and 
a snap shot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 1. 
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Figure 7.4.  Morphology of M08 during CDV dosing protocol (experiment 2)  
Cultures of M08 at P11 were visualised at 320x total magnification under light microscopy and 
a snap shot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 2. 
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Figure 7.5.  Morphology of P08 during CDV dosing protocol (experiment 1) 
Cultures of P08 at P11 were visualised at 320x total magnification under light microscopy and a 
snap shot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 1. 
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Figure 7.6.  Morphology of P08 during CDV dosing protocol (experiment 2) 
Cultures of P08 at P11 were visualised at 320x total magnification under light microscopy and a 
snap shot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 2.  
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Figure 7.7.  Morphology of A09 during CDV dosing protocol (experiment 1) 
Cultures of A09 at P11 were visualised at 320x total magnification under light microscopy and a 
snap shot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 1. 
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Figure 7.8.  Morphology of A09 during CDV dosing protocol (experiment 2) 
Cultures of A09 at P11 were visualised at 320x total magnification under light microscopy and a 
snap shot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 2.   
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Figure 7.9.  Morphology of H09 during CDV dosing protocol (experiment 1) 
Cultures of H09 at P11 were visualised at 320x total magnification under light microscopy and 
a snapshot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 1. 
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Figure 7.10.  Morphology of H09 during CDV dosing protocol (experiment 2) 
Cultures of H09 at P11 were visualised at 320x total magnification under light microscopy and 
a snapshot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 2.  
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Figure 7.11.  Morphology of HEKs during CDV dosing protocol  
Cultures of HEKs at P3 were visualised at 320x total magnification under light microscopy and a 
snapshot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 1. 
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Figure 7.12.  Morphology of HEKs during CDV dosing protocol  
Cultures of HEKs at P3 were visualised at 320x total magnification under light microscopy and a 
snapshot taken 12 and 36 hours after being dosed with and without CDV in CDV dosing 
protocol experiment 2.  
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Figure 7.13. Example image showing induction of apoptosis in mouse keratinocytes 
This image is included to show the morphological appearance of apoptosing keratinocytes. It 
shows the effects of treatment with 0, 2.5, 5, and 10 µg/ml tanshinone IIA (A-D respectively) in 
mouse keratinocytes 48 hours post treatment. Membrane blebbing, chromatin condensation 
and nuclear fragmentation increase the dose dependent manner. Apoptosing cells are 
indicated with an orange arrow. Image taken from (Li et al., 2012).  
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7.3.3 Relative expression of HPV oncogenes, E6 and E7 
Relative expression of HPV genes E2, E6 and E7 were assessed and normalised to stable house-
keeping genes TBP2 and HRPT, which are constitutively expressed in keratinocytes. Expression 
was quantified relative to CaSki cDNA as a standard.  
Relative expression of HPV genes was investigated using RNA extracted from CDV treated and 
untreated clonal cell lines at each time point of the CDV dosing protocol as previously 
described. RNA was reverse transcribed to cDNA prior to performing qPCR and analysis, as 
previously described.  
Relative expression levels of E2, E6 and E7 for CDV treated and untreated vulval cell lines (M08 
and P08) and vaginal cell lines (A09 and H09) are illustrated in Figure 7.14 and Figure 7.15, 
repectively (Appendix IV). In vulval cell lines M08 and P08, E2 was absent which is consistent 
with the expression profiles presented in Figure 5.6. In M08, relative expression of E6 and E7 
was detected at levels comparable with CaSki and appeared relatively stable in CDV treated 
and untreated cells at all time point. After 12 and 36 hours treatment, there was no significant 
difference in E6 and E7 expression between treated and untreated samples of M08 (12 hours, 
E6: p = 2.3733., E7: p = 2.1443, at p < 0.05 (2-tailed t-test)). In P08, E6 and E7 appear stable 12 
hours after treatment with and without CDV at approximately 50% of the levels detectable in 
CaSki; there was no significant difference in E6 and E7 expression between treated and 
untreated samples of P08 after 12 hours (E6: p = 1.9663., E7: p = 1.9534). However E6 and E7 
mRNA increased three fold at 36 hours after CDV treatment to levels 40-50% higher than 
found in CaSki. Expression of E6 and E7 was found to be significantly different after treatment 
with CDV compared to no dose control at this time-point (36 hours: E6 P = 0.0062, E7 p =  
0.0103). In vulval cell line A09, relative quantification ratios of E2, E6 and E7 were all lower 
than observed with CaSki. mRNA levels for HPRT could not be quantified in the 36 hours 
sample and despite several repeats this problem was not resolved, thus normalisation to both 
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Figure 7.14. Relative expression of HPV E2, E6, and E7 in treated and untreated clonal cell 
lines M08 and P08  
Relative expression of HPV oncogenes E2, E6 and E7 was investigated in 10µM CDV treated 
and untreated P11 M08 and P08. Relative expression was assessed during the CDV dosing 
protocol. An initial assessment was performed 24 hours after seeding. Cultures were dosed 24 
hours after seeding and relative expression assessed 12 hours and 36 hours after being treated 
(36 and 60 hours after seeding). Expression is relative to CaSki as a standard; a value of 1 
indicates the same level of expression detected in the CaSki cell line. HPV gene expression 
levels were normalised to house-keeping genes TBP2 and HRPT. Error bars signify standard 
deviations. There was no statistically significant difference in E6 and E7 expression at 12 and 
36 hours between treated and untreated M08 (12 hours, E6: p = 2.3733., E7: p = 2.1443) (P < 
0.05, p < 0.05 (2-tailed t-test)). There was noo statistically significant difference in E6 and E7 
expression at 12 hours in treated and untreated P08 (E6: p = 1.9663., E7: p = 1.9534), however 
expression of E6 and E7 was found to be statistically different 36 hours after treatment (E6 P = 
0.0062, E7 p =  0.0103).  
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Figure 7.15. Relative expression of HPV E2, E6, and E7 in treated and untreated clonal cell 
lines A09 and H09 
Relative expression of HPV oncogenes E2, E6 and E7 was investigated in 10µM CDV treated 
and untreated P11 A09 and H09. Relative expression was assessed during the CDV dosing 
protocol. An initial assessment was performed 24 hours after seeding. Cultures were dosed 24 
hours after seeding and relative expression assessed 12 hours and 36 hours after being treated 
(36 and 60 hours after seeding). Expression is relative to CaSki as a standard; a value of 1 
indicates the same level of expression detected in the CaSki cell line. HPV gene expression 
levels were normalised to house-keeping genes TBP2 and HRPT. The absent data highlighted 
with a red star, represents anomalous HPRT expression, and as a result relative expression of 
HPV genes could not be normalised to both TBP2 and HPRT and was therefore not presented.  
Error bars signify standard deviation. In H09, E2 relative expression was stable in treated and 
untreated samples at both time points; there was no significant difference between treated 
and untreated samples (E2, 12 hours: p = 1.4351., 36 hours: p = 1.3841 , at p < 0.05 (2-tailed t-
test). There was no significant difference in E6 and E7 expression between treated and 
untreated samples of H09 (12 hours, E6: p = 2.3144., E7: p = 1.8341., 36 hours, E6: p = 1.0768., 
E7: p = 1.6055) at p < 0.05 (2-tailed t-test). 
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HPRT and TBP2 could not be performed and data was therefore not presented. Figure 7.16 
illustrates the missing data set by normalising E2, E6 and E7 to TBP2 only. In vaginal cell line 
H09, relative expression of E2 was stable in treated and untreated samples at both time 
points; there was no significant difference between treated and untreated samples at 12 and 
36 hours (12 hours: p = 1.4351., 36 hours: p = , at p < 0.05 (2-tailed t-test)). Relative expression 
of E6 and E7 was detected at levels comparable with CaSki and appeared relatively stable in 
CDV treated and untreated cells at all time points; there was no significant difference in E6 and 
E7 expression between treated and untreated samples (12 hours, E6: p = 2.3144., E7: p = 
1.8341., 36 hours, E6: p = 1.0768., E7: p = 1.6055 at p < 0.05 (2-tailed t-test)). 
 
7.4 Discussion 
The main conclusions of these experiments were as follows:  
1. A more considerable response to CDV was detected in vulval clonal cell lines (M08 and 
P08) compared to vaginal clonal cell lines (A09 and H09) through viable cell counts 
(with statistical significance). 
2. Reponse to CDV was detected in HEK cell line through viable cell counts and was 
comparable and a more marked effect was not obvious in clonal cell lines (no 
significant difference statistically).  
3. Cell cytoplasmic enlargement was observed during microscopic analysis of CDV treated 
clonal cell lines, but not in HEK lines. 
4. It could not be concluded that CDV induces apoptosis in treated clonal or HEK cell 
lines. 
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Figure 7.16. Relative expression in A09 normalised to TBP2  
Relative expression of HPV oncogenes E2, E6 and E7 was normalised to house-keeping gene 
TBP2 only, in order to give an example of the expression levels obtained 36 hours after cells 
were treated with and without 10µM CDV (highlighted with red star). Error bars signify 
standard deviation.  
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5. In all clonal cell lines except P08, CDV treatment did not result in decreased E6 and E7 
expression levels (with statistical significance). 
The data on viable cell counts is consistent with results generated in earlier experiments and 
confirmed that the cells had been treated with CDV at an approximate IC50 dose. However the 
morphological data showed enlarged cells post treatment with CDV. Enlarged cells are more 
consistent with CDV preventing DNA replication and cell division, but not interfering with 
cellular growth pathways, and might be indicative of cell senescence.  Confirmation of 
apoptosis could not be carried out through FACS (annexin V/7- 7-AAD staining) as previously 
explained; keratinocytes adhered to the lining of the tubes leading to the counting chamber 
causing repetitive blockage problems; this problem was not resolved and therefore data was 
not generated.  The data on E6 and E7 expression were generally consistent, i.e. that dosing 
with CDV at approximately IC50 levels did not result in reduced levels of mRNA encoding HPV 
E6 and E7 in any of the cell lines.   
7.4.1 Correlating viability, morphology and oncogene expression in P08 
A link between cell viability, morphology and oncogene expression in response to CDV 
treatment was evident in clonal cell line P08, which appeared to respond distinctly differently 
to the other cell lines. The surviving fraction of cells 12 hours after treatment was 0.59 (59%) 
and 24 hours later (36 hours after being treated) survival fraction had increased by 9% (0.68 = 
68%). P08 keratinocytes appeared extensively enlarged 12 hours after CDV treatment, 
however 36 hours after treatment keratinocytes appeared to have reduced and recovered 
tessellation pattern within the monolayer. Similarly, 36 hours after CDV treatment expression 
levels of E6 and E7 were approximately 10 fold higher than untreated cells at the same time 
point (and at all time points throughout the study, which were maintained at relatively stable 
levels).  The increase in E6 and E7 36 hours after CDV treatment reached expression levels 
comparable to CaSki.  
 232 
 
One possible explanation for the viability and morphology data would be that a sub-population 
of cells were unaffected by CDV treatment (i.e. remained viable) and may have rapidly 
proliferated, accounting for a higher survival fraction 36 hours after CDV treatment, and 
causing keratinocyte morphology to become gradually restored within the cell culture.  The 10 
fold increase in E6 and E7 expression after treatment at the same time point may play a part in 
the revival of the keratinocytes described. Expression of HPV oncogenes E6 and E7 are 
required for optimal proliferation of cervical carcinoma cells (HeLa) (DeFilippis et al., 2003) and 
have been shown to generate keratinocyte cell lines with indefinite growth potential through 
transfection of plasmids with intact E6 and E7 ORFs (Hawley-Nelson et al., 1989). Increased 
levels of E6 and E7 36 hours after CDV dosing might therefore be associated with the increased 
survival fraction and reversion to the typical keratinocyte morphology. 
7.4.2 CDV sensitivity in HPV positive and negative lines 
Response to CDV in HPV positive and negative cell lines (clonal lines and HEK lines, 
respectively) was investigated through annexin V viable cell counts and microscopic analysis of 
cell morphology.  Cell cytoplasmic enlargement was observed post treatment in clonal lines 
but this was not observed in the HEK line. However viable cell counts were reduced post 
treatment in both clonal and HEK lines. In this study reduced viable cell counts were detected 
in response to CDV regardless of HPV presence or absence. In the confinement of this study, 
CDV was not found to have increased sensitivity in cells infected with HPV, in contrast to the 
published literature. 
HEK cell lines are human epidermal keratinocytes with foreskin origin, and provided a HPV 
negative keratinocyte model for anogenital sites. The literature suggests that cells infected 
with HPV are more sensitive to CDV than HPV negative cells (Johnson and Gangemi, 1999). 
Specifically in a study by Andrei and colleagues (2001), annexin V staining showed that CDV 
reduced the percentage of viable cells, while no significant changes in the percentages of 
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viable cells were noted in HPV negative primary human keratinocytes. Moreover, reduced 
viable counts detected in HPV positive lines were further found to be correlated with induction 
of apoptosis. 
The results from this study are not consistent with existing literature; a sensitivity of CDV to 
HPV infected cells was not found. Similarly the reduction of viable counts for HPV negative HEK 
lines with no observed morphological changes also confounded interpretation of data. For that 
reason, subjective morphological analyses were not considered in this instance, and viable cell 
count data only taken in to account (which is a more accurate, and more commonly used 
method of assessing response to drug treatment). The actual cause of reduced viable counts 
also remains unclear and requires further investigation. 
7.4.3 Strengths and weaknesses 
The data presented are based on two separate CDV dosing protocols, and within each protocol 
cell cultures were prepared in duplicate. Viability counts were robust, as manual trypan blue 
cell counts were performed in triplicate from duplicate TC dishes, and combined for each 
dosing protocol. A mixture of quantitative and qualitative measures were assessed, and the 
data describing morphological appearance in particular are necessarily subjective; it should be 
stressed that the microscopic images presented represent only a small portion of the cell 
cultures that were assessed. The E6 and E7 expression data was assessed in the first of the 
CDV dosing protocols (i.e. at several time points and in four different cell lines), and relative 
quantification of gene expression was calculated from duplicate repeats. 
7.4.4 Mechanism of action of CDV 
Most studies that have looked at the effects of CDV in vitro are consistent in finding that 
treatment reduces cell proliferation, and several suggest that this effect is greater in HPV 
positive cells compared to HPV negative cells (Johnson and Gangemi, 1999, Andrei et al., 
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2000). In terms of comparing response to CDV in HPV positive or negative keratinocytes in this 
study, morphological analysis of keratinocytes suggested that HPV positive lines were most 
susceptible to CDV treatment, however surviving fractions showed that response to CDV in 
HEKs and M08 were comparable both 12 and 36 hours after treatment.  
There is less consistency in whether authors attribute the effects of CDV on proliferation to 
apoptosis. In the experiments described in this chapter, no morphological evidence for 
apoptosis was observed and this is consistent with the results of Abdulkarim et al., 2002. It is 
difficult to explain why published reports of induction of apoptosis by CDV are so variable. It 
seems likely that the variety of experimental systems (cell lines), the dose levels and assays 
employed, may contribute. The genetic background of the cell lines is likely to be particularly 
important especially with regard to p53 mutational status.  
Since evidence of apoptosis was not confirmed in response to CDV treatment in this study, the 
results observed in a parallel study (undertaken by Miss Aine Flynn - Cardiff Univeristy, HPV 
Research Group) have been included for speculation. Induction of caspase-3 activity was 
assessed as a marker of apoptosis following treatment of the M08, A09 and HEK cells with 
CDV.  Caspase-3 activity was assessed using a fluorogenic assay for activated caspase and by 
western blotting for cleaved caspase-3, and did not increase in response to CDV treatment in 
either the M08 or A09 cell lines (data shown in Appendix V). Similarly, there was no increase in 
p53 levels or phosphorylation in response to CDV treatment, or in levels of the p53 
transcriptional target p21 (Appendix VI). Taken together, these results strongly suggest that in 
this model of early neoplasia, at these specific dose levels, treatment with CDV did not induce 
cellular apoptosis.  
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8 Whole transcriptome sequencing  
8.1 Results 
The transcriptome represents all the transcripts present in a cell at a particular time point, and 
can be assessed through RNA sequencing (RNA-seq). RNA-sequencing is a quantitative, and 
highly sensitive method of transcript profiling, with several advantages over other techniques, 
as described previously. RNA-seq was performed using RNA extracts of clonal cell lines 12 
hours after CDV treatment (and no dose control) as part of the CDV dosing study. Generated 
transcript profiles of treated and untreated cells at the same time point, allowed differential 
gene expression to be analysed. Gene transcripts also underwent gene ontology over-
representation analysis (GO ORA) which involved the grouping of significant gene sets into 
related functional categories for easier interpretation (Ashburner et al., 2000); GO groups are 
biological process (BP), cellular component (CC), and molecular function (MF), as previously 
described. RNA-seq followed by differential gene expression and GO analysis, was performed 
on CDV treated and untreated cell lines to investigate the molecular mechanism(s) of action of 
CDV; RNA-seq provided a more in depth approach for examining gene transcripts that 
encompasses  the entire genome, and could potentially provide a more thorough insight in to 
the mechanism of action of CDV. 
In HPV positive cell lines, CDV treatment has previously been suggested to induce apoptosis 
and reduce expression of HPV oncogenes E6 and E7 (Andrei et al., 2001, Abdulkarim et al., 
2002, Amine et al., 2009), as previously described. Based on this published research, we had 
expected to observe apoptosis in response to CDV, however this was not apparent; as 
described in chapter 7, cell viabililty counts were reduced in response to CDV treatment, and 
the morphology of keratinocytes appeared to be consistent with cellular senescence. Cellular 
senescence, like apoptosis, is thought to be a programmed protective response of a cell to 
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damage. Cellular senescence has been shown to occur as a result of inflicting damage to 
cultured cells. DNA damage to human fibroblasts have been shown to induce terminal growth 
arrest resulting in phenotypic changes that resemble cells undergoing senescence (Di Leonardo 
et al., 1994, Robles and Adami, 1998). Given that CDV may be incorportated into DNA and RNA 
causing chain termination, and possibly stalling of transcription and of replication forks, it is 
also possible that treatment with CDV could result in DNA damage and stress responses. Thus, 
transcript profiles of CDV treated cell lines were investigated for significantly expressed gene 
transcripts relating to induction of apoptosis, senescence, stress response pathways, and 
response to DNA damage.     
Clonal cell lines previously characterised at a molecular level (chapter 5) were found to possess 
distinct HPV gene expression profiles (via real-time quantitative reverse-transcription PCR 
(qRT-PCR)) and HPV integration status (via amplification of papillomavirus oncogene 
transcripts (APOT)). Therefore HPV gene transcripts were investigated to confirm HPV 
expression profiles and HPV integrated transcripts in clonal cell lines.   
In summary, clonal cell line transcript profiles generated through RNA-seq were used to: 
1. validate HPV gene expression profiles previously determined by qRT-PCR 
2. validate HPV integration status previously determined by APOT 
3. assess differentially expressed genes to define transcript variation between clonal cell 
lines from the same patient but with different HPV gene expression profiles 
4. assess differentially expressed genes to define transcript variation in treated vs. 
untreated clonal cell lines   
This section of research was novel as it was the first time cells of this type have undergone a 
high sensitivity next generation sequencing technique for transcriptome profiling.  
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8.1.1 Aims and objectives 
The central aim was to assess differential gene expression encompassing the entire 
transcriptome in clonal cell lines after treatment with CDV, and validate gene expression 
profiles and HPV integration status characterised previously.    
The following objectives structured this section of work: 
1. Investigate whether RNA-seq gene transcripts are consistent with qRT-PCR expression 
profiles obtained previously  
2. Investigate whether RNA-seq integrated gene transcripts are consistent with HPV 
integrated transcripts detected previously via APOT 
3.  Investigate differentially expressed genes in clonal cell lines after treatment with CDV 
that are related to: 
a. HPV E6 and E7 genes 
b. Genes involved in apoptosis 
c. Genes involved in senescence  
d. Genes involved in stress response pathways 
e. genes involved in DNA damage response. 
8.1.2 Study sample 
Clonal cell lines derived from VIN; M08 (HPV16 integrated) and P08 (HPV16 status inconclusive 
(chapter 5)), were subjected to CDV dosing and subsequent RNA extraction, as previously 
described. The following RNA extracts underwent SOLiD™ transcriptome sequencing and 
analysis: 
1. clonal cell line M08 12 hour no treatment 
2. clonal cell line M08 12 hours post treatment with 10 µM CDV  
3. Cell line P08 12 hours no treatment 
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4. Cell line P08 post 12 hours post treatment with 10 µM CDV  
8.2 Quality control 
Quality control of RNA extracts was carried out to ensure RNA quality was sufficient for 
SOLiD™ transcriptome sequencing. The sequence data generated for each sample was also 
assessed to ensure they met the expected quality standards for inclusion in down-stream data 
analyses.  
8.2.1 RNA quality control  
RNA extracts were initially analysed using NanoDrop 2000 spectrophotometer to obtain RNA 
concentration and assess RNA purity, as previously described. RNA spectrophotometric 
measurements showed that sample quality was adequate since the ratio of absorbance at 260 
nm and 280 nm fell between 1.8 and 2.2 for all samples.  The following RNA concentrations 
were obtained:  
Cell line M08 12 hours post no treatment = 136 ng/µl  
Cell line M08 12 hours post 10 µM CDV = 149 ng/µl 
Cell line P08 12 hours post no treatment = 211 ng/µl 
Cell line P08 12 hours post 10 µM CDV = 187 ng/µl 
Quantitation and quality control of RNA was also performed using an Agilent 2100 Bioanalyzer 
through Central Biotechnology Services (CBS) (Cardiff University). The RNA integrity numbers 
(RIN) generated by Agilent 2100 were greater than 7 (all samples had RIN scores of 10) and 
were therefore suitable for SOLiD RNA sequencing (Appendix VII).  
8.2.1.1 Main findings 
Total RNA extracts were found to be suitable for SOLID™ transcriptome sequencing. 
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8.2.2 Quality control of sequence data 
Total RNA extracts underwent SOLiD™ transcriptome sequencing and analysis. Resulting 
sequence data was obtained for 3/4 samples; due to a fault in the library preparation process, 
no sequence data was generated from untreated P08. The 3 remaining sequence data sets had 
low data yield and reduced read quality; untreated M08 generated the most sequence reads at 
368 million, and CDV treated M08 and P08 generated 134 and 190 million sequence reads, 
respectively. The percentage of sequence reads that mapped successfully to target was low in 
all 3 samples, with 16.2% mapped reads in untreated M08, 47% in CDV treated M08, and 
48.2% in CDV treated P08. 
Although the percentage of mapped reads was low for all samples, for the purposes of this 
thesis the available sequence data sets for 3 out of 4 samples were recommended of sufficient 
quality for provisional down-stream sequence analysis.  
As SOLiD™ sequencing data was not generated for untreated P08, CDV treated P08 was used 
to validate HPV gene expression profiles and HPV integration status of P08, in later sections.  
8.2.3 Quality control of transcript reads 
Sequence data was translated to transcript reads, which were checked to identify any 
underlying issues with transcript distributions for each sample. Box plots of raw transcript 
counts, Reads Per Kilobase exon Model per million mapped reads (RPKM values normalised for 
gene length), and edgeR normalised counts were prepared for each sample as shown in Figure 
8.1. The box plots were showed similar distributions to each other illustrating that there were 
no underlying issues with transcript data distribution in any of the samples.  
 
 
 240 
 
 
 
 
Figure 8.1. Box plots of raw counts (A), RPKM values (B),and edgeR normalised counts (C) for 
transcript data of untreated M08, CDV treated M08, and CDV treated P08.  
Each box plot illustrates the smallest value, lower-median-upper quantile, and largest value, 
for each sample, which provides an indication of the distribution of each data set.  Illustration 
kindly provided by Dr Peter Giles (Wales Gene Park).  
A 
B 
C 
 241 
 
A pair-wise comparison of transcript reads for each sample was also carried out to assess 
samples for anomalies against each other. MvA plots were produced from pair-wise 
comparisons as illustrated in Figure 8.2; all comparisons were found to resemble a right 
pointing arrow centred around a red zero fold-change line, showing there were no 
irregularities in the edgeR normalised data in these plots. Additionally, the data distribution 
appeared more tightly focussed around the red zero fold-change line in Figure 8.2(A), 
compared to Figure 8.2(B) and (C) which were more dispersed. Prior to performing more 
detailed analysis of this data, pair-wise comparisons of transcript reads indicated that there 
were more differences in transcripts reads between cell lines M08 and P08, than between CDV 
treated and untreated cells of the same cell line (M08).  
8.2.3.1 Main findings 
Transcript reads for each sample showed no underlying irregularities and transcript data was 
accepted as adequate for down-stream analyses. Prior to carrying out more detailed down-
stream analyses of transcript data, pairwise comparisons gave an indication of possible 
differences in transcript profiles between each sample.  
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Figure 8.2. MvA plots for all pairwise comparisons of transcript data.  
MvA plots compare transcript reads for untreated M08 vs. CDV treated M08 (A), untreated 
M08 vs. CDV treated P08 (B), and CDV treated M08 vs. CDV treated P08 (C). All pair-wise 
comparisons are illustrated as scatter plots that are centred around a red zero fold change line. 
Illustration kindly provided by Dr Peter Giles (Wales Gene Park). 
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8.3 SOLiD™ transcript data  
8.3.1 Validation of HPV gene expression  
qRT-PCR was previously performed using RNA extracts of M08 and P08 to quantify HPV16 E2, 
E4, E5, E6, and E7 gene expression. E2 expression was not detected in M08 and P08. E6 and E7 
gene expression was detected in M08 and P08 at all passages, however E4 and E5 was 
detected at all passages in P08 but not at any passage in M08 (Figure 5.6). 
Mapped transcripts of SOLiD™ sequence data for M08 and P08 were visualised using the 
Integrative Genomic Viewer (IGV) (Figure 8.3) to assess transcript profiles using HPV16 
genome model (NC_001526) as reference. In M08, mapped transcript reads of E6 and E7 were 
present however E2, E4, and E5 transcripts were not. In P08, mapped transcript reads for a 
small region of E2 were detected, and transcript reads mapped to full length E4, E5, E6, and E7.  
8.3.1.1 Main findings  
SOLiD™ transcription profiles of clonal cell lines M and P visualised through IGV were 
consistent with transcription profiles previously obtained by qRT-PCR. This validated the use of 
both qRT-PCR and SOLiD™ transcriptome sequencing coupled with IGV as methods of 
determining gene expression profiles in these cell lines.  
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Figure 8.3. IGV screen shot showing a histogram of M08 and P08 mapped transcript reads 
with reference to HPV genome model (downloaded from NCBI, accession no: NC_001526.2).  
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8.3.2 Validation of HPV integration status 
APOT was performed using RNA extracts of clonal cell line M and P to investigate the presence 
of HPV integrated transcripts as part of molecular characterisation (Table 5.2). In M08 at early 
and late passages, APOT detected multiple sized type 1 integrated transcripts at different sites 
mapping to chromosome 3q28, specifically within LEPREL1 gene. In early and late passages of 
P08, episomal HPV transcripts were detected as E7-E1 spliced to E4 constructs; integrated 
transcripts were not detected. 
8.3.2.1 Clonal cell line M08 
SOLiD™ transcript data for untreated M08 was visualised as Circos plots to identify HPV-human 
fusion transcripts (integration), as shown in Figure 8.4A; grey lines associating the HPV genome 
with the human genome represent pair-end reads where one read mapped to HPV16 and the 
other to human sequence. Multiple grey lines visible as a thick black streak linked the E6/E7 
region of the HPV genome with chromosome 3 of the human genome, representing multiple 
fusion transcripts of E6/E7 and chromosome 3. This was consistent with APOT data previously 
obtained which detected integration within chromosome 3q28 (LEPREL1). Single grey lines also 
linked E6/E7 with other human genomic loci in the Circos plot, but these were not detected 
previously by APOT and were difficult to interpret. The fusion transcript in the Circos plot 
linking E6/E7 and chromosome 3 was also visualised through IGV, shown in Figure 8.4B. This 
also confirmed that the integrated transcript was constructed of E6/E7 fused to chromosome 
3, specifically within the gene LEPREL1; again this was consistent APOT data. Single grey lines 
that linked the HPV genome with various other loci of the human genome were not identified 
through IGV.  
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Figure 8.4. SOLiD™ transcript data for M08 visualised as Circos plots and through Integrative 
Genomic Viewer (IGV).  
Linkage between HPV genome and the human genome in untreated M08 illustrated as a Circos 
plot (A), and through Integrative Genomic Viewer (IGV) as a split-screen shot used to visualise 
mapped locations of HPV-human fused transcripts (B). In Circos plots, possible HPV integrated 
transcripts were represented by grey lines connecting the HPV genome (downloaded from 
NCBI, accession no: NC_001526.2) with chromosomes (chr) of the human genome (UCSC 
human reference hg19 site); Multiple grey lines connect the HPV genome with chromosome 3, 
illustrated by a black streak suggesting an integrated transcript. Single grey lines also link HPV 
with other regions of the human genome. In IGV, the same reference genomes were used to 
define transcript locations; transcript reads that map within expectation are represented by 
gray shaded tags whilst those mapping over extended distances are illustrated as coloured 
tags, with the colour indicating the chromosome to which the transcript corresponded. 
Transcript fusion between HPV16 E7 and chromosome 3, specifically within LEPREL1 (multiple 
cyan coloured tags) is illustrated in the split-screen.  
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8.3.2.2 Clonal cell line P08 
SOLiD™ transcript data for CDV treated P08 was visualised in a Circos plot as illustrated in 
Figure 8.5A. Multiple grey lines visible as a dark grey streak linked E6 of the HPV genome with 
chromosome 10 of the human genome. This represented a fusion transcript of E6 and 
chromosome 10; APOT did not detect any integrated transcripts in P08. Single grey lines also 
linked E6, E7 and E4 with other human genomic loci; these were also not detected previously 
by APOT. This fusion transcript of E6 and chromosome 10 could not be identified when the 
data was visualised through IGV, however, episomal HPV constructs were detected using IGV 
(Figure 8.5B), which consisted of E7-E1 spliced to E4 transcripts (consistent with previous APOT 
data).  
8.3.2.3 Main findings 
SOLiD™ HPV integration status in M08 and P08 visualised through IGV was consistent with HPV 
integration status previously determined by APOT. This validated the use of both APOT and 
SOLiD™ transcriptome sequencing coupled with IGV as methods of determining HPV 
integration status in these cell lines.  
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Figure 8.5. SOLiD™ transcript data for P08 visualised as Circos plots and through Integrative 
Genomic Viewer (IGV).  
Linkage between HPV genome and the human genome in untreated P08 illustrated as a Circos 
plot (A), and through Integrative Genomic Viewer (IGV) as a split-screen shot used to visualise 
mapped locations of HPV-human fused transcripts (B). In Circos plots, possible HPV integrated 
transcripts were represented by grey lines connecting the HPV genome (downloaded from 
NCBI, accession no: NC_001526.2) with chromosomes (chr) of the human genome (UCSC 
human reference hg19 site). Multiple grey lines connected HPV genome with chromosome 10, 
illustrated by a dark grey streak suggesting an integrated transcript. Single grey lines also 
linked HPV with other regions of the human genome. In IGV, the same reference genomes 
were used to define transcript locations; transcript reads that mapped within expectation are 
represented by gray shaded tags whilst those mapping over extended distances are illustrated 
as multiple coloured tags, and the colour used indicates the chromosome to which the 
transcript corresponded. Transcript fusion was only detected between HPV E6, E7 and E4 (pale 
blue horizontal lines linking HPV transcripts), illustrating multiple episomal fused constructs. 
Multiple coloured tags were not visible, suggesting the absence of integrated fused transcripts.  
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8.3.3 Differential gene expression  
Differentially expressed genes were identified between CDV treated and untreated samples of 
M08; differentially expressed genes could not be assessed in P08 as sequence data was not 
generated for the untreated sample. As part of DEG analysis, corrected p-values were used to 
identify transcripts that showed a significant difference between the mean expression of 
untreated compared to CDV treated. The data was filtered using a false discovery rate (FDR) 
multiple testing correction and a cut-off of p<0.05, to identify transcripts where there was 95% 
certainty of there being a real difference in expression and an FDR of 5%. A heatmap showing 
the results of this analysis is shown in Appendix VIII.   
In total 39688 transcripts were tested, 2158 were significant at p<0.05, and after FDR 
correction (p<0.05) 66 gene transcripts were identified as being statistically differentially 
expressed after treatment with CDV in M08. Of these 66, genes with a large range of 
apparently unrelated functions were found to be significantly under-expressed due to CDV 
treatment. Among a large number of poorly annotated genes, this list included genes for 
matrix proteins (PRELP), transmembrane proteins and sodium channel subunits (TMEM174, 
SCN2A), heparanases (HPSE), heme group catabolism (HMOX1), gemini bodies (GEMIN4), 
histone components (H2BFM), potential tumour suppressors (CSMD1) and coagulation factor 
receptors (F2RL3) and nucleotide metabolism (RGL1). Only two significantly overexpressed 
genes were observed, these encoded chemokines (CCL20) and deoxyguanosine kinase that is 
involved in maintaining mitochondrial DNA (DGUOK). Cell cycle control genes encoding cyclin 
dependent kinases, cyclins, DNA polymerases, p53, telomerase and others relating to cellular 
CDV phosphorylation (i.e. NME1/NME2, guanylate kinases etc) were not found to be 
significantly differently expressed.  
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8.3.3.1 Main findings 
A range of genes were significantly differentially expressed as a result of CDV treatment in 
M08, however no biological mechanism was apparent. This justified further a more directed 
means of analysing overexpressed genes through GO analysis.    
8.3.4 Gene Ontology – Over Representation Analysis (GO ORA) 
The list of genes found to be differentially expressed in CDV dosed M08 was difficult to 
interpret, therefore GO ORA was applied to the significant gene transcripts to sort them in to 
GO categories; GO ORA identified groups of functionally or structurally related genes that were 
differentially expressed. This made assessment more relevant from a biological perspective 
and easier to interpret by identifying potential relationships between gene transcripts. 
In total, 374 categories were identified as differentially expressed in M08 as a result of CDV 
treatment. The top 500 most significant (p<0.05) individual gene transcripts underwent GO 
ORA. GO categories were identified using the database at the Gene Ontology project that 
related to various search terms (The Gene Ontology Consortium, 2013). 
Initially, only the top 20 most significant GO categories were considered Table 8.1. Of the 20 
GO categories, 12 (60%) were found to be related to adenine and guanine nucleotide 
biosynthesis, nucleobase metabolic process, RNA polymerase activity, and DNA-directed RNA 
polymerase II. These encompassed all 3 GO groups (BP, CC, and MF). The gene DGUOK listed 
under the GO term ‘nucleobase metabolic process’, was overexpressed 2577 fold in CDV 
treated M08 compared to no treatment, and was also present in the top 66 significantly 
expressed genes. 
Among the 374 GO categories identified were four which related to senescence. These 
categories were (CC) senescence-associated heterochromatin focus, (BP) senescence-   
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GOID Ontology Term p.value 
GO:0003938 MF IMP,dehydrogenase,activity 0.000227 
GO:0003899 MF DNA-directed,RNA,polymerase,activity 0.000387 
GO:0034062 MF RNA,polymerase,activity 0.000387 
GO:0021891 BP olfactory,bulb,interneuron,development 0.001128 
GO:0005665 CC DNA-directed,RNA,polymerase,II,,core,complex 0.001367 
GO:0006177 BP GMP,biosynthetic,process 0.001446 
GO:0033129 BP positive,regulation,of,histone,phosphorylation 0.001907 
GO:0009112 BP nucleobase,metabolic,process 0.002108 
GO:0014805 BP smooth,muscle,adaptation 0.00215 
GO:0000428 CC DNA-directed,RNA,polymerase,complex 0.002532 
GO:0055029 CC nuclear,DNA-directed,RNA,polymerase,complex 0.002532 
GO:0046037 BP GMP,metabolic,process 0.002576 
GO:0021889 BP olfactory,bulb,interneuron,differentiation 0.002614 
GO:0030880 CC RNA,polymerase,complex 0.002617 
GO:0006385 BP 
transcription,elongation,from,RNA,polymerase,III, 
promoter 0.002816 
GO:0006386 BP termination,of,RNA,polymerase,III,transcription 0.002816 
GO:0071496 BP cellular,response,to,external,stimulus 0.003371 
GO:0031401 BP positive,regulation,of,protein,modification,process 0.003675 
GO:0061042 BP vascular,wound,healing 0.003765 
GO:0070534 BP protein,K63-linked,ubiquitination 0.003893 
   
Table 8.1. Top 20 most significant Gene Ontology groupings  
Based on 500 most significantly differentially expressed transcripts. BP = biological process, CC 
= cellular component and MF = molecular function. 
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associated heterochromatin focus assembly, (BP) cell aging and (BP) aging which are broadly 
associated withcharacteristics of cellular senescence. No evidence of differential expression of 
GO groups relating to apoptosis or DNA repair was observed.  
8.3.4.1 Main findings 
In the top 500 most significant gene transcripts of 374 GO categories, 4 categories were 
associated with cellular senescence. Over half of the 20 most significant GO categories 
appeared to be associated with nucleotide synthesis and processing, and the remaining 
associated with RNA polymerase activity. 
 
8.4 Discussion  
The main findings of these investigations were: 
1. RNA sequence data was not generated for sample corresponding to untreated P08. 
2. The quality of sequence data was below threshold value for all samplesn but deemed 
suitable for anaylsis, here. 
3. There was consensus between HPV gene expression visualised through IGV and qRT-
PCR, confirming:  
i. expression of E6 and E7 and absence of E2, in M08. 
ii. Expression of E4, E5, E6 and E7 in P08, and presence of partial transcripts of 
E2. 
4. There was consensus between HPV integration status determined by sequencing and 
APOT for: 
i. integrated transcripts of E7-3q28 (LEPREL1) in M08 
ii. episomal HPV transcripts corresponding to E7-E1 spliced to E4 in P08. 
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5. DEG analysis and GO ORA showed that a large percentage of the top 20 most 
significant GO categories were involved in nucleotide synthesis and processing and 
RNA polymerase activity.   
6. DEG analysis and GO ORA showed that 4 GO categories relating to cellular senescence 
were found over 300 GO categories comprising the top 500 most significant gene 
transcripts. 
The aims of performing RNA sequencing on M08 and P08 were to confirm HPV gene 
expression and integration status, which had previously been characterised using other 
molecular techniques. RNA sequencing was considered a sensitive method with which to 
validate data from qRT-PCR and APOT.  Also, this study made an attempt to define the 
molecular mechanism(s) of action of CDV by investigating the transcriptomes of CDV treated 
and untreated cells using differential gene expression and GO analyses. Exploring the entire 
transcriptome without restriction to predefined hypotheses could potentially identify 
unknown mechanism(s) of action of CDV at a molecular level. 
8.4.1 Failure to generate sequence data and low data yield 
Total RNA extracts underwent SOLiD™ RNA-seq but sequence data was not generated for 1/4 
samples. This was due to an error in library preparation. Unfortunately insufficient RNA was 
available for this procedure to be repeated. 
SOLiD™ RNA-seq generated sequence data for 3/4 total RNA extracts, but the sequence data 
was of low data yield and reduced read quality; this refers to the quantity of sequence data 
obtained and how well the sequence data mapped to reference. The minimum sequencing 
yield specified post sequencing varies, and is crudely estimated and dependent on the 
sensitivity of an experiment. RNA-sequencing data sets tend to map less well to reference due 
to more frequent occurrence of low quality reads and sequence artefacts which can contribute 
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to reduced sequence read quality. The quality of the RNA undergoing RNA-seq (i.e. partially 
degraded RNA) might otherwise affect the quantity of the sequence data generated, and might 
have occurred after RNA integrity had been investigated, prior to being sequenced.  
8.4.2 Strengths and weaknesses 
Techniques such as ‘first generation’ Sanger-sequencing and RNA microarrays have been used 
to generate transcript profiles of cells but are limited to predefined selections of genes (i.e. the 
primer sequences present in the amplification, or on the microarray). RNA sequencing 
provides a  sensitive, high throughput technique of transcriptome profiling (Wang et al., 
2009)with advantages over other methods, including the  generation of transcripts comprising 
the entire transcriptome, quantifying and mapping transcripts more precisely, the potential to 
identify transcript splice variants, and assess differential gene expression. Thus far RNA-seq 
has been used to characterise the transcriptomes of a small selection of eukaryotic organisms 
(Mortazavi et al., 2008, Nagalakshmi et al., 2008), and this was the first time HPV16 infected 
vulval and vaginal keratinocyte cells had undergone transcriptome sequencing. 
Sequence data for untreated P08 was not generated, therefore a comparison between CDV 
treated and untreated cells of P08 could not be carried out. Hence assessments of HPV genes 
expressed and HPV integration status using sequence data for CDV treated P08. This was not 
thought to influence the data but it is possible that both integration and HPV gene expression 
could be altered by CDV treatment.   
RNA sequencing data validated HPV integration data previously determined by APOT, and qRT-
PCR HPV gene expression data, this increased confidence in all of the techniques used. There 
were some discrepancies identified with APOT data when RNA-seq data was visualised as 
Circos plots to illustrate HPV and human fused transcripts, i.e. Circos plots suggested the 
presence of low frequency integration events that were not detected by APOT or visualised 
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using IGV. These data were interpreted as low-frequncy integrations events (in Circos plots 1 
link = 1 mapped transcript) but equally they could potentially be artefacts of the RNA-seq 
process. This could potentially be determined by examination of RNA-seq data sets from cell 
lines that were HPV untransformed and genetically stable. 
In P08, transcripts were mapped to only a short region of E2.  E2 PCR data previously showed 
that a truncated E2 fragment was present in P08 and integrated transcripts were not detected 
via APOT (episomal E7-E1 spliced to E4 transcripts were detected). RNA-seq data visualised 
through IGV also confirmed the episomal transcript described, however when visualised 
through Circos plots, multiple linkages (= multiple transcripts) were observed between HPV 
E6/E7 and a region in chromosome 10.  Integration at this site was not confirmed due to time 
restrictions. It was thought that integration disrupting E2 would result in loss of transcription 
of downstream ORF. However, transcripts of E4 and E5, were detected in P08 through qRT-PCR 
and confirmed through IGV. This potential integrated transcript was not explored further due 
to project time restrictions, but interrogation of RNA with primers mapping to this integration 
loci would provide interesting future work and contribute to fully characterising P08. 
The main weakness of these analyses was the small sample size, lack of replicates and the fact 
that with the exception of HPV gene expression, data were not confirmed by independent 
qPCRs. 
8.4.3 Reponse to CDV in M08 
The GO analysis showed that following CDV treatment genes belonging to several ontologies 
were significantly over-represented. These ontologies included several relating to nucleotide 
synthesis and processing, and RNA polymerase activity. CDV is an nucleotide analogue and 
therefore competes with natural nucleotides (adenine, guanine, cytosine and thymidine), 
during DNA synthesis by incorporating in to the extending DNA strand. Classically, CDV is a 
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prodrug and required phosphorylation before it is activated, and has a high affinitiy for viral 
RNA polymerase. It has also been shown to have affinitiy (but relatively less) for human RNA 
polymerase.  It could be proposed that expression of genes involved in nucleotide metabolism 
might be altered just as a result of adding a nucleotide analogue to the media through dosing 
cells in culture with CDV.  Similarly, RNA polymerase genes were also significantly 
overexpressed which may be linked with affinity of CDV for RNA polymerase. The specific gene 
DGUOK listed under ‘nucleobase metabolic process’ was overexpressed significantly. The 
protein product of DGUOK has previously shown to be required for the phosphorylation of 
several deoxyribonucleosides and certain nucleotide analogues widely employed as antiviral 
and chemotherapeutic agents (Van Rompay et al., 2003). This could suggest that considerable 
over expression of DGUOK might be linked to phosphorylation of CDV into the active form.  
One other study has previously examined the transcriptional response to CDV using genome 
wide technology. This was a study by De Schutter and colleagues, which examined SiHa 
(HPV16+), HeLa (HPV18+) and HaCaT (HPV negative) immortalized cell lines and primary 
human keratinocytes 24, 48 and 72 hours after treatment with 50 μg/mL (159 μM) CDV usng 
whole genome gene expression microarrays, with validation of the array data by qRT-PCR De 
Schutter (De Schutter et al., 2013). In SiHa cells twenty genes showed similar changes in 
expression in both the 48 and 72 hour samples. Expression was also examined in HeLa, HaCaT 
and normal keratinocytes at 72 hours. Only 2 genes (AOX1 and CLIC3) were differentially 
expressed in all 4 cell lines. GO analysis of differentially expressed genes showed ‘immune 
response’ and ‘inflammatory response’ to be the only functional groupings up-regulated in all 
four cell lines. Further functional analysis showed that HPV positive cells showed differential 
regulation of genes linked to “cell death of tumour cells” following CDV treatment. It is not 
clear why there was little consistency between the De Schutter study and the current 
investigation, though it was notable that the published study used both higher doses and 
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longer treatment periods. The time period of 12 hours was chosen for the current study to 
ensure that changes in expression related to a response to CDV rather than showing 
characteristics of cells that had survived CDV treatment. 
It was perhaps surprising that genes involved in DNA damage and stress responses did not 
appear to be effected by CDV treatment, given that cells were treated with an IC50 equivalent 
dose of CDV more noticeable effects were expected. It might be possible that such effects 
might have been noted if a longer or shorter time frame had been examined or if higher or 
lower doses of CDV had been examined.  
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9 General discussion 
 
The aims of this study were to develop novel in vitro models of HPV-associated vulval and 
vaginal neoplasia and to use them to investigate the mechanism of action of the nucleoside 
analogue Cidofovir.  
Working with early passage short term cell lines was technically challenging and time 
consuming. Nonetheless, clonal cell lines were successfully isolated from heterogeneous vulval 
and vaginal cell lines and were characterised with respect to HPV integration state and gene 
expression. These analyses suggested that the clones differed in terms of HPV integration 
state, integration sites and in patterns of gene expression. These cells lines represent the best 
available models with which to investigate the molecular biology and treatment of HPV 
associated early stage neoplasia. Potential advantages of the clonal lines include the small 
number of passages between their derivation and use, and the fact that they were derived 
from neoplasia rather than cancers. It is also potentially useful that different patterns of HPV 
gene expression were present, as this may allow investigation of how potential therapeutics 
are affected by individual HPV gene products. For instance E5 expression was absent in the 
M08 line; E5 expression has a dramatic effect on the composition of cell membranes (DiMaio 
and Petti, 2013) and may affect uptake of drugs across the cell membrane. Whether HPV is 
integrated or episomal is also likely to influence response to drug treatments, as treatments 
that induce an interferon mediated response are likely to result in clearance of episomal HPV 
infection, but may be less effective in the presence of integrated infections (Pett et al., 2006) 
It appears likely that clonal lines representing episomal and integrated infection were derived 
for PC09 and these are likely to be useful in investigating the effects of integration on HPV 
gene expression (as has been the case for the CIN1-derived W12 cell line (Pett and Coleman, 
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2007). For the majority of the study it appeared that episomal and integrated lines had also 
been derived from PC08, however the E2 PCR sequencing and mRNA sequencing data sets, 
obtained towards the end of the project, suggest that clonal line P08 actually contains 
integrated HPV. This shows that DIPS and APOT failed to detect integration, possibly because 
of the particular sequence context within which the integration event occurred. The failure of 
APOT and DIPS to detect this integration event does not appear to be due to the sensitivity of 
the assays, as the failure of the E2 PCRs to amplify any product except the truncated one, 
suggests that this event was present in every cell. 
A further strength is that these lines represent true natural infections, with HPV gene 
expression under the control of native promotor in the natural target cell. This is a significant 
advantage over artificial systems where HPV genes are placed under the control of non-native 
promotors in cells that are not the natural target. 
The clonal cell lines do have several limitations as models of neoplasia. For instance, they are 
likely to be less useful in the study of agents that induce cell-mediated immune responses, as 
immune effector cells are not present in monolayer cultures. Furthermore, when grown in a 
monolayer cells do not accurately recapitulate a stratified epithelium and this also limits the 
accuracy of the model. Despite being genetically and temporally close to the original biopsy, a 
degree of selection will have occurred during the development of these lines as only cells that 
survived single cell cloning and grew rapidly thereafter were used. 
A dose of 10 µM was used to investigate the effects of CDV on cell proliferation, morphology 
and gene expression. These studies demonstrated that: 
1. CDV reduced cell proliferation in all four HPV-positive clonal lines and also in the HPV 
negative HEK cells. The surviving fractions at 36 hrs ranged from 49% to 76% for the 
HPV positive lines. The surviving fraction for the HEK cells was 62%. Overall response 
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to CDV in terms of cell viability was comparable in HPV positive and HPV negative 
lines; a specific increased sensitivity for CDV to HPV positive cell lines was not found, 
here. 
2. CDV treatment did not cause significant reduction in expression of HPV E6 or E7. In the 
P08 cell line, treatment appeared to significantly increase E6 and E7 mRNA levels at 
one timepoint. 
3. CDV treatment at this dose did not appear to have major effects on the host cell 
transcriptome.  
There was no evidence that CDV was selective for HPV positive cells. This is in marked contrast 
to observations made in clinical practice. In the RT3VIN clinical trial (UK, 2013) approximately 
half of the patients treated with CDV showed a complete histological response, which was 
preceded by ulceration of the lesion, but not of surrounding normal tissue (Dr Amanda 
Tristram – RT3VIN Chief Investigator – personal communication). Both HPV positive and 
negative cells responded to CDV treatment in vitro, but in vivo normal cells are apparently 
unaffected; this could mean that the cell line model was inadequate. Specifically this appears 
to suggest that the model of normal cells, rather than the model of HPV infected cells could be 
at fault. The likely explanation for this difference is the presence in vivo of a fully stratified 
squamous epithelium with an intact stratum corneum composed of fully differentiated 
keratinised cells at the epithelial surface.  
A study by Cundy and colleagues (Cundy et al., 1997) investigated uptake of radiolabelled CDV 
following topical application of a 1% CDV gel to the skin of rabbits. Uptake through intact and 
abraded skin was assessed in two groups each containing four rabbits. The final bioavailability 
of CDV in the intact skin group was 2.1% of the applied dose, however in the abraded skin 
group final bioavailability was increased 20 fold to 41%. The half-life of CDV applied in this way 
was 2.61 hours relative to an intravenous half-life of 5.4 hours. The authors interpreted these 
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findings as suggesting rapid absorption of the topical drug across the skin was facilitated when 
the stratum corneum was removed. They explained these observations by noting that CDV is a 
dianion at physiological pH and in the presence of an intact stratum corneum, the highly polar 
molecule displays low permeability. A similar study of topical uptake of 1% CDV across mouse 
skin also observed considerable increases in uptake (400 fold increase) following tape stripping 
of the stratum (Aspe et al. 1999).  
These data may be highly relevant in the context of the current study, and may suggest that 
where proliferating cells are exposed at the epithelial surface (which they are, by definition, in 
VIN3) they are likely to be more vulnerable to the effects of CDV than when they are protected 
by an intact stratum corneum. The presence or absence of an intact cornified layer would 
hence explain the contrasting results observed in clinical practice and in vitro. 
The mRNA sequencing data provided useful confirmation that the earlier assays had been 
conducted properly. However it is puzzling as to why greater differences were not observed in 
gene expression between the CDV treated and untreated samples. The dose used was 
sufficient to reduce proliferation of the treated sample by 50% and it seems highly unusual 
that this could occur without causing more significant changes in gene expression. This may 
suggest that the time frame for sampling (12 hours) was too short or the dose was too low. 
Higher doses and longer time frames were used in a similar study that did identify significant 
changes in the gene expression (De Schutter et al., 2013). This raises the question of, what 
constitutes the correct dose? In the context of this project, the correct dose is the one that 
most accurately approximates the dose received in vivo. In the RT3VIN clinical trial, patients 
applied 1% CDV gel, hence the maximum dose possible, assuming a single application 
represents around 1 gram of gel, would be 1% of 1 g = 10 mg. If CDV was taken into cells at the 
maximum level seen in animal studies this would equate to a maximum possible dose of 10 mg 
x 0.021 = 210 µg. It is difficult to relate this to the concentrations used in cell culture, as this 
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dose would be spread over lesions that may vary considerably in size and uptake through 
rabbit skin may be different to uptake through human skin, but it suggests that the dose of 10 
µM (which equates to 3.15 µg/ml) may be towards the lower end of the physiologically 
relevant range. It should also be noted that the relevance of in vitro data may also be limited 
by the short time frames used for dosing studies.  In the RT3VIN trial, patients applied CDV 
three times per week for 24 weeks. This could not be replicated in vitro because long-term low 
level dosing with CDV would be likely to produce resistance (as recently described for SiHa 
cells by De Schutter et al. 2013) while excessive repetitive dosing with CDV would be likely to 
kill the population. Additionally it would have been impossible to relate such data to undosed 
controls which would quickly have become confluent. 
It therefore seems that while this study has produced data that contradicts several of the 
proposed mechanisms of action of CDV, i.e. reduced expression of HPV E6 and E7 (Abdulkarim 
et al., 2002, Amine et al., 2009) and induction of apoptosis (Andrei et al., 2000, Amine et al., 
2009) has not produced data to conclusively support an alternative mechanism. Future work 
would be useful to study uptake of CDV through cornified epithelia and this could be achieved 
using organotypic raft cultures that have recently been developed in our laboratory.  
9.1 Conclusion 
 A selection of early passage clonal cell lines derived from VIN3 and VaIN3 lesions were 
successfully isolated and maintained in culture, representing a novel cell culture system of 
vulval and vaginal neoplasia.  They have been shown to comprise a selection of unique 
naturally occurring HPV16 infected cell lines with differing phenotypic and molecular 
characteristics. A CDV dosing protocol was optimised in these cell lines and was used to assess 
cellular response(s) to CDV treatment. Under the conditions described CDV did cause a 
reduction in cell viability, although the mechanism of action could not be confirmed; based on 
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viable counts, cells infected with and without HPV were found to be sensitivie to CDV 
treatment.   Under the conditions described, it cannot be confirmed whether CDV induces 
apoptosis. CDV did not appear to reduce E6 and E7 expression levels. Cell enlargement was 
observed in response to CDV treatment also. DEG analysis showed that 60% of the top 20 most 
significant gene transcripts were azssocaited with nucleotide syntheses and RNA polymerase 
activity. Additionally, 300 GO categories comprising the top 500 most significant gene 
transcripts were associated with cellular senescence. The actual mechanism by which CDV 
reduces cell proliferation requires further investigation. 
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Appendix 1 – PC08, PC09, and clonal cell culture data 
Cell line Cumulative 
days in 
culture 
Initial cell count 
(seeding cell 
no.) (X105) 
Initial count 
adjusted for PE* 
(X105) 
Final cell count 
(total cell no.) 
(X106) 
 
DT 
 
PD 
A09 
 
 
12 
27 
40 
62 
76 
84 
8 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
4.3 
8 
14 
14 
20 
10 
2.53 
2.66 
2.02 
4.75 
5.64 
6.45 
Mean DT 
Total PD 
 
 
   1.76 
 
 
36.21 
D09 
 
 
 
 
9 
21 
36 
49 
70 
86 
8 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
14 
7.5 
10 
20 
16 
20 
1.40 
2.16 
2.52 
1.87 
3.16 
2.30 
 
 
 
 
 
 
Mean DT 
Total PD 
 
 
   2.23 
 
 
38.52 
H09 
 
 
 
 
 
9 
21 
36 
49 
70 
86 
8 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
3.3 
7.5 
8 
8 
13 
10 
2.75 
2.70 
2.30 
3.90 
2.21 
1.34 
 
 
 
 
 
 
Mean DT 
Total PD 
 
 
   1.88 
 
 
33.50 
M08 
 
 
 
 
13 
21 
41 
51 
63 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
8 
2 
3.6 
7.6 
8 
2.30 
2.20 
4.46 
1.80 
2.13 
 
 
 
 
 
Mean DT 
Total PD 
 
 
   1.69  
24.98 
P08 
 
 
 
 
13 
21 
41 
51 
63 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
6 
1.5 
3 
8 
8 
2.49 
2.48 
4.73 
1.77 
2.13 
 
 
 
 
 
Mean DT 
Total PD 
 
 
   1.77  
23.96 
Y08 
 
 
 
 
13 
21 
30 
41 
51 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
5.4 
1.7 
5 
4.5 
7 
2.56 
2.35 
1.81 
2.29 
1.84 
5.07 
3.41 
4.96 
4.81 
5.45 
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Mean DT 
Total PD 
 
 
   1.81 
 
 
38.52 
PC08 
 
 
 
 
 
7 
14 
23 
29 
35 
42 
51 
58 
66 
73 
80 
87 
94 
101 
 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.7 
5 
7.8 
5.3 
5.5 
8.4 
8.5 
4.3 
6.3 
14.3 
7.3 
10 
8.3 
1.1 
1.3 
1.0 
1.2 
0.9 
0.9 
1.1 
1.3 
1.3 
1.1 
0.9 
1.0 
0.9 
1.0 
0.9 
5.27 
6.70 
7.59 
6.71 
6.78 
6.49 
6.73 
5.41 
6.96 
8.16 
7.18 
7.68 
7.36 
7.78 
Mean DT 
Total PD 
 
 
   1.1 
 
 
98.68 
PC09 
 
 
 
 
 
7 
15 
28 
35 
42 
51 
57 
63 
70 
79 
86 
94 
101 
108 
115 
122 
129 
 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
1.6 
12.3 
3.03 
3 
2.2 
3.9 
4.2 
2.8 
5.3 
3.3 
8.5 
4.3 
6.3 
7.3 
7.3 
10.3 
8.3 
10 
0.9 
1.4 
2.4 
1.4 
1.1 
1.5 
1.0 
0.9 
1.2 
1.3 
1.3 
1.1 
1.0 
1.0 
0.9 
1.0 
0.9 
7.94 
5.65 
5.49 
5.06 
6.47 
6.14 
5.78 
6.72 
5.78 
7.14 
5.41 
6.96 
7.18 
7.28 
7.68 
7.36 
7.65 
Mean DT 
Total PD 
 
 
   1.2 
 
 
111.58 
 
Figure I.a. Raw data from short-term culture of clonal cell lines and heterogeneous PC08 and 
PC09 
Clonal cell lines A09, D09, H09, M08, P08 and Y08 underwent short term culture  for 84, 86, 86, 
63, 63, and 51 days, respectively . Heterogeneous PC08 and PC09 cell lines underwent a more 
lengthy cell culture period for 101 and 129 days, respectively. The raw data underlying these 
cell culture periods are illustrated and the calculated doubling time (DT) and population 
doublings (DT). * represents initial cell count corrected for plating efficiency (PE); every seeded 
cell would not give rise to colonies (even in highly proliferating lines like SiHa and HeLa, which 
show PE values of 0.2-0.5. To correct for PE in the calculations a PE of 0.2 has been assumed 
(i.e. approximately one fifth of cells would establish and give rise to colonies). 
 281 
 
Appendix II – Example of qRT-PCR fluorescence curves in M08 
(cell culture confluency study) 
 
 
 
E7 – Amplification curve 
E7 – melt curve 
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E6 – amplification curve 
E6 – melt curve 
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Figure II.a. An example of real-time fluorescent traces of HPV genes and housekeeping genes 
in cell line M08 
qPCR amplification and melt curves are illustrated for HPV 16 E6, E7 and housekeeping genes 
TBP2 performed to investigate the effect of confluency on HPV expression levels (relative to 
CaSki).  
 TBP2 – melt curve 
 TBP2 – amplification curve 
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Appendix III - Example of qRT-PCR fluorescence curves in H09 
(molecular characterisation study) 
 
 
 
E2 – amplification curve 
E2 – melt curve 
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E7 – amplification curve 
E7 – melt curve 
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E6 – amplification curve 
E6 – melt curve 
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 TBP2 – amplification curve 
 TBP2 – melt curve 
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Figure III.a. An example of real-time fluorescent traces of HPV genes and housekeeping 
genes in cell line H09  
qPCR amplification and melt curves are illustrated for HPV 16 E2, E6, E7 and housekeeping 
genes TBP2 and HPRT. Gene expression (relative to CaSki) was performed during short-term 
culture. 
HPRT – amplification curve 
HPRT  – melt curve 
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Appendix IV - Example of qRT-PCR fluorescence curves in H09 
(CDV dosing study) 
 
 
  
E2 – amplification curve 
E2 – amplification curve 
E2 – melt curve 
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E6 – melt curve 
E6 – melt curve 
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E7 – amplification curve 
E7 – melt curve 
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HPRT – amplification curve 
HPRT – melt curve 
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Figure IV.a. An example of real-time fluorescent traces of HPV genes and housekeeping 
genes in CDV treated and untreated cell line H09  
qPCR amplification and melt curves are illustrated for HPV 16 E2, E6, E7 and housekeeping 
genes TBP2 and HPRT. Gene expression (relative to CaSki) was performed during CDV dosing 
protocol. 
TBP2 – amplification 
curve 
TBP2 – amplification 
curve 
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Appendix V – Caspase-3 activity via analysis of apoptotic cells in 
A09 and M08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.a. Caspase-3 activity in M08 and A09 cells in response to Cidofovir and ionising 
radiation 
Caspase-3 activity was assessed using the Caspase-3 activity kit from Cell Signalling 
(Massachusetts USA) which used a fluorogenic substrate (Ac-DEVD-AMC) for activated 
caspase-3 to quantify apoptotic cells. Positive and negative assay controls were included (AMC 
and water). Cells were treated for 12, 36 and 72 hrs with IC50 doses of CDV plus or minus 
ionising radiation. Illustration kindly provided by Miss A. Flynn (Cardiff University, HPV 
Research Group).  
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Appendix VI – Capsase-3 activity via analysis of western blots in 
A09 and M08 
 
 
Figure VI.a. Western blots for cleaved Caspase-3 in M08 and A09 cells in response to 
Cidofovir and ionising radiation 
Levels of cleaved Caspase-3 activity were assessed by western blotting using the cleaved 
caspase 3 antibody (Asp 175 #9664) from Cell Signalling (Massachusetts USA). Illustration 
kindly provided by Miss A. Flynn (Cardiff University, HPV Research Group).  
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Appendix VII – Assessment of RNA integrity using Agilent  
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 300 
 
 
 
 
 301 
 
 
Figure VII.a. RNA integrity data obtained using Agilent   
RNA Integrity Number (RIN) values were >10 and therefore suitable for SOLiD™ RNA-
sequencing . 
In the illustration, clonal cell lines M08 untreated, M08 CDV treated, P08 untreated and P08 
CDV treated are referred to as: MB (TIFF), MD (TIFF), PB (TIFF) and PD (TIFF), respectively.     
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Appendix VIII – Heat map showing differential gene expression in 
M08 and P08 
 
 
 
Figure VIII.a. Heat map showing differentially expressed genes in M08 and P08  
Green indicates reduced gene expression and red indicates increased gene expression. 
 
